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Glucocorticoids have been the most widely used anti-inflammatory drugs. However,
chronic excessive exposure to glucocorticoids causes numerous side effects,
including obesity, hypertension and type II diabetes. Thus dissociated steroids with
anti-inflammatory efficacy and reduced metabolic side effects are an attractive
therapeutic goal. A previous study has shown that 5a-tetrahydro corticosterone
(5aTHB), produced by steroid 5a-reductases in rodents, is an activator of
glucocorticoid receptor (GR). Therefore, we hypothesized that 5aTHB may possess
some of the properties of the parent steroid to transactivate and transrepress genes
regulated by GR and have shown it possesses some of the characteristics of a
dissociated steroid.
In cultured cells, 5aTHB has weaker effects than corticosterone to induce GR
translocation but was synergistic with corticosterone. 5cxTHB did not induce the
expression of PEPCK or TAT or glucocorticoid responsive reporter genes. In
contrast however in bone marrow derived macrophages, 5aTHB increased the
secretion of anti-inflammatory cytokine IL-10 and suppressed LPS-induced
production of pro-inflammatory cytokines TNFa and IL-6.
In C57BL/6 mice following acute administration of 5aTHB, glucose tolerance and
insulin sensitivity were not affected, and hepatic PEPCK and TAT were not
increased. In mice that were chronically infused with 5aTHB, body and organ
weights, glucose tolerance, insulin sensitivity, or expression of glucocorticoid
responsive genes in liver and adipose tissue were not changed. Elowever circulating
ACTH was suppressed and in whole blood, LPS-induced production of TNFa was
suppressed. In mice suffering from peritonitis induced by LPS, 5aTHB suppressed
IL-6 levels in peritoneal fluid to a similar extent as corticosterone.
Therefore the contribution of 5a-reductase type 1 (5aRl) to protect metabolic tissues
from adverse metabolic effects of glucocorticoids was tested in 5aRl deficient mice.
I
Circulating corticosterone was elevated in animals receiving corticosteroid with no
difference between genotypes. Infusion of corticosterone induced a greater elevation
in insulin and free fatty acids during a glucose tolerance test in 5aRl-null mice,
compared to wild-type controls. In the mesenteric adipose tissue, angiotensinogen
expression was only increased in 5aRl-null mice receiving corticosterone. However
suppression of TNFa and IL-6 by corticosterone in the whole blood was independent
of genotype.
In conclusion, 5aTHB is a weak GR ligand, but possesses some anti-inflammatory
properties similar to those of corticosterone, potentially acting through GR-protein
interactions as opposed to GR-GRE interactions. 5aTHB could be a prototype for a
selective anti-inflammatory drug with limited metabolic toxicity. Thus inhibition of
5aRl may cause detrimental metabolic effects without inducing immune suppression.
II
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Glucocorticoids are steroid hormones that modulate energy homeostasis in the body,
especially during starvation or stress. Over the last fifty years they have been the
most widely used agents to control inflammation and immune activation. Their
therapeutic significance has drawn enormous amounts of interest in research from a
broad range of areas. This thesis will investigate the mechanisms of glucocorticoid
action with respect to their metabolic and anti-inflammatory roles. It will focus on
one of the 5a-reduced metabolites of glucocorticoids in rodents, 5a-tetrahydro
corticosterone (5aTHB), which has been shown to mimic some actions of its 'parent',
corticosterone. This chapter will introduce the background information underpinning
the investigation of effects of 5aTHB.
1.1 Glucocorticoids
Glucocorticoids are members of the steroid hormone family with 21 carbon atoms.
Like all the other steroid hormones, they are derived from the
cyclopentanoperhydrophenanthrene structure which is three cyclohexane rings and a
single cyclopentane ring, labelled A, B, C, and D, respectively. Each of the 21








Figure 1.1 The cyclopentanoperhydrophenanthrene structure of glucocorticoid with
21 carbon atoms. The three cyclohexane rings and the single cyclopentane ring are
identified by letters and the individual carbon atoms by numbers.
1.1.1 Steroidogenesis in the adrenal cortex
Glucocorticoids are synthesized and released from the cortices of adrenal glands,
where mineralocorticoids (aldosterone, deoxycorticosterone (DOC)) and sex steroids
(androgens) are also generated. According to cell morphology and function, the
adrenal cortex is divided into three zones which are, from outer to inner, the zona
glomerulosa, zona fasciculata and zona reticularis.
All adrenocorticosteroids are derived from the same precursor, cholesterol which is
either synthesised within the adrenal gland or is taken up from the circulation.
Cholesterol circulates in association with lipoproteins and is taken into cells of
adrenal cortex by means of receptor-mediated endocytosis in humans (Higashijima,
et al. 1987); whereas in rats, receptor-mediated endocytosis and non-endocytotic
3
pathways are involved (Gwynne, et al. 1984). Then the cholesterol is transported
directly to the mitochondrion or it is stored in lipid droplets as cholesterol ester until
required. Mitochondrial uptake of free cholesterol is the rate limiting step of
steroidogenesis and is regulated by StAR (Steoidogenic Acute Regulatory protein)
(Christenson and Strauss 2001). Mitochondrial cholesterol is then cleaved to form
pregnenolone by cholesterol side-chain cleavage (SCC) enzyme, cytochrome
P450scc (gene name: CYP11A1). The pathways of biosynthesis of glucocorticoids
and mineralocorticoids are shown in Figurel.2. A series of cytochrome P450
enzymes are involved. The nomenclature for these enzymes is adopted from their
gene names, which are listed in Table 1.1 shown together with their intracellular
localizations.
The active glucocorticoid in human circulation is Cortisol, while corticosterone is the
main glucocorticoid in rodents. Since Cortisol is the final product of 17a-
hydroxylated pregnenolone or progesterone in zona fasciculata of adrenal cortex, the
17a-hydroxylase (CYP17) is a prerequisite enzyme for human glucocorticoid
biosynthesis (Chung, et al. 1987; Picado-Leonard and Miller 1987). The zona
glomerulosa does not express 17a-hydroxylase, thus Cortisol production is excluded
from this zone. In rodents, 17a-hydroxylase is absent in adrenal cortex (Luu-The, et
al. 2005), and thus corticosterone is the active glucocorticoid instead of Cortisol. The
final steps in the biosynthesis of glucocorticoids and mineralocorticoids are catalyzed
by 11 P-hydroxylase and aldosterone synthase, encoded by CYP11B1 and CYP11B2,
respectively, that share 95% sequence homology. In rodents, 11-deoxycorticosterone
is converted into aldosterone by aldosterone synthase (CYP11B2) in the zona
glomerulosa and into corticosterone by 11 P-hydroxylase (CYP11B1) in the zona
fasciculata (Domalik, et al. 1991; Ogishima, et al. 1992).
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Gene Enzyme Localization






HSD3B2 3P*Hydroxysteroid dehydrogenase type
2 isozyme (3P-HSD2)
Table 1.1 Nomenclature of enzymes involved in adrenal steroidogenesis and their
intracellular localizations.
5
Figure 1.2 The pathways of biosynthesis of glucocorticoids and mineralocorticoids
in adrenal cortex. DOC=l 1-deoxycorticosterone.
1.2 Regulation of glucocorticoids
1.2.1 The hypothalamic-pituitary-adrenal (HPA) axis
Endogenous glucocorticoids, Cortisol in humans and corticosterone in rodents, are
controlled by the hypothalamic-pituitary-adrenal (HPA) axis. The biosynthesis and
secretion of glucocorticoids from the adrenal glands is under the stimulus of
adrenocorticotropic hormone (ACTH), released from the anterior pituitary into the
circulation. ACTH, a peptide hormone with 39 amino acids, is cleaved from a larger
241-amino-acid precursor, pro-opiomelanocortin (POMC) inside the anterior
pituitary cells. Synthesis ofPOMC and secretion ofACTH into circulation are
activated by corticotrophin-releasing hormone (CRH) and arginine vasopressin
(AVP). Secretion of CRH, a 41-amino-acid peptide, is stimulated by stressors,
produced in neurons within the paraventricular nucleus (PVN) of the hypothalamus
and transported through the hypophyseal portal blood to the anterior pituitary where
CRH stimulates POMC gene transcription, cleavage, and ACTH secretion.
Elevated circulating Cortisol or corticosterone levels exert negative control on POMC
transcription and the consequent ACTH secretion from the pituitary and on CRH and
AVP transcription in hypothalamus. This completes the negative feedback loop of
the HPA axis thereby maintaining the physiological level of glucocorticoids in the
body (Dostert and Heinzel 2004; Stewart 2002).
Chronic pharmacological treatment with glucocorticoids causes prolonged
suppression of the HPA axis even months after cessation of therapy. Secondary
adrenocortical insufficiency is anticipated after withdrawal of steroid treatment
which is characterized by glucocorticoid and ACTH deficiency. Primary
adrenocortical insufficiency (Addison's disease) is caused by glucocorticoid and
mineralocorticoid deficiency, where ACTH levels are markedly elevated (Nieman
and Chanco Turner 2006). In contrast when endogenous glucocorticoid levels are
high as in Cushing's syndrome due to a cortisol-secreting adrenal adenoma,
circulating ACTH levels are hardly detectable (Stewart 2002). Cushing's syndrome
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can also arise with elevated ACTH concentrations, as in ectopic ACTH syndrome or
ACTH-secreting pituitary adenoma (Howlett, et al. 1986).
1.2.2 The immune-endocrine axis
Control of the immune system by the central nervous system is mediated in part by
the HPA axis (Dostert and Heinzel 2004). Various pro-inflammatory cytokines, such
as interleukin (IL)-l, IL-2, IL-6, tumor necrosis factor (TNF)-a, and interferon
(IFN)-y are released upon immune stimulation and can activate the HPA axis by
increasing the secretion of CRH from hypothalamus and ACTH from pituitary. This
in turn increases the release of glucocorticoids to mediate anti-inflammatory events
(Sapolsky, et al. 2000).
1.2.3 Circadian rhythm
Under basal conditions, circulating glucocorticoid levels demonstrate a 24-hour
circadian rhythm, which is regulated by the pulsatile release ofACTH (Stewart
2002). In humans, Cortisol levels are highest in the morning on waking and slowly
decline during the day, reaching a trough level in the late afternoon, evening and
nocturnal period (Lupien, et al. 2007). In rodents which are nocturnal animals, the
circadian peak occurs in the evening with the circadian nadir in the morning (Windle,
et al. 1998).
1.3 Glucocorticoid signalling
Glucocorticoids exert their numerous effects through direct interaction with two
types of receptors, glucocorticoid receptor (GR, type II corticosteroid receptor) and
mineralocorticoid receptors (MR, type I corticosteroid receptor). Both are members
of the superfamily of nuclear hormone receptors that includes GR, MR, progesterone
receptor (PR), androgen receptor (AR) and estrogen receptor (ER). This thesis
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focuses on how glucocorticoid signalling via GRs influences metabolism and
inflammation.
1.3.1 Steroid hormone receptors
Steroid hormone receptors are modular proteins that act as transcription factors to
transduce the signals of their cognate ligands. According to functional and structural
analyses, steroid receptors are composed of a common series of domains, referred to
as A to F (Figure 1.3). C includes the DNA-binding domain (DBD); E contains the
ligand binding domain (LBD) that controls the receptor's functions. Many actions of
steroid hormones require receptors to form a dimer. The critical dimerization domain
is within Domain C and consists of two zinc finger regions; the LBD is also involved
in dimerization. DNA sequences that recognise and bind to receptors are known as
hormone response elements. The amino acids responsible for receptor recognition of
the response element are within the P box of the DBD. Many hormone receptors are
located in the cytoplasm and are translocated to the nucleus upon ligand binding.
Nuclear localization signals (NLS) for nuclear pore recognition are localized in
domain C and E. The transcriptional competence of steroid receptors is exerted by
two activation functions (AFs), AF-1 (also called t-1 or enh-1) and AF-2. AF-1 is
constitutively active and located in the A/B-domain. AF-2, a ligand-inducible
activation function, is in the LBD. Domain F is essential for ligand binding of GR,
PR and AR but not ERa (Lazar 2002; Schoneveld, et al. 2004).
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Figure 1.3 Domain structures of nuclear receptors, modified for GR (Beato and Klug
2000; Duma, et al. 2006; Lazar 2002). Domain A/B, N terminal domain; Domain C,
DNA binding domain (DBD); Domain D, hinge region; Domain E, ligand binding
domain (LBD); Domain F is essential for ligand binding.
1.3.2 GR Trafficking
The intracellular distribution ofER, AR and PR depends on nuclear-cytoplasmic
diffusion and ATP-dependent cytoplasmic-nuclear shuttling (Beato and Klug 2000).
The nuclear localization signals are the passport for receptors to translocate into the
nucleus with or without ligand binding. However, this is not the case for the GR.
Ligand-free GR is tethered in the cytoplasm to the heat shock protein (hsp) 90/hsp70
-based chaperone complex (Figure 1.4) (Pratt, et al. 2006). One molecule ofGR is
bound to a dimer of hsp90 and one molecule of immunophilins (IMM) which
includes FKBP51, FKBP52 or CyP-40. The amounts of essential hsp70 are variable
but substoichiometric. Hsp90 is characterized by a unique binding pocket for ATP. It
binds to the LBD ofGR, while other non-essential co-chaperones, such as Hop (hsp
organizing protein), hsp40 and p23, are assembled into the complex, whereupon an
ATP-dependent hydrophobic cleft is open for steroid binding. This is the rate-
limiting step in the overall assembly process, since the preceding stage when GR
10
binds to hsp90 is rapid (Kanelakis, et al. 2002). Then GR undergoes a
conformational change upon assembly of the heterocomplex (Pratt et al. 2006).
Since glucocorticoids are small and highly lipophilic molecules, they can readily
pass the cell membrane by passive diffusion and bind to their cytoplasmic cognate
receptor. Upon binding of ligand, GR is activated, the hydrophobic pocket closes and
the ability to form persistent complexes with hsp90 is lost. The linkage between GR
and hsp90 chaperone machinery becomes much more dynamic. The dissociation of
GR with hsp90 facilitates the exposure of the NLS ofGR, which enables GR to
translocate into nucleus (Pratt et al. 2006), however the dynamically bound hsp90
chaperone machinery is also essential in GR trafficking. It has been proposed by
Pratt that the hsp90-GR heterocomplexes are moved along microtubules by
cytoplasmic dynein, the motor protein with the immunophilins connecting the
heterocomplexes to dynein (Pratt et al. 2006).
When they arrive at the nuclear membrane, GR-hsp90 heterocomplexes travel
through nuclear pores by means of facilitated diffusion, which involves the transport
receptors called importins and exportins to take the signalling proteins in and out of
nucleus, respectively (Gorlich and Kutay 1999; Pratt, et al. 2004).
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Figure 1.4 The heterocomplex ofGR-hsp90-immunophilin in the cytoplasm of
glucocorticoid-free cells. One molecule of GR binds to a dimer of hsp90 and one
molecule of immunophilin (IMM). The blank steroid structure in the GR indicates
that the hydrophobic ligand-binding cleft is open and can be accessed by
glucocorticoids. The small co-chaperone p23 helps to stabilize the complex once it is
formed.
1.3.3 Molecular mechanisms mediated by GR
Following translocation into nucleus, glucocorticoid bound GRs interact with the
regulatory regions of responsive genes by multiple means, and regulate gene
expression positively or negatively, which are classified respectively as
transactivation or transrepression mechanisms ofGR signalling.
1.3.3.1 Transactivation
Glucocorticoid induced transactivation is mediated by GR binding to the
glucocorticoid response elements (GREs) in the responsive regions of target genes. A
consensus GRE is defined as the 15-bp imperfect palindrome GGTACAnnnTGTTCT
(position numbered relative to the dyad axis of symmetry as -6,-5,-4,-3,-2,-
l,nnn,l,2,3,4,5,6; n is any nucleotide) in which the 3' half is most conserved and the
5' half highly flexible (Barnes 1998). It has been realized however that only the
12
nucleotides at the positions -3, -2, +2, +3 and +5 of these are of critical importance.
Two GR monomers bind in turn to the 3' and then 5' half sites to form a GR
homodimer through the dimerization domain in the GR DNA-binding domain
(Schoneveld et al. 2004). The homodimer formation is rate-limiting for high affinity
DNA binding by GR and only possible when the GR contacts DNA (Drouin, et al.
1992). In a few genes, it has been found that the GR homodimer binds simply to the
GREs, while some other genes require the recruitment of several transcription factors
or coactivators, such as C/EBP, FoxA (Schoneveld et al. 2004), CBP/p300, P/CAF
and steroid receptor coactivator (SRC)-l (Smoak and Cidlowski 2004), to bind
adjacent to sites other than GREs. The recruited form is referred to as the
glucocorticoid responsive unit (GRU). A number of genes are regulated through this
model, such as phenylethanolamine N-methyltransferase (PNMT) (Ross, et al. 1990;
Tai, et al. 2002) and the genes coding for the enzymes in the gluconeogenesis
pathway including phosphoenolpyruvate carboxykinase (PEPCK) (Sugiyama, et al.
1998), tyrosine aminotransferase (TAT) (Grange, et al. 1991), aspartate
aminotransferase (AAT) and glucose-6-phosphatase (G6Pase) (Dostert and Fleinzel
2004).
Besides the GR homodimer binding to GREs, a monomeric GR can bind the DNA at
the GRE half-sites (GREl/2s) in combination with additional elements, including
other transcription factors, GREs or multiple GREl/2s. For example, the enhancer of
the mouse mammary tumor virus (MMTV) gene contains four directly repeated
GRE1/2s. The two proximal of those can be bound by two GR monomers to form a
homodimer (Truss and Beato 1993). However, this kind of dimerization is different
from the one binding to the palindromic GREs because: firstly, the spacer length
between the GRE 1/2s is less constrained; secondly, the affinity ofGR for the
GRE 1/2s is lower than for a palindromic GRE; thirdly, the dimerization on the
directly repeated GRE1/2s is mediated by the ligand binding domain not the DNA
binding domain used for binding to the palindromic GREs (Schoneveld et al. 2004;
Truss and Beato 1993).
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GR can also transactivate the transcription of some anti-inflammatory proteins whose
genes have no GRE consensus sequence. Instead GR binds directly to other
transcriptional factors to control transcription. IkB (inhibitor of nuclear factor-kappa
B (NFkB)) and anti-inflammatory cytokine IL-10 are thought to be activated by GR
by this mechanism although the exact transcription factors involved have not been
elucidated (Barnes 1998). The only report to date that has confirmed the indirect
induction of gene transcription by glucocorticoids is that of the IL-10 gene. GR binds
to and increases the transcriptional activity of STAT3 (Signal Transducer and
Activator of Transcription 3) to promote IL-10 expression in human B cells
(Unterberger, et al. 2008).
1.3.3.2 Transrepression
The transrepression induced by glucocorticoids is mediated through either direct or
indirect interaction between GRs and target genes. The direct GR binding to the
negatively regulated GRE inhibits the expression of responsive genes. This is often
accompanied by recruitment of other transcription factors or co-activators. A
consensus sequence of a negative GRE is ATYACnnTnTGATCn, which is more
variable than that of a positive GRE (Schoneveld et al. 2004). It is exemplified by the
negative control ofCRH and POMC by glucocorticoids. GR binds the negative GRE
predominantly as monomer in the CRH gene (Malkoski and Dorin 1999) and as a
trimer in the POMC gene (Drouin, et al. 1993b).
Glucocorticoid induced repression of inflammatory responses does not involve direct
binding ofGR to DNA, but interaction ofGR with other transcription factors such as
NFkB and activator protein-1 (AP-1) that are pro-inflammatory transcription factors.
NFkB consists of homodimers or heterodimers assembled from several subunits in
which the p65/p50 heterodimer is the predominant combination. GR binds to the p65
subunit by protein-protein interaction and results in the inhibition of the gene
transcription mediated by NFkB. Similarly, AP-1 is comprised of a Jun family
member (c-Jun, v-Jun, Jun-B, or Jun-D) homodimerized with another Jun protein or
heterodimerized with a Fos protein (c-Fos, Fos-B, Fra-1, or Fra-2). GR physically
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interacts with the Jun subunit so as to inhibit the gene transcription (Smoak and
Cidlowski 2004).
Another model ofGR transrepression involves competition for the coactivators of
NFkB. The coactivators, such as cAMP response element binding protein (CREB) -
binding protein (CBP) and SRC-1, are required for the maximal transcription ability
ofNFkB. GR can compete with NFkB and thus repress the transcription induced by
this transcription factor (Schoneveld et al. 2004; Smoak and Cidlowski 2004).
These models ofGR-protein mediated regulation have been shown to be GR
dimerization-independent, e.g. through GR monomer (Bledsoe et al. 2002; Heck, et
al. 1994).
1.3.4.3 Non-genomic glucocorticoid signalling
Transactivation and transrepression of gene transcription are mediated by the
genomic mechanisms of glucocorticoid signalling, in which the translocation ofGR
into the nucleus and transcription of regulated genes are the most time-consuming
steps, requiring 15-150 min to exhibit the effects. However, some rapid
glucocorticoid effects, taking place within 5 min or even within seconds, are likely to
be mediated by non-genomic mechanisms (Haller, et al. 2008). It is hypothesized that
the rapid non-genomic effects are mediated in three ways. Firstly, glucocorticoids
themselves may interfere non-specifically with the physico-chemical properties of
cellular membranes, e.g. plasma and mitochondrial membranes. High concentrations
of glucocorticoids have been shown to intercalate into membranes without binding to
GRs, resulting in alteration of the activities of membrane-associated proteins, thereby
reducing Ca2+ and Na+ cycling across plasma membranes, and increasing the proton
leak of the mitochondria of immune cells (Buttgereit and Scheffold 2002; Stahn, et al.
2007). These changes could impair ATP production which in turn will contribute to
the anti-inflammatory and immunosuppressive effects of glucocorticoids (Song and
Buttgereit 2006). Secondly, glucocorticoids may mediate non-genomic effects by
binding to membrane-bound glucocorticoid receptors (mGR). The mGR has been
identified in human (Gametchu, et al. 1993) and murine (Chen, et al. 1999)
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lymphoma cells, and in normal human monocytes in peripheral blood (Bartholome,
et al. 2004). It is suggested that the mGR is a variant of the classical cytosolic GR
produced by differential splicing or promoter switching or post-translational editing,
as overexpression of classical GR did not increase the mGR on the cell surface
(Bartholome et al. 2004). Thirdly, the classical cytosolic GR also may mediate non-
genomic effects of glucocorticoids. Chaperone proteins, such as SRC, that are
released from the GR-chaperone complex upon ligand binding, are shown to
contribute to the rapid glucocorticoid effects (Croxtall, et al. 2000). Another example
of a GR-dependent (specific GR inhibitor RU486-sensitive) and transcription-
independent (actinomycin D-insensitive) process involves the release of arachidonic
acid within minutes (an essential mediator for cell growth and metabolic or
inflammatory reactions) from cell membrane-associated phospholipids (Croxtall et al.
2000; Song and Buttgereit 2006).
1.3.4 Isoforms of GR
Two human GR have been identified and are termed hGRa and hGRp. They are 777
and 742 residues long, respectively (Hollenberg, et al. 1985) and are identical up to
residue 727 and diverge beyond this point. The two receptor isoforms originate from
the same gene and differ by alternative splicing of the final ninth exon. A large
portion of the LBD is encoded in exon 8. Exon 9 encodes two alternative extreme
carboxyl terminal ends of LBD and the 3' untranslated regions, which results in the
additional 50 amino acids of hGRa and additional non-homologues 15 amino acids
of hGRp (Encio and Detera-Wadleigh 1991). The shortened LBD of hGRp is
reported to be unable to bind glucocorticoid agonist, but RU-38486, a glucocorticoid
antagonist, has been shown to bind to hGRp (Lewis-Tuffin, et al. 2007). Both
isoforms are widely expressed in virtually all human tissues (Boullu-Ciocca, et al.
2003), although at the transcript level, hGRp is much less abundant than hGRa, and
the ratio varies between 1:40-2800 (DeRijk, et al. 2002). Unlike hGRa, hGRp is
located largely in the nucleus independent of the presence of glucocorticoids. hGRp
will bind to hsp90, although this binding is not affected by addition of ligand (de
Castro, et al. 1996).
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The isoform hGRa is commonly referred to as bonafide hGR, since only hGRa
binds hormones and modulates the expression of glucocorticoid-responsive genes in
a hormone-dependent fashion. hGRP cannot affect gene expression by itself but
interferes with hGRa activity. hGRfl heterodimerizes with ligand-bound hGRa to
decrease the transactivation and transrepression activity of hGRa (DeRijk et al.
2002). Thus hGR(3 is thought to function as a dominant negative inhibitor of hGRa
and to participate in defining the sensitivity of target tissue to glucocorticoids
(Boullu-Ciocca et al. 2003; Oakley, et al. 1996). hGRp can be up- or down- regulated
in different tissues in response to glucocorticoid treatment (DeRijk et al. 2002) and
the ratio of hGRa/hGRP is found to be critical in the modulation of gene
transcription (Lewis-Tuffin and Cidlowski 2006). Decreased hGRa/hGRP ratio in
inflammatory cells correlates with the development of glucocorticoid resistance in
patients receiving steroid therapy for several diseases including asthma, leukemia,
ulcerative colitis and nasal polyposis (Lewis-Tuffin and Cidlowski 2006). In obese
patients, the ratio of hGRa/hGRP is also decreased in circulating monocytes (Boullu-
Ciocca et al. 2003).
Until now the p isoform ofGR has been found in human and zebrafish only, and the
zebrafish GRP displays similar functions to its human equivalent (Schaaf, et al.
2008). GRp is not present in mice. Therefore the GR referred to in this thesis is
mainly the classically ligand-dependent GR unless otherwise stated.
1.4 Effects of glucocorticoids
Physiologically, glucocorticoids exert a broad range of effects in target systems
throughout the body, increasing the availability of substrates for energy supply, and
allowing for adaptations to changing demands of the environment, e.g. alterations in
behaviour and immune responses.
The pathological effects of glucocorticoids can be exemplified in "Cushing's
syndrome" caused by endogenous or exogenous glucocorticoid excess, which was
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reported by Harvey Cushing in 1912, and characterized by hypertension, central
obesity, insulin resistance and impaired glucose tolerance (Cushing 1912), all of
which are risk factors for cardiovascular disease (Haffner 2006). These
characteristics are also found in patients with the metabolic syndrome (also known as
syndrome X, the insulin resistance syndrome, and the "deadly quartet"). Over the
past two decades, there has been a striking increase in the worldwide prevalence of
metabolic syndrome (Eckel, et al. 2005). Similarities between the Cushing's
syndrome and the metabolic syndrome have stimulated interest in the role of
glucocorticoids in the pathogenesis of the metabolic syndrome (Walker 2006).
The anti-inflammatory effects of glucocorticoids were first noticed and reported by
Hench in 1949, who won a Nobel Prize for his findings (Hench 1950; Hench and
Kendall 1949). From then on, research into glucocorticoids has been extensive and
intense. The pharmaceutical industry has developed a number of synthetic
glucocorticoids such as dexamethasone, betamethasone, triamcinolone, prednisone,
prednisolone and methylprednisolone (Liberman, et al. 2007) which have become the
most commonly prescribed agents for the treatment of a wide variety of
inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease,
asthma, psoriasis, vasculitis (Goulding, et al. 1998), polymyalgia rheumatica, chronic
obstructive pulmonary disease (Lowenberg, et al. 2008), autoimmune, and allergic
diseases. They are also used to reduce organ allotransplant rejection (Liberman et al.
2007).
Chronic and systemic use of glucocorticoids is hampered by severe side effects.
Iatrogenic Cushing's syndrome is common in patients who take glucocorticoids
chronically (Liberman et al. 2007). Other adverse effects of glucocorticoids include
osteoporosis, growth retardation, skin atrophy, myophathy, glaucoma and "steroid
psychosis" (Lupien et al. 2007).
1.4.1 Carbohydrate, protein, and lipid metabolism
Glucocorticoids act to provide energy and prepare a man or an animal for a "fight or
flight" response when required (e.g. facing a perceived danger or starvation). The
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levels of blood glucose and free fatty acids are increased by glucocorticoids through
their actions on carbohydrate, protein and lipid metabolism, opposing the effects of
insulin (Andrews and Walker 1999; Walker 2007b). In tissues that are important for
metabolism, including liver and adipose tissue, glucocorticoids can upregulate the
enzyme 11P-hydroxysteroid dehydrogenase type 1 (11P-HSD1, details are in Section
1.6.1) which regenerates the active form of glucocorticoids, thereby amplifying the
GR activation in these tissues (Stewart, et al. 1999; Walker 2007a).
In the liver, glucocorticoids activate gluconeogenesis with increased transcription of
the key enzymes involved in this pathway, such as PEPCK (the rate-limiting enzyme)
(Sugiyama et al. 1998), G6Pase (van Schaftingen and Gerin 2002) and fructose-1,6-
diphosphatase (FDPase) (Fleig, et al. 1984) as well as aminotransferases, e.g. TAT
and AAT (Dostert and Heinzel 2004). Glucocorticoids increase triglyceride storage
(Mantha, et al. 1999) and thereby promote fat accumulation within the liver (Stravitz
and Sanyal 2003); they also increase hepatic glycogen synthase and inhibit the
glycogen phosphorylase to facilitate glycogen deposition, providing long-term
protection against stress and starvation (Bollen, et al. 1998; van Schaftingen and
Gerin 2002). Glucocorticoids inhibit glucose uptake and utilization in peripheral
tissues including skeletal muscle and adipose tissue, where proteolysis and lipolysis
are activated in order to provide glucogenic substrates, e.g. amino acids and free fatty
acids respectively, into the circulation (Buren, et al. 2002; Olefsky 1975). Other
hormones such as catecholamines, glucagon and epinephrine exert amplified actions
through the permissive effects of glucocorticoids (Sapolsky et al. 2000):
catecholamines can increase lipolysis in adipose tissue and glycogenolysis in skeletal
muscle; glucagon and epinephrine also stimulate gluconeogenesis in the liver.
Overall, the efficiency of glucose production is promoted (Exton 1979), causing an
elevation in blood glucose and insulin resistance.
In adipose tissue, glucocorticoids stimulate the differentiation of preadipocytes into
mature adipocytes which are capable of storing triglycerides (Wiper-Bergeron, et al.
2007). Triglycerides are efficient form to store energy (Hillgartner et al. 1995). They
undergo lipolysis to release glycerol and non-esterified (free) fatty acids (NEFAs),
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the latter being a major source of fuel for oxidative metabolism (Coppack et al. 1994).
Glucocorticoids have important effects on fatty acid metabolism. NEFA release from
adipocytes in vitro is activated by glucocorticoids (Baxter & Forsham 1972).
Lipoprotein lipase (LPL) activity andmRNA expression are also increased by
glucocorticoids (Fried et al. 1993; Ong et al. 1992). Effects of glucocorticoids in vivo
are different between acute and chronic glucocorticoid activations. During fasting
and stress with stimulus of elevated catecholamines, elevated glucocorticoids
activate LPL, and potentiate NEFA release from circulating triglycerides into the
circulation (Samra et al. 1998). If feeding occurs, insulin-stimulated trigs storage in
adipose tissue is decreased and NEFA release is sustained. During recovery from
stress when catecholamine diminishes while glucocorticoid effects are sustained, re-
feeding increases insulin levels when trigs are released from liver, intravascular
lipolysis activated, and lipolysis diminished and trigs storage upregulated in adipose
tissue (Macfarlane et al. 2008). Chronic exposure to glucocorticoids in human has
similar effects to those during recovery from stress, with increased hydrolysis of
circulating TAG and NEFAs release from subcutaneous adipose tissue (Krsek et al.
2006) but re-esterification and storage in visceral adipose tissue, resulting in the
redistribution of body fat from peripheral fat to central adipose tissues, such as
visceral, abdominal, facial, and neck, causing central obesity. Increased
cardiovascular morbidity and mortality in human is associated with intra-abdominal
adipose deposition, as opposed to subcutaneous fat (Gathercole, et al. 2007;
Macfarlane et al. 2008). Elowever, in rodents, chronic glucocorticoid excess results in
lose, rather than gain, body weight (Elliott et al. 1971).
1.4.2 Salt and water homeostasis and blood pressure control
Glucocorticoids regulate blood pressure through a variety of actions on kidney and
vasculature. In the kidney, glucocorticoids play a critical role in the maintenance of
normal glomerular filtration rate and renal blood flow. Excess exposure of
glucocorticoids in the kidney causes the nitric oxide-mediated vasodilatation of
afferent and efferent arterioles and results in the increase in glomerular plasma flow
which is responsible for the increase in glomerular filtration rate (De Matteo and
May 1997). In the proximal tubule where GRs not MRs are expressed,
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glucocorticoids do not alter sodium transport directly but enhance the activity of ion
transporters including apical Na+-H+ exchanger (Baum, et al. 1994), basolateral
Na+/K+-adenosine triphosphatase (Na+/K+-ATPase) (Lee, et al. 1995) and NaHCCL
cotransporter (Ruiz, et al. 1995); and they also upregulate angiotensin II receptors in
higher mammals such as dogs and humans (Brem 2001). In the distal tubule and
cortical collecting duct which is a target of aldosterone (Fuller and Young 2005)
enriched with MR (Todd-Turla, et al. 1993), sodium reabsorption can be stimulated
by glucocorticoids. This is mediated through both GRs and MRs (Naray-Fejes-Toth
and Fejes-Toth 1990) although predominantly MRs. Na+ entry across the Na+
channels and the activity ofNa+/K+-ATPase (Laplace, et al. 1992) are increased.
Although MR has 10-fold higher affinity for endogenous glucocorticoids than do
GRs and glucocorticoids are present in 100-fold excess to aldosterone in the
circulation (Edwards, et al. 1988; Naray-Fejes-Toth and Fejes-Toth 1994; Nishi and
Kawata 2007), MRs are protected from glucocorticoids by 11 P-hydroxysteroid
dehydrogenase type 2 (11P-HSD2) which inactivates glucocorticoids (details are in
Section 1.6.1) in this renal segment (Cole 1995; Roland, et al. 1995). When 1 ip-
HSD2 activity is impaired, glucocorticoids induce hypertension because of
inappropriate activation ofMRs (Edwards et al. 1988; Funder, et al. 1988)
Glucocorticoids exert vasoconstrictive effects in vascular smooth muscle (VSM)
mainly via GR mediated processes although MR is also present (Brem 2001).
Glucocorticoids enhance pressor responses to other vasoconstrictive hormones, e.g.
catecholamines and angiotensin II (Sapolsky, et al. 2000). Glucocorticoids have
permissive effects on catecholamine synthesis in vascular and cardiac tissue during
stress, since the rate-limiting enzyme in epinephrine synthesis, phenylethanolamine
N-methyltransferase (PNMT), is induced by glucocorticoids (Kennedy and Ziegler
1991; Wurtman and Axelrod 1966). Glucocorticoids activate the renin-angiotensin-
system by increasing the transcriptional abundance of both angiotensinogen and
angiotensin-converting enzyme, and by upregulating the ATI (angiotensin II
receptor type 1) (Sato, et al. 1994). Moreover, the a-adrenergic and vasopressin
receptors are also increased. Glucocorticoids also modify cation transport to induce
contractile effects in VSM. The expression of calcium-activated potassium channel
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(Kca) in VSM cells, a protein allowing for the potassium efflux from cells causing
hyperpolarization and relaxation, is diminished by glucocorticoids, leading to a net
increase in vascular tone (Brem, et al. 1999; Nelson and Quayle 1995).
Glucocorticoids downregulate the expression ofNa+-Ca+ exchanger (Slc8al) in VSM
9+
cells (Smith and Smith 1994). This decrease reduces exchanger Ca efflux from
cytosol ofVSM cells and potentiates pressor responses to angiotensin II and
vasopressin (O'Donnell and Owen 1994). Furthermore, several vasodilatory proteins
are downregulated by glucocorticoids: Nitric oxide (NO)-mediated endothelial
dilatation is reduced by glucocorticoids by inhibiting the NO synthase (Mitchell and
Webb 2002); guanylate cyclase activity induced by natriuretic, diuretic and
vasorelaxant atrial natriuretic peptide (ANP) in VSM cells is attenuated (Nuglozeh,
et al. 1997; Yasunari, et al. 1990); biosynthesis of vasodilator prostaglandin 12 is
reduced (Falardeau and Martineau 1989).
1.4.3 Anti-inflammatory and immunosuppressive actions
Glucocorticoids have profound anti-inflammatory and immunosuppressive effects
that are mediated at many levels.
At the molecular level, glucocorticoids inhibit effects ofpro-inflammatory
transcription factors NFkB and AP-1 that play crucial roles in increasing the
transcription of several inflammatory proteins including: (i) cytokines such as IL-1J3,
IL-2, IL-3, IL-6, IL-11, TNFa, granulocyte-macrophage colony-stimulating factor
(GM-CSF); (ii) chemokines that attract inflammatory cells to the inflammatory sites,
such as IL-8, RANTES ("Regulated on Activation, Normal T-cell Expressed and
Secreted", also known as CCL5), monocyte chemoattractant protein (MCP)-l, MCP-
3, MCP-4, macrophage inflammatory protein (MlP)-la and eotaxin (Barnes 1998);
(iii) adhesion molecules involved in lymphocyte extravasation and tissue fibrosis
such as endothelial leukocyte adhesion molecule (ECAM)-l and intracellular
adhesion molecule (CAM)-l. The repressive actions of glucocorticoids are exerted
either by GR binding directly to a subunit ofNFkB or AP-1 to block the gene
transcription, or by causing transactivation of IkB, which sequesters NFkB
preventing its translocation into the nucleus, thereby inhibiting gene transcription
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(Auphan, et al. 1995). The production of inflammatory mediators such as
prostaglandins, histamine, nitric oxide, bradykinin, eicosanoids, are also inhibited by
glucocorticoids (Sapolsky et al. 2000; Stewart 2002). In addition, glucocorticoids can
enhance the expression of anti-inflammatory cytokines such as IL-4, IL-10 and
transforming growth factor (TGF)-(3 (Elenkov and Chrousos 2002; Sorrells and
Sapolsky 2007), as well as other anti-inflammatory proteins including annexin-1
(also known as lipocortins-1) and its receptor (Sawmynaden and Perretti 2006), and
IL-1 receptor antagonist.
At the cellular level, glucocorticoids inhibit both innate and adaptive immune
responses. In innate immunity, glucocorticoids induce cell apoptosis in basophils and
eosinophils (Schleimer and Bochner 1994; Yoshimura, et al. 2001). Monocyte
differentiation into macrophages, and macrophage phagocytosis and secretion of pro¬
inflammatory cytokines are suppressed by glucocorticoids (Baybutt and Holsboer
1990). Lymphocyte trafficking and proliferation are inhibited by glucocorticoids
(Milad, et al. 1994; Tait, et al. 2008). Glucocorticoids have both positive and
negative influences on neutrophils: activation functions of neutrophils, including
chemotaxis, adhesion and transmigration, are significantly inhibited (Goulding et al.
1998) whereas glucocorticoids also induce delays in neutrophil apoptosis which
potentially prolong inflammatory responses (Cox 1995; Franchimont 2004). In
adaptive immunity, glucocorticoids inhibit the production of IL-12 from the antigen-
presenting cells (APCs) such as monocyte/macrophages and dendritic cells, resulting
in a change in phenotype mode of response of immune cells from Thl (mediating
cellular immunity and secreting IL-2 and IFN-y) to Th2 (mediating humoral
immunity and secreting anti-inflammatory cytokines IL-4 and IL-10) (Elenkov and
Chrousos 2002; Franchimont 2004). Glucocorticoids cause dendritic cells to
maintain an immature state, which decreases their ability to express
histocompatibility complex (MHC) class II and to present antigens to naive and
memory T cells (Banchereau and Steinman 1998). Glucocorticoids also induce
apoptosis in T-cells, resulting in suppressed inflammation. Moreover, exposure to
glucocorticoids causes involution of the thymus. CD4+CD8+ thymocytes are
exquisitely sensitive to glucocorticoids and even the physiological increases in
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endogenous levels achieved during a stress response can cause apoptosis (Ashwell, et
al. 2000).
1.4.4 Bone and calcium metabolism
Glucocorticoids play an important role in the regulation of bone remodelling. Long-
term systemic exposure of glucocorticoids increases the risk of developing
osteoporosis in adults, and in children leads to growth retardation and delayed
puberty. Fractures are common in vertebral bodies and ribs in patients with continued
glucocorticoid treatment due to bone loss (more so in cancellous and trabecular than
in cortical bone) (Schacke, et al. 2002).
Glucocorticoids regulate bone remodelling in numerous ways. They reduce the
number of bone cells by inducing apoptosis in osteoblasts and osteocytes (Silvestrini,
et al. 2000), and suppress the proliferation of osteoblasts (Schacke et al. 2002).
Transcription of osteocalcin, the main osteoblast-specific non-collageous bone
protein (Ducy, et al. 1996) and a key determinant of bone formation, is inhibited by
glucocorticoids via GR binding to the negative GRE in the promoter region of the
gene (Mancini, et al. 2004; Schoneveld et al. 2004). Glucocorticoids also enhance the
differentiation and activation of osteoclasts, favouring bone resorption (Lacey, et al.
1998). Moreover, glucocorticoids suppress the activity ofmediators of bone
homeostasis including growth hormone, insulin-like growth factor (IGF)-l, and
TGF-(3 (Schacke et al. 2002). Calcium metabolism is also affected by glucocorticoids.
As a consequence of decreased gastrointestinal Ca2+ absorption and an increased
renal Ca2+ excretion, glucocorticoids reduce serum Ca2+ level which, in turn,
stimulates the release of parathyroid hormone, resulting in increased osteoclastic
bone resorption (Lane, et al. 1998).
1.4.5 Skin and muscle
Prolonged topical or even systemic and inhaled use of glucocorticoids induces
atrophy of the skin. The epidermis, dermis and subcutis are affected, resulting in the
irreversible striae rubrae distensae and impaired wound healing. Hypertrichosis in
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women and perioral dermatitis are also common after topical use of glucocorticoid
on the face (Schacke et al. 2002). Glucocorticoids suppress cell proliferation of
keratinocytes and dermal fibroblasts (Perez, et al. 2001), decrease the transcription of
tenascin-C (Fassler, et al. 1996), and reduce the biosynthesis of elastin (Russell, et al.
1995), collagen type I and III (Oikarinen, et al. 1992; Oikarinen, et al. 1998),
hyaluronic acid and sulphated glycosaminoglycans (Sarnstrand, et al. 1982). A
thinner homy layer and decreased synthesis of epidermal lipids account for increased
transepidermal water loss.
In the muscle, as described in Section 1.4.1, glucocorticoids exert catabolic effects
with decreased glucose uptake and protein synthesis and increased protein
degradation. Higher doses and chronic use of glucocorticoid treatment may lead to
myopathy (Schacke et al. 2002). At the transcriptional level, glucocorticoids
transactivate the expression of glutamine synthetase, which catalyzes the formation
of glutamine that is then exported from skeletal muscles (Falduto, et al. 1989; LaPier
1997).
1.4.6 Central nervous system (CNS)
Brain is an important target for glucocorticoids. In rodents, both GRs and MRs are
expressed in discrete brain regions including hippocampus, hypothalamus,
cerebellum, and cortex (Stewart 2002). In humans, glucocorticoids are of great
importance for the control of cognition, memory, arousal, sleep, behaviour and mood
(Fietta 2007). Many psychiatric problems occur in patients with glucocorticoid
excess or deficiency, such as mania, hallucinations, delusions (Schacke et al. 2002),
depression, euphoria, psychosis, apathy, and lethargy (Stewart 2002). Elevated
glucocorticoid levels which occur in patients with severe traumatic stress result in
brain atrophy (McEwen and Magarinos 2001).
Glucocorticoids exert direct effects on the hippocampus via both GRs and MRs that
are highly expressed and co-expressed in single cells in this region (Nishi and
Kawata 2007). Thus the hippocampus is a glucocorticoid-sensitive and vulnerable
region in the brain. Neuronal serotonin (5-HTia) receptor gene transcription is down-
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regulated by glucocorticoids via interaction with GR-MR heterodimers binding to the
negative GRE of the gene in hippocampal CA1 pyramidal cells (Ou, et al. 2001) and
may play a critical role in the development of depression (Schacke et al. 2002).
Hippocampal CA3 region dentate granule neurons respond differently to
glucocorticoids compared with neurons from the CA1 region. Concentrations that
activate GRs in the CA1 neurons hardly affect cell function in the dentate. However,
dentate granule cells require hormone levels to be within the physiological range. In
the absence of glucocorticoids, apoptosis in these cells is dramatically increased
(Joels 2007; Mirescu and Gould 2006).
Glucocorticoids are important in both the formation and extinction ofmemory. Three
of the most important brain areas containing GRs are the hippocampus, amygdala
and frontal lobes which are known to be involved in learning and memory (Lupien et
al. 2007). Elevated glucocorticoid levels partly contribute to impaired memory and
cognitive functions (Schacke et al. 2002). Experiments in rodents suggest that
continuous predominant MR activation accompanied by additional moderate GR
activation by glucocorticoids helps maintain low levels of anxiety and improved
cognition. High MR with high GR activation results in high anxiety and a decline in
cognition. Therefore, a balanced MR:GR activation system appears to be important
for optimum cognitive functions (de Kloet, et al. 2008).
1.5 Dissociated steroids
As stated above, chronic and systemic application of glucocorticoids in treatment of
inflammatory diseases is often accompanied with wide range of side effects, in which
the metabolic consequences of glucocorticoid excess is associated with significantly
increased morbidity and mortality, principally through cardiovascular disease
(Lowenberg et al. 2008; Walker 2007b). Therefore, there is an enormous interest in
developing new GR ligands with limited side effects during therapy, especially the
metabolic side effects.
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The term "dissociated steroids" refers to the pharmaceutical design of new
glucocorticoids with anti-inflammatory efficacy dissociated from undesirable side
effects (Catley 2007; Schacke, et al. 2004). It has been argued that the adverse
metabolic effects of glucocorticoids are mediated through the transactivation
mechanism ofGR whereas anti-inflammatory effects are mainly through
transrepression. Moreover, the transrepressive effects of glucocorticoids alone are
sufficient to mediate the anti-inflammatory effects (Schacke et al. 2002). Previously
a few dissociated steroids have been reported, including RU24858 (Vayssiere et al.
1997) and ZK216348 (Schacke, et al. 2004) that were first shown to have similar
anti-inflammatory effects to conventional steroids but reduced side effects. However,
subsequent studies have then revealed they were not completely dissociated in vivo
(reviewed by Catley 2007). Deflazacort (Calcort - Shire Pharmaceuticals Ltd) is the
dissociated steroid that has reached patients. It is an oxazoline derivative of
prednisolone in clinical trial for 20 years and was licensed in the UK in 1998.
However, additional pharmacologic studies are still required to determine the
appropriate ratio of bioequivalence for the anti-inflammatory potency in humans in
order to compare its potency in respect to side effects including fuel metabolism
(Walker 2000).
1.6 Metabolism of glucocorticoids
The activation ofGR is dependent on ligand concentrations. Circulating
glucocorticoids are principally regulated by secretion of steroid from the adrenal
cortex; but are also influenced by the activity of steroid metabolising enzymes.
Steroid metabolism can involve hormone inactivation (e.g. Cortisol conversion to
cortisone), hormone reactivation (e.g. conversion of cortisone to Cortisol) or the
generation of an active metabolite (e.g. testosterone conversion to 5a-
dihydrotestosterone).
The principal metabolic clearance of glucocorticoids takes place in liver via A-ring
reduction by A-ring reductases, including 5a- and 5P- reductases and 3a-
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hydroxysteroid dehydrogenase (3a-HSD). Glucocorticoids in target cells are also
directly metabolized by locally expressed 11P-hydroxysteroid dehydrogenases (1 ip-
HSDs). The major metabolic processes and metabolites involved in corticosterone
metabolism in rodents are presented in Figure 1.5. Minor metabolic routes involving






















Figure 1.5 Metabolic pathway of corticosterone in rodents. B=corticosterone; DHC
= 11-dehydrocorticosterone; DHB = dihydrocorticosterone; THB =
tetrahydrocorticosterone.
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1.6.1 11p-hydroxysteroid dehydrogenases (1ip-HSDs)
As shown in Figure 1.6, 1 l(3-HSDs, type 1 and type 2, catalyse the inter-conversion
of active glucocorticoids (Cortisol in human and corticosterone in rodents) with their
inert 11-keto derivatives (cortisone in human and 11-dehydrocorticosterone (11-
DHC) in rodents), thereby modifying local glucocorticoid levels in tissue specific
manner. The two enzymes are encoded by two distinct genes. HSD11B1 is located on
chromosome 1 in humans and in mice; and HSD11B2, on chromosome 16 in humans
and on chromosome 8 in mice. Both enzymes are membrane-bound microsomal
enzymes; they are members of short-chain alcohol dehydrogenase superfamily
(Grundy, et al. 1997).
1.6.1.1 11p-HSD2
1 lp-HSD2 is a high affinity (Km = lOnM) nicotinamide adenine dinucleotide
(NAD+)-dependent dehydrogenase which rapidly inactivates glucocorticoids
(Albiston, et al. 1994; Brown, et al. 1996a; Brown, et al. 1996b). 11[3-HSD2 is highly
expressed in mineralocorticoid target tissues, such as distal nephron, sweat glands,
salivary glands and colonic mucosa (Albiston et al. 1994; Edwards et al. 1988;
Funder, et al. 1988). Intracellularly, MR is associated with 11 (1-HSD2 at the
endoplasmic reticulum membrane (Odermatt, et al. 2001). This distribution pattern is
consistent with two critical roles of 11P-HSD2 in glucocorticoid inactivation. First,
11P-HSD2 protects MR from inappropriate glucocorticoid access. In the absence of
11P-HSD2, glucocorticoids activate mineralocorticoid pathways causing sodium and
water retention, hypokalemia and hypertension (Stewart, et al. 1988). These
symptoms are seen in transgenic 11P-HSD2 null mice (11P-HSD2"7") (Kotelevtsev, et
al. 1999), in patients with an inherited impairment of 11P-HSD2 (the syndrome of
apparent mineralocorticoid excess, SAME) (Ulick, et al. 1979), or when patients or
animals are treated with an inhibitor of 11P HSD2 (e.g. licorice which contains
glycyrrhetinic acid) (Stewart, et al. 1987). Secondly, 1 lp-HSD2 prevents
glucocorticoids from binding to GR. This is important in perinatal development
when excess glucocorticoids can cause deleterious effects in tissues like the brain
(Holmes, et al. 2006). 11P-HSD2 also acts as a barrier in the placenta and again
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offers protection of the fetus from high levels of glucocorticoids in the maternal
circulation (Brown et al. 1996a). In utero, exposure to high glucocorticoids
programmes offspring to develop hypertension and hyperglycaemia in adult life
(Lindsay, et al. 1996a; Lindsay, et al. 1996b).
1.6.1.2 11P-HSD1
11P-HSD1 is predominantly a reductase in intact cells and tissues, regenerating
active glucocorticoids from inactive circulating 11-keto derivatives. It has a lower
affinity (Km of 1 OOnM for 11 -ketosteroids) and uses NADPH as a preferred co-
factor (Agarwal, et al. 1989). 1 lp-HSDl has been found in liver, adipose tissue, lung,
skeletal muscle, bone, vascular smooth muscle, anterior pituitary gland, brain (e.g.
PVN of hypothalamus, hippocampus, and cerebral cortex), macrophages and adrenal
cortex in humans (Holmes and Seckl 2006). It is also present in rat but not human
kidneys (Tomlinson, et al. 2004). The levels of 1 lp-HSDl, particularly in the liver,
are high enough to provide a significant source of circulating active glucocorticoid
hormone (Seckl and Walker 2004). 1 lp-HSDl helps maintain homeostatic control of
metabolism and has been implicated in the development of the metabolic syndrome
and cardiovascular disorders. This is exemplified in a number of transgenic modified
animal models. Mice with adipose-selective overexpression of 1 lp-HSDl (aP2-
HSD1 mice) (Masuzaki, et al. 2001) have the metabolic syndrome, i.e. central
obesity, glucose intolerance, insulin resistant-diabetes, hyperlipidemia, hyperphagia
and hypertension (Masuzaki, et al. 2003). Similarly mice with overexpression of
11P-HSD1 restricted to the liver (apoE-HSDl mice) exhibit an attenuated metabolic
syndrome with modest insulin resistance, fatty liver, dyslipidemia and hypertension
with increased expression of hepatic angiotensinogen, but normal glucose tolerance
and body weight (Paterson, et al. 2004). In contrast, 1 lp-HSDl null mice are
protected and resist adverse effects of high fat feeding on glucose intolerance,
visceral adiposity, hyperlipidemia and insulin resistance (Kotelevtsev, et al. 1997;
Morton, et al. 2001; Morton, et al. 2004).
11P-HSD1 is expressed in a number of immune cells including human
myelomonocytic cell line (Gingras and Margolin 2000), T and B lymphocytes in
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mice (Zhang, et al. 2005), and murine and human dendritic cells and macrophages
(Freeman, et al. 2005; Gilmour, et al. 2006; Zhang et al. 2005). The enzyme may
facilitate local production of glucocorticoids as part of the local response in
inflammation. In a mouse model of thioglycollate-induced sterile peritonitis, 11P-
HSD1 activity is rapidly increased in cells isolated from the peritoneal cavity
(Gilmour et al. 2006). These cells also show delayed acquisition of phagocytic
capacity and clearance of apoptotic neutrophils from the peritoneum (Gilmour et al.
2006).
Selective 1 lp-HSDl inhibitors can reduce blood glucose levels in mice with
hyperglycemia (Alberts, et al. 2002). Impaired activity of 1 lp-HSDl has been found
to be neuroprotective (Holmes and Seckl 2006). In aged animals, chronic elevation
of plasma corticosterone results in cognitive impairment and a loss of circadian
periodicity (Landfield, et al. 1981; Landfield, et al. 1978) whereas 1 ip-HSDl-null
mice are protected from age-related cognitive decline (Yau, et al. 2001). In humans,
elderly patients with type 2 diabetes treated with the 1 lp-HSDl inhibitor
carbenoxolone show improved cognitive function (Sandeep, et al. 2004); whereas
subjects in old age with increased Cortisol levels have smaller hippocampus and
memory deficits (Lupien, et al. 1998).
Expression of 11P-HSD1 has been found in human adult bone and normal osteoblast
cells (Cooper, et al. 2000; Eyre, et al. 2001), whereas 1 lp-HSD2 is expressed in
human and rodents osteosarcoma cell lines, but only where 1 lp-HSDl is not present
(Bland, et al. 1999). Expression of 1 lp-HSDl in osteoblast cells affects
glucocorticoid dependent differentiation and bone forming functions (Eijken, et al.
2005; Eijken, et al. 2006). Clinical studies have shown that bone responses to
glucocorticoids were strongly correlated to serum cortisone levels rather than Cortisol
(Pierotti, et al. 2008). Overexpressionof 1 lp-HSDl in an osteosarcoma cell line
results in increased cell differentiation and inhibition of cell proliferation (Rabbitt, et
al. 2002). However, osteoblasts from 1 ip-HSDl-null mice exhibit normal bone mass,
cell growth and differentiation potential (Justesen, et al. 2004). Strikingly, 1 lp-
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HSDl-null mice are completely lacking bone marrow adipocytes, though the
function of these cells is unknown (Justesen et al. 2004).
1.6.2 A-ring reductases
Steroid A-ring reductases include 5a- and 5P- reductases and 3a-HSD (see Figure
1.6). Reactions catalyzed by 5a- and 5P- reductases involve the irreversible trans or
cis reduction of the double bond at position A4'5, yielding trans 5a- and cis 5P~
dihydro glucocorticoids respectively. The 5a- and 5P- reduction is followed promptly
with a further reduction by 3a-HSD to produce 5a- and 5p- tetrahydro metabolites.
This two-step A-ring reduction, introducing four hydrogens, is common to a variety
of other steroid hormones including aldosterone, progesterone, and androgens
(testosterone and androstenedione). The interactions between these pathways,
particularly that of 5a-reduction, and regulation of glucocorticoid action will form
the focus of this thesis.
1.6.2.1 5(3-reductase
5p-Reductase is a member of the aldo-keto reductase (AKR) superfamily and
catalyses the reduction of the A-ring A '5 double bond, yielding cis 5P-dihydro
steroids. Only one form of the enzyme has been cloned and purified in human or rat,
and it is not homologous to the 5a-reductases (Kondo, et al. 1994; Okuda and Okuda
1984). 5P-Reductase is a cytosolic enzyme, utilising NADPH as a co-factor (Okuda
and Okuda 1984). The enzyme is expressed predominantly in liver and much less in
kidney (Gorsline, et al. 1988). In the liver, it plays an important role in bile acid and
steroids metabolism. Human 5P-reductase has equal affinity for Cortisol and bile acid
precursors, and higher affinity for progesterone and androgens than Cortisol (Okuda
and Okuda 1984). Mutations in 5p-reductase results in congenital defects in bile-acid
metabolism (Lemonde, et al. 2003; Palermo, et al. 2008; Shneider, et al. 1994).
5p-Reduction is regarded as a catabolic step in steroid metabolism and 5p*reduced
metabolites are thought to be biologically inactive (Mclnnes, et al. 2004). However,
the 5p-reduced pregnane type steroids have been found to activate the pregnane-X-
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receptor, an orphan nuclear receptor whose endogenous ligands are intermediate
metabolites in the bile acid synthetic pathway, suggesting its role in regulating the
endogenous biosynthesis of bile acids (Goodwin, et al. 2003).
1.6.2.2 3a-Hydroxysteroid dehydrogenases (3a-HSDs)
3a-HSDs are also members of the AKR superfamily; they catalyse the prompt
reduction of the 5a- and 5(3- reduced dihydrosteroids, producing 5a- and 5(3-
tetrahydro derivatives (Penning 1999). They are expressed in cytosolic (soluble) or
microsomal sub-fractions and utilize NADPH as preferred co-factor (Degtiar and
Kushlinsky 2001).
In human, four isozymes have been cloned from four genes, which are AKR1C1
(20a(3a)-HSD), AKR1C2 (3a-HSD type 3), AKR1C3 (3a(17[3)-HSD type 2), and
AKR1C4 (3a-HSD type 1) (Dufort, et al. 1996; Khanna, et al. 1995; Lin, et al. 1997).
They share at least 84% sequence identity (Penning, et al. 2000). In humans the four
isozymes are differentially expressed in different tissues. Liver expresses high equal
levels of all four isozymes, and is the main site ofAKR1C4. Lung expresses high
levels of three isozymes but low levels ofAKR1C4. AKR1C2 and AKR1C3 are
dominant isozymes in prostate and uterus; within the latter all four isozymes are
expressed in low levels. In brain, four isozymes are also present in low levels with
AKR1C1 and AKR1C2 being higher. AKR1C1 is the major isozyme in testes and
AKR1C3 is dominant in mammary gland (Penning, et al. 2000). The 3a-HSD
enzymes are also found in other tissues such as kidney, small intestine and colon (Lin
et al. 1997). However, in the rat, only one isozyme (AKR1C9) has been identified
and cloned (Lin, et al. 1999).
In human liver, AKR1C4 plays an important catabolic role in steroid metabolism
acting as a reductase to protect from circulating steroid excess; for instance, active
5a-DHT is reduced to the inactivated 5a-tetrahydro form (Khanna et al. 1995).
AKR1C2 (type 3 isozyme) is identical to the bile acid binding protein and is
inhibited by bile acids (Hara, et al. 1996; Khanna et al. 1995). In contrast, the
prostate AKR1C2 functions in the reverse direction as an oxidative enzyme, forming
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the active 5a-DHT (Penning, et al. 2000). In the rat liver, the single isozyme
AKR1C9 functions as a reductase to catalyze steroid metabolism and as a bile acid
binding protein (Degtiar and Kushlinsky 2001). It does not catalyze the HSD
activities on 170- or 20a- keto as the human isozymes do, nor does it act as a
dehydrogenase (Penning, et al. 1986).
1.6.2.3 5a-reductases
5a-Reductases are hydrophobic proteins, and are located in the microsomal and
plasma membrane/nuclear fractions of cells (Andersson and Russell 1990). They
catalyze the nicotinamide adenine dinucleotide phosphate (NADP(H))-dependent
reduction of A4'5 double bonds in a number of steroid substrates containing 3-keto at
A4,5 double bonds . Two isozymes, type 1 and type 2 (5aRl and 5aR2, respectively),
have been cloned from different genes, SRD5A1 and SRD5A2. Rat and human
sequences of the two isozymes share 60% and 77% homology in amino acid
sequence respectively (Normington and Russell 1992; Russell and Wilson 1994).
The two isozymes differ in their biochemical properties, tissue distribution, and
affinity to substrates. When examined in vitro, the 5aRl has broad neutral to basic
pH optimum range of 6.0 - 8.5, while the 5aR2 has distinct pH optima that are
narrow and acidic around pH 5.0 (Normington and Russell 1992). 5aR2 has Km
values in nanomolar range for steroid substrates, whereas 5aRl has micromolar
affinities (Normington and Russell 1992). The isozymic proteins are detected in
different tissues, and this distribution is species specific. In humans, both isozymes
are present in liver, adipose tissue and brain (Doering, et al. 2002; Mackenzie, et al.
2008); 5aRl is found in nongenital skin and 5aR2 is mostly present in tissues of
male reproductive system including prostate, epididymis, seminal vesicle and genital
skin. However in rats, 5aRl, but not 5aR2, is found in liver (Normington and Russell
1992). Both isozymes are detected in brain and epididymis; and within the ventral
prostate, 5aRl is found in basal epithelial cells and 5aR2 in stromal cells (Russell
and Wilson 1994; Torres and Ortega 2003). The two isozymes have different affinity
for steroids. In rats 5aRl has 10-20 fold higher affinity for androgens, progesterone,
and corticosterone than 5aR2 (Normington and Russell 1992).
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Different properties of the isozymes result in diverse physiological significance.
5aR2 is essential for development of normal male sexual characteristics in humans as
it is primarily responsible for converting testosterone to 5a-dihydrotestosterone (5a-
DHT), the latter being a more potent androgen than its parent hormone. Mutations in
5aR2 in human results in male pseudohermaphroditism characterized by normal
male internal urogenital tracts but feminised external genitalia in childhood
(Andersson, et al. 1991). This disorder is however species specific as male mice with
deficiency in 5aR2 or in both isozymes have fully formed internal and external
genitalia and are fertile, but have smaller prostates and seminal vesicles than wild
type controls (Mahendroo, et al. 2001). Congenital syndrome of deficiency in 5aRl
has not been reported in humans. Normington and Russell (1992) suggest 5aRl plays
a largely catabolic role in the metabolism of steroid hormones. Some clues to its role
may be inferred from mice with transgenic disruption of the gene. In the female
5aRl knockout mice, two thirds exhibit parturition disturbances (Mahendroo, et al.
1996). This is due to the failure of cervical ripening because of prolonged exposure
to elevated progesterone levels (Mahendroo, et al. 1999). Moreover, approximately
half of embryos die in the type 1-null mice, caused by chronic elevated levels of
plasma estrogen (Mahendroo, et al. 1997) through diversion of testosterone in the
absence of 5aRl. Female mice lacking both isozymes show parturition defects and
fecundity defects similar to those in the mice without 5aRl (Mahendroo et al. 2001).
1.7 5a-Reduction of glucocorticoids in
Metabolic Syndrome
1.7.1 5a-Reduced metabolites of glucocorticoids
It is known that some 5a-reduced metabolites of steroid hormones have biological
activity. While A-ring reduced androgens are recognised as more active than the
parent steroid, 5a-reduced products of other steroids are less active than the parent.
The 5a-reduced metabolites of aldosterone have anti-natriuretic and kaliuretic
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activities of aldosterone that regulate water and electrolyte metabolism in
adrenalectomized rats (Kenyon, et al. 1985; Kenyon, et al. 1983), and have the
capacity to increase blood pressure in adrenalectomized spontaneously hypertensive
rats (SHR) (Gorsline, et al. 1986). In the case of progestogens, 5a-tetrahydro
progesterone acts like a sedative and activates the GABA(A) receptor (gamma-
aminobutyric acid (A) receptor, the brain's major inhibitory neurotransmitter),
decreasing anxiety and reducing seizure activity (Smith, et al. 1998).
Previous work has suggested that 5a-reduced glucocorticoids are biologically active.
5a-Dihydrocortisol (5aDHF) was capable of competing with dexamethasone for
specific cytoplasmic binding sites in hepatoma tissue culture cells (Baxter and
Tomkins 1971). When male rats were administered for seven days with 5a-dihydro
corticosterone (5aDHB) and 5aDHF, hepatic activities of PEPCK and FDPase were
significantly decreased; and the treatment of 5aDHB also decreased blood insulin
(Golf, et al. 1984). However, it has been reported that 5aDHB had very limited
ability to compete with dexamethasone for binding sites on GR and was practically
devoid of glucocorticoid activity (Carlstedt-Duke, et al. 1977). Recent work by
Mclnnes et al. (2004) has also shown that 5aDHB was less effective than 5a-
tetrahydro corticosterone (5aTHB) in displacing dexamethasone from binding sites
in rat hepatocytes and increasing the induction ofMMTV reporter gene in transiently
transfected Hela cells. Moreover, when 5aTHB was administered to
adrenalectomised rats, it was active to transactivate gluconeogenic genes (e.g.
PEPCK and TAT) in vitro, and to suppress the circulating ACTH levels (Mclnnes et
al. 2004). These intriguing findings create interest about the potential effects of 5a-
reduced glucocorticoids on GR activation in tissues where the enzyme is expressed,
and suggest that 5a-reduced metabolites could contribute to the metabolic or anti¬
inflammatory effects of its parent hormone, although the effects of 5a-reduced
metabolites on the immune system have as yet not been reported. If this hypothesis is
true, selective inhibition of 5a-reductase might have a role in reducing endogenous
glucocorticoid action, for example in metabolic syndrome, by removing the
component mediated by 5a-reduced glucocorticoid metabolites.
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1.7.2 5aR1 in Metabolic Syndrome
Research by our group and others has found increased 5a-reduction of
glucocorticoids in obese subjects that correlate with insulin concentrations (Andrew,
et al. 1998; Tomlinson, et al. 2008a). Analogous findings have been observed in
rodents. Transcription and activity of both 5aRl and 5(3-reductase in liver are
increased in obese Zucker rats, with 5aRl being induced to a greater extent. Insulin
sensitization can ameliorate the increase in A-ring reductases in rats (Livingstone, et
al. 2000a; Livingstone, et al. 2005). Furthermore, decreased 5a-reductase activity is
associated with weight loss in obese humans (Tomlinson et al. 2008a; Tomlinson, et
al. 2008b). These findings are consistent with the concept that 5a-reduced
glucocorticoids contribute to GR signalling, e.g. in liver: if increased 5a-reductase
activity increases concentrations of 5a-reduced metabolites and these increase GR
signalling, this could contribute to the metabolic syndrome in obesity. However,
there are several unknowns. Without knowing the relative contribution of 5a-reduced
glucocorticoids and the parent steroid to GR signalling, it is unclear whether the
effects of upregulation are harmful or protective. If 5a-reduced metabolites are fully
biologically active, increased 5a-reductase activity would exacerbate the adverse
effects of glucocorticoids; however, if 5a-reduced metabolites are inactive, or
partially active (as partial agonists), then increased 5a-reductase activity would
reduce GR activation and act as a more conventional clearance mechanism for the
active parent hormone. The concentrations of 5a-reduced metabolites that are
available for GR binding are unknown; these may be rapidly conjugated and excreted.
Against this background, more recent findings in our lab (within the tenure of this
thesis) have demonstrated that 5aRl deficient mice with high-fat diet exhibited
metabolic syndrome characterised by glucose intolerance and fatty liver, suggesting
that inhibition of 5aRl may cause detrimental metabolic side effects, probably by
allowing accumulation of the parent glucocorticoid which then plays the major role
in GR activation (Livingstone, et al. 2008). Similar data with 5aRl inhibitors are not
yet available in humans. The physiological contribution of 5a-reduced glucocorticoid
metabolites therefore needs to be studied further.
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This thesis has focused on the potential pharmacological role for 5a-reduced
glucocorticoid metabolites, and has investigated the effects of 5aTHB compared to
the parent hormone corticosterone.
1.8 Hypothesis and Aims
The hypothesis of this thesis is that 5a-reduced glucocorticoids modify GR action.
The primary aim of this thesis is to investigate the effects of 5aTHB, which will be
addressed as follows:
1. To investigate the effects of 5aTHB on GR translocation in vitro using transiently
transfected green fluorescent protein (GFP)-tagged GR by fluorescent microscopy;
2. To investigate the effects of 5aTHB on transactivation and transrepression of
glucocorticoid regulated genes in vitro-,
3. To investigate the effects of acute or chronic administration of 5aTHB in vivo on
HPA axis, fuel metabolism and immune responses in mice;
4. To investigate the pharmacological effects of 5aTHB in vivo on inflammation
induced by intraperitoneal administration of lipopolysaccharide (LPS);






All chemicals and reagents were purchased from Sigma, Poole, UK unless otherwise
stated. All enzymes for molecular biology were purchased from Promega,
Southampton, UK. All tissue culture media used for cell culture were purchased from
Lonza (previously Cambrex), Verviers, Belgium. All flasks and plates were either
Corning® or Costar®, both purchased from Corning Incorporated, NY, USA. All
radioactively labelled steroids and radioactive isotopes were purchased from
Amersham (now GE Healthcare), Little Chalfont, UK. All HPLC grade solvents
were purchased from Rathburn Chemicals, Walkerburn, UK. All epi-steroids were
from Steraloids, Newport, USA. Sources other than these are indicated in parenthesis.
Room temperature (RT) was 18-20 °C.
2.2 Buffers and Solutions
2.2.1 Preparations for animal experiments
2.2.1.1 Glucose (20% w/v) in saline for intraperitoneal (i.p.) injection
Glucose (1 g) was dissolved in saline (5ml; 0.9% NaCl w/v, B.Braun Melsungen AG,
Germany).
2.2.1.2 Mini-pump loading solutions
Corticosterone or 5aTHB (8.33 mg) were weighed and dissolved in glass vials in a
mixture (2 ml) ofDMSO and propylene glycol (1:1 v/v) and mixed thoroughly by
sonicating for approximately 15 min. The solution was prepared immediately before
use. The loaded mini-pumps were kept at RT.
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2.2.1.3 Lipopolysaccharide (LPS) solutions
LPS (1 g) was dissolved in Dulbecco's phosphate buffered saline (DPBS, 1 ml,
without Mg2+ or Ca2+), mixed thoroughly and stored in -20 °C. This stock LPS
solution was diluted with DPBS to 0.001, 0.01, 0.1, 1 and 10 ng/pl, on the day before
treatment (stored in 4 °C).
2.2.2 Preparations for molecular biology
2.2.2.1 DEPC-treated water
Diethylpyrocarbonate (DEPC; 5 drops) was added to distilled water (500 ml), shaken
gently and allowed to remain at RT for 16-24 hours prior to sterilisation in an
autoclave.
2.2.2.2 EDTA buffer
Ethylene diamine tetraacetic acid (EDTA, 0.5 M) was dissolved in distilled water,
adjusted to pH 8.0 by addition ofNaOH (10 M), sterilised in an autoclave and stored
atRT.
2.2.2.3 10xTBE buffer
Trizma base (108 g), boric acid (55 g) and EDTA buffer (0.5 M, 40 ml, see 2.2.2.2)
were dissolved in distilled water, the pH was adjusted to 8.0 by addition ofNaOH
(10 M), and the volume adjusted to 1 L. The solution was sterilised in an autoclave
and stored at RT.
2.2.2.4 0.5xTBE buffer




Bromophenol blue (0.25% w/v), xylene cyanol (0.25% w/v) and Ficoll® (a nonionic
synthetic polymer of sucrose, 25% w/v) were dissolved in DEPC-treated water and
stored at 4 °C.
2.2.3 Preparations for enzymology
2.2.3.1 Potassium phosphate buffer (0.2 M)
KH2PO4 (27.22 g) was dissolved in distilled water (800 ml). The pH was adjusted to
7.3 by addition ofKOH (10 M), and volume adjusted to 1 L. The buffer was stored at
4 °C.
2.2.3.2 Glucose/Hepes buffer
Hepes (4-(2-Hydroxyethyl)piperazine-l-ethanesulfonic acid, 1.19 g, 5 mM) and
sucrose (85.58 g, 250 mM) were dissolved in distilled water. The pH was adjusted to
7.4 with HC1 (1 M), and volume adjusted to 1 L. The solution was stored at 4 °C.
2.2.3.3 Tyrosine (10 M)
Tyrosine (0.186g) was dissolved in 0.2 M potassium phosphate buffer (150 ml) by
heating at 60-70°C for 1.5 h until the solution became clear.
2.2.3.4 a-Ketoglutarate (0.3 M)
a-Ketoglutarate (0.2216g) was dissolved in 0.2M potassium phosphate buffer (8 ml),
mixed thoroughly and kept on ice immediately prior to use.
2.2.3.5 Pyridoxal phosphate (1.33 M)
Pyridoxal phosphate (0.003g) was dissolved in potassium phosphate buffer (10ml,
see 2.2.3.1), placed on ice and protected from direct light.
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2.2.3.6 NaOH (10 M)
NaOH (40g) was dissolved in distilled water (100ml), allowed to cool and stored at
RT.
2.2.4 Preparations for biochemical assays
2.2.4.1 Borate buffer
Boric acid (8.25 g), NaOH (2.70 g) and HC1 (1 M, 3.5 ml) were dissolved in distilled
water. The pH was adjusted to 7.4 with HC1 (1 M) before bovine serum albumin
(BSA, 5.0 g, Fraction V) was added and dissolved in the solution. The final volume
was adjusted to 1 L. The buffer was stored at -20°C and thawed at RT immediately
before use.
2.2.4.2 Phosphate buffered saline (PBS)
Five PBS tablets were dissolved in distilled water (1 L), yielding phosphate buffer
(0.01 M) containing KC1 (2.7 mM) andNaCl (137 mM), pH 7.4, sterilised in an
autoclave and stored at RT.
2.3 General animal husbandry
2.3.1 Maintenance of animals
Animals were maintained under controlled conditions of light (lights on 07:00-19:00)
and temperature (18-20 °C) and allowed access to standard chow (Special Diet
Services, Witham, UK) and drinking water ad libitum. All experiments were
performed under the project licence (JR Seckl, PPL No: 60/01562) and personal
licence (Yang, PIL No: 60/10364) and under the guidelines of the UK Home Office.
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2.3.2 Mini-osmotic pump implantation
2.3.2.1 Loading of mini-osmotic pumps
Mini-osmotic pumps (Model 2002; Alzet®, Cupertino, US, 0.5 pl/h, 14 days) were
fully loaded (approximately 247 pi) with the steroid solutions (see 2.2.1.2) following
the manufacturer's instructions and kept in a cool and dry place at RT before surgery.
2.3.2.2 Implantation of the mini-osmotic pumps
The surgical procedures were carried out by Dr. Dawn Livingstone, Centre for
Cardiovascular Science, Queen's Medical Research Institute. Animals were injected
subcutaneously with buprenorphine (Alstoe Animal Health, York, UK; 0.05 mg/kg
body weight, 1 in 10 diluted in saline (0.9% w/v, B.Braun Melsungen AG,
Germany)), and anaesthetised with isoflurane (Merial Animal Health Ltd, Essex,
UK). The loaded mini-osmotic pumps were implanted subcutaneously through dorsal
incisions which were then closed with staples. Following surgery, mice were allowed
to recover under observation in a warm box (30 °C) before being transferred to
individual clean cages.
2.4 Specific animal procedures
2.4.1 Systolic blood pressure measurement
Mice were pre-warmed in a hot box (33 °C, 5 min) prior to measurement of systolic
blood pressure using a computerised tail cuff plethysmography system (Evans, et al.
1994). Each mouse was restrained in a darkened perspex tube mounted on a platform
(Harvard Instruments) designed to position the pressure transducer at the base of the
tail. The pressure transducer is a combined computer controlled compression cuff
with photoelectric pulse detector. On inflation, blood flow through the tail was
prevented, and upon deflation the return of blood flow was detected by the
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transducer (Evans et al. 1994). The program software (written in Turbo Pascal v 6.0)
controlled the pressure and detected the pulsation signals, which were amplified and
filtered before being digitised. The blood pressure trace, shown as amplitude on the
screen, was generated. On deflation, a threshold of the minimum amplitude was
estimated by the program to be the value of systolic blood pressure (mmHg). The
final value of pressure was the mean of four successful measurements.
2.4.2 Glucose tolerance test
Food was withdrawn from animals for six hours from 08.00h. Glucose (20% w/v in
saline) was administered by intraperitoneal injection (10 pi per gram body weight) to
give a total dose of 2 g of glucose per kg. Blood was collected via tail nicks before
injection and at 15, 30, 60 and 90 min post-injection. Food was restored immediately
after collection of the last sample. Blood was taken into EDTA microvettes (Sarstedt,
Germany), and plasma was prepared immediately by centrifugation (1000 g, 5 min, 4
°C) then stored at -20 °C for later analysis.
2.4.3 Terminal procedures for animals with glucocorticoid
infusions
Animals were decapitated in the morning of the last day of infusion within 1 min of
disturbing of the home cage. Trunk blood was collected immediately into tubes
containing either heparin (1 unit/ml) or EDTA (0.5 M). Five pads of adipose tissue
(omental, retroperitoneal, epididymal, mesenteric and subcutaneous) and six organs
(thymus, kidneys, left adrenal, liver, spleen and right quadriceps muscle) were
dissected, weighed and snap frozen on dry ice. Two pieces of liver (<100 mg) were
snap frozen, and the remainder was immersed in ice cold glucose/FIepes buffer for
preparation of cytosol. The right adrenal was fixed in formalin (10% v/v). After
fixation for 24 hours, it was weighed following removal of associated fat tissue. An
aliquot of heparinized blood was used for LPS activation. Plasma was collected by
centrifugation (1000 g, 5 min, 4 °C) then frozen (-80 °C) and used to measure
corticosterone, ACTH and 5aTHB concentrations.
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2.4.4 Activation of whole blood by LPS
A series of solutions of LPS were prepared in DPBS (10 pi), containing 0 (DPBS
alone), 0.01, 0.1, 1, 10 and 100 ng of LPS, and added to six 2 ml-round-bottom tubes
respectively. Heparinized aliquots of whole blood collected from each animal were
dispensed into the six tubes (90 pi for each). Then they were gently mixed and
incubated in a shaking water bath (18 h, 37 °C). Supernatant from each tube was
collected after centrifugation (1,000 g, 5 min, 4 °C) and stored at -80 °C until
required for quantification of cytokines.
2.5 Molecular Biology
2.5.1 RNA extraction
2.5.1.1 RNA extraction from tissues and cultured cells
TRIzol® reagent (Invitrogen, Paisley, UK) was used for isolation of total RNAs from
cells and tissues. It contains phenol and guanidine isothiocyanate, which disrupts
cells and dissolves cell components but maintains the integrity ofRNA during
homogenization or lysis.
Freshly collected tissues were snap frozen on dry ice immediately after dissection
from the animal. Each sample was cut into small pieces (50-100 mg) and
homogenized in TRIzol reagent (1 ml) (Model Ultra-Turrax T8 homogenizer, IKA
Labortechnik, Germany). Homogenised samples were used directly or stored at -
80°C until required.
Cells incubated in six-well plates were washed with PBS and then lysed in the
TRIzol® reagent (1 ml per 10 cm2 growth area) by shaking the plates and passing the
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lysate through a pipette. The cell lysate was harvested from each experiment and
stored at -80°C until required.
Tissue homogenates or cell lysates were allowed to equilibrate to RT. After 5min at
RT to allow complete dissociation of the nucleoprotein complexes, chloroform (0.2
ml) was added; samples were vortexed (15 sec) and then incubated at RT for a
further 3 min. The mixture was separated by centrifugation (12,000 g, 15 min, 4 °C,)
into three phases, a lower red, phenol-chloroform phase containing proteins, an
interphase containing DNAs, and a colourless upper aqueous phase containing RNA.
This upper phase was transferred into another Eppendorf tube and RNA was
precipitated by adding isopropanol (500 pi per ml TRIzol®) with incubation (10 min,
RT) following centrifugation (12,000 g, 10 min, 4 °C). The supernatant was removed
and ethanol (75% v/v in DEPC-treated water, 1 ml per ml TRIzol®) was added to the
white RNA pellet. RNA was re-suspended by vortexing and then re-precipitated by
centrifugation (7,500 g, 5 min, 4 °C). The ethanol supernatant was removed and the
RNA pellet was air-dried briefly before being dissolved in DEPC-treated water (40
pi for tissues, 20 pi for cells) by pipetting and incubation (10 min, 60 °C). Samples
were stored at -80 °C until required.
2.5.1.2 RNA extraction from adipose tissue
Extraction ofRNAs from adipose tissue was carried out using RNeasy Lipid Tissue
Mini Kit (Qiagen Ltd, West Sussex, UK), which integrates phenol/guanidine-based
lysis and silica-gel membrane purification of total RNA.
Fresh subcutaneous fat and retroperitoneal fat were snap frozen on dry ice
immediately after removal from mice. Adipose tissue (<100 mg) was homogenized
in QIAzol Lysis Reagent (1 ml), a monophasic solution of phenol and guanidine
thiocyanate. Sample homogenate was either used directly or stored at -80 °C until
required.
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When the homogenate was equilibrated to RT, chloroform (200 pi) was added
following vortexing. The mixture was separated by centrifugation (12,000 g, 15 min,
4 °C) into an upper aqueous phase containing RNA, a white interphase with DNA,
and lower organic phases where protein remained. The aqueous supernatant (600 pi)
was collected into another Eppendorf tube and ethanol (70% v/v in DEPC-treated
water, 600 pi) was added to the aqueous supernatant to provide appropriate binding
conditions. Then the samples were applied to an RNeasy Mini Spin Column where
the total RNA bound to the membrane, while phenol and other contaminants were
eluted by two reagents applied successively (Buffer RW1 and Buffer RPE) by
centrifugation (15 sec, >8000 g, RT). Purified RNA was then dissolved in RNase-
free water (20 pi) by direct addition ofwater to the column membrane, and eluted
into a fresh tube by centrifugation (1 min, >8000 g, RT).
2.5.1.3 RNA extraction from mouse pituitary
RNAs from mouse pituitaries were isolated using the RNeasy Mini Kit (Qiagen Ltd,
West Sussex, UK), which is a technology for purification of total RNA by a silica-
based membrane.
Fresh pituitaries were dissected from animals and snap frozen on dry ice. When
required, each pituitary was ground with a little dry ice (twice the volume of tissue)
in a mortar which was also cooled with dry ice. The pituitary powder was transferred
into an Eppendorf and mixed with the supplied Buffer RLT (350 pi, containing
guanidine thiocyanate) in which the ground tissue was soaked, protecting the RNA.
The mixture was transferred directly into a QIAshredder spin column (Qiagen Ltd,
West Sussex, UK) which was placed in a collection tube then centrifuged (12,000 g,
2 min, RT) to fully disrupt the tissue. The lysate was cleared of very small amounts
of insoluble materials by further centrifugation (12,000 g, 3 min, RT) without the
QIAshredder, and the resultant supernatant was carefully removed and transferred
into a new Eppendorf.
Ethanol (70% v/v in DEPC-treated water, 350 pi) was added to the lysate. The
subsequent processes were the same as described above in 2.5.1.2.
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2.5.2 RNA quantification
RNA (1 pi) was diluted in DEPC-treated water (99 pi) and mixed by brief vortexing
before quantification using a GeneQuant spectrophotometer (Pharmacia Biotech,
Sweden). The RNA concentration was determined by the absorbance at 260nm
wavelength (A260), and the purity by the ratio of RNA/DNA (A260/A280). Low
ionic strength and low pH solutions (such as water) increase the absorbance at 280
nm (Wilfinger, et al. 1997). Therefore, RNA samples with the A260/A280 ratio of
their dilutions between 1.5 and 1.8 were deemed suitable for use.
2.5.3 Reverse transcription
First strand complementary DNA (cDNA) synthesis was performed using the
Reverse Transcription System (Promega). RNA samples were diluted in DEPC-
treated water to 0.1 pg/pl in a final volume of 10 pi. Then the diluted RNA (5 pi) was
incubated with DEPC-treated water (4.5 pi) and master mix (9.5 pi) which contains
the reagents provided as follows:
MgCl2 (25 mM, 4 pi)
Random primers (0.5 pg/pl, 1 pi)
Reverse transcription 10* buffer (2 pi)
PCR nucleotide mix (containing dATP, dCTP, dGTP and dTTP, 10 mM each, 2 pi)
AMV (Avian Myeloblastosis Virus)-reverse transcriptase (22 units/pl, 1 pi)
RNasin (RNase inhibitor, 40 units/pl, 1 pi)
Negative control reactions to confirm the absence of contaminating genomic DNA
were performed in parallel for each RNA sample. These controls were prepared as
above but with DEPC-treated water replacing AMV-reverse. Additionally, a negative
control reaction containing water instead ofRNA was performed to demonstrate that
Reverse Transcriptase System reagents were not contaminated with RNA.
The reverse transcription system for each sample was incubated in a 200 pi
Eppendorf tube in a PCR machine (G-Storm, GRI Lid, Essex, UK). Samples were
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heated at 42 °C for 15 min and 99 °C for 5 min, and then chilled to 4°C. The
resultant cDNA was stored at -20 °C until required.
2.5.4 Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PCR) was carried out using the TaqBead™ Hot Start
Polymerase kit (Promega). cDNA template was first diluted 1 in 5 in the nuclease-
free water provided, and then 5 pi of the dilution was added to each PCR reaction
containing the following reagents:
TaqBead1 M Hot Start Polymerase (1.25 u/bead, 1 bead)
Nuclease-free water (32 pi)
Magnesium-free 10* reaction buffer (5 pi)
MgCl2 (25 mM, 3 pi)
PCR nucleotide mix (containing dATP, dCTP, dGTP and dTTP, 10 mM each, 1 pi)
Primers (forward and reverse, 20 pmol/pl, 2 pi each)
A negative control reaction containing nuclease-free water instead of cDNA was
prepared in parallel to confirm the absence of cDNA contamination in the PCR
reagents.
Thermal cycling was performed using the G-Storm PCR machine with the lid heated
to 100 °C. Samples were heated to 95 °C for 5 min for initial denaturation, then
underwent 35 cycles of PCR amplification, which consisted of denaturation at 95 °C
for 45 sec, primer annealing at 55 °C for 45 sec, and elongation at 72 °C for 1.5 min.
Upon completion of the PCR programme, samples were incubated at 72 °C for a
further 5 min to ensure elongation of products to full length and chilled to 10 °C
prior to gel electrophoresis. The details of primer sequences were listed in Table 2.1.
The PCR products (5 pi) were separated by electrophoresis on an agarose gel (2.0%
w/v in 0.5><TBE buffer). For each gel, the DNA fragments of known fragment sizes
(100 bp (base pair) ladder; Promega), shown on a photo taken under UV light, were
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resolved to identify the bands equivalent in size to those anticipated for the genes of
interest.
2.5.5 Real-time PCR
Quantification of transcript abundance was performed using the LightCycler®480
(Roche Diagnostics, Mannheim, Germany). Sample cDNA was diluted 1 in 32 in
DEPC-treated water, except for those from adipose tissue (1 in 8) and pituitary (1 in
16). Intron-spanning primers and probes for TAT, PEPCK and Agt were designed,
and other primer-probe sets for the genes of interest were purchased from TaqMan®
Gene Expression Assays (AppliedBiosystems, UK) (Table 2.2). All probes had a
FAM reporter dye at the 5' end and a nonfluorescent quencher at the 3' end.
The diluted cDNA sample or standard (2 pi) was added into a 384-well plate before
addition of the freshly prepared master mix (8 pi) which consisted of the following
components:
Primers (forward and reverse, 12 pmol/pl, 0.5 pi each)
The corresponding probe (4 pmol/pl, 0.5 pi)
LightCycler®480 Probes Master (2><conc.) (5 pi, Roche Diagnostics)
Water provided (2.5 pi)
Samples were heated to 95 °C for 5 min for initial denaturation, and underwent 50
cycles of PCR amplification which included denaturation at 95 °C for 10 sec, primer
annealing at 60 °C for 30 sec and elongation at 72 °C for 1 sec. Once these cycles
were completed, samples were cooled to 40°C for 30sec prior to completion. During
the amplification, relative DNA concentrations presented were determined by
plotting fluorescence against cycle number on a logarithmic scale, thus a straight line
was constituted to show the increase ofDNA quantity during the exponential phase
when DNA quantity doubled every cycle.
The LightCycler®480 Software (Version LCS480, Roche Diagnostics) determines
the value of the crossing point (Cp), which represents the cycle at which the rate of
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increase of fluorescence is highest and where the logarithmic phase of a PCR begins,
by calculating the second derivatives of entire amplification curves where the
maximum is determined as Cp (Molenkamp, et al. 2007). The standard curve for
each primer-probe set was generated in triplicate by serial dilution of cDNAs pooled
from different samples representing all groups under study. Individual samples were
analysed in duplicate and the mean was used to calculate the transcript abundance.
The corresponding amounts ofRNA from each sample were determined by
interpolating the results onto the standard curve, and then abundances were divided
by the amount ofRNA from a housekeeping gene, cyclophilin, measured in the same
sample; this process normalized for the variations in the amount and quality ofRNAs
between samples. RT negative controls were used to confirm the absence of
contamination with genomic DNA.
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For CTA CAG GAG CTG CCT TCA AT
122





For AAC ACA GCG AGA GTG TGT CG
160





For ATG GCG CCT ATG TTT ACC AC
500





For AAT TGG TCC GAT CTT GCT TG
408





For AAC AAA AGT GCC CCA GTG TC
646
Rev AGT TTG CCA TCC GGT TAC AG
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Table 2.2 Primers and probes designed for genes (with Accession number) or





For CCG GTC CGC CCT TCT G
Rev TCC GGG AAA TGC TCC ATC T
Mouse
(NMJ46214)
For GCC AGT CCG CCC ATC TG
Rev TCT GGG AAG TGC TCC ATC T





For AGT TGA ATG TGT GGG TGA TGA CA
Rev CTG GGT TGA TGG CCC TTA AG
Mouse
(NM_011044)
For GTC GAA TGT GTG GGC GAT GAC
Rev CTG GGT TGA TAG CCC TTA AG





For CTG GGC AAG ATG GGT GAC A
Rev GGA GTT CAA GGA GGA TGC TGTT
Mouse
(NM_007428)
For CTG AAC AAC ATT GGT GAC ACC
Rev TGA GTT CGA GGA GGA TGC TATT
Probe CCC CCG AGT GGG AGA GGT TCT






CRF Receptor 1 Mm00432670_ml
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2.6 Biochemical assays
2.6.1 Quantification of corticosterone by radioimmunoassay
(RIA)
Borate buffer (pH 7.4) was prepared as previously described (see 2.2.4.1), and
thawed at RT immediately before use. Plasma samples were diluted (10% v/v) in
borate buffer and denatured (30 min, 80 °C) to release corticosterone from its
binding proteins. A series of solutions representing a range of concentrations of
corticosterone was prepared (0, 0.63, 1.25, 2.5, 5, 10, 20, 40, 80, 160 and 320 nM
dissolved in borate buffer) to constitute a standard curve. Samples and standards (20
... 3
pi each) were mixed with 50 pi of tritiated corticosterone (l,2,6,7-[ H]4-B; 80
Ci/mmol, final concentration was 1.5 nM; Amersham, Bucks, UK) plus
corticosterone antibody (final concentration 1:10,000), a kind gift from Dr
Christopher Kenyon, University of Edinburgh (MacPhee, et al. 1989), and then
adjusted up to a total volume of 70 pi on a 96-well plate with the borate buffer. Anti-
rabbit scintillation proximity assay (SPA) beads (50 pi, Amersham, Bucks, UK) were
added to each well, and the plate was allowed to incubate (16-20 h, RT). Scintillation
occurred when the SPA beads bound to that fraction of primary antibody which was
associated with [ H]4-B. Due to the competition between binding of unlabelled and
labelled corticosterone to the primary antibody, the extent of scintillation decreases
as the concentration of unlabelled corticosterone increases. The degree of
scintillation was quantified using a liquid scintillation counter (Microbeta Plus,
Wallac 1450, Turku, Finland), and data (Bound/Bound at zero) used to construct a
semi-log standard curve from which the concentration of corticosterone in each
sample was calculated. Standard curves were acceptable if R>0.99, and data
acceptable if duplicate values differed by less than the coefficient of variation, i.e.
<10%. The detection limit of the assay was 0.6 nM.
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2.6.2 Quantification of glucose by hexokinase assay
Plasma glucose was determined quantitatively using Infinity Glucose Hexokinase
Liquid Stable Reagent (Thermo Electron, Melbourne, Australia). A series of
solutions representing a range of concentrations of glucose (0, 2.8, 5.6, 8.3, 11.1,
13.9, 16.7, 22.2, 33.3 and 44.4 mM in distilled water) was prepared to construct a
standard curve. Standards and samples were incubated with reagent at a ratio of
1:125 in a 96-well plate (3 min, RT) during which time hexokinase catalysed the
phosphorylation of glucose by ATP producing ADP and glucose-6-phosphate. The
latter was then oxidised to 6-phosphogluconate with the associated reduction of
NAD+ to NADH by glucose-6-phosphate dehydrogenase. The amount ofNADH
formed was proportional to the concentration of glucose in the sample and standards.
The absorbance (340 nm) of the reaction product was measured by OPTImax1M
Tunable Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). The
concentrations of glucose in plasma samples were calculated from the standard curve
obtained by plotting the absorbance versus the concentrations of glucose standards.
The Rvalues of the acceptable standard curves were >0.99. Samples were assayed in
duplicate. The intra-assay coefficients of variation were <10%. The limit of detection
of this assay was 0.038 mM.
2.6.3 Quantification of insulin by enzyme-linked
immunosorbent assay (ELISA)
Insulin was quantified using Ultra Sensitive Rat Insulin ELISA Kit (Crystal Chem
Inc., Downers Grove, USA) by means of anti-rat/mouse insulin antibody and
standard rat insulin, which was also suitable for determination ofmouse insulin
concentration. A series of solutions representing a range of rat insulin concentrations
(0, 0.1, 0.2, 0.4, 0.8, 1.6, 3.2 and 6.4 ng/ml in sample diluent provided) was prepared
to construct a standard curve in which supplied sample diluent was used as control.
Samples and standards were diluted (5 pi in 95 pi diluent) and incubated (2 h, 4 °C)
in a 96-well plate coated with guinea pig anti-insulin antibody allowing plasma
insulin to bind to the antibody. Then wells were washed five times with washing
buffer supplied to remove unbound insulin. The immobilized guinea pig anti-insulin
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antibody/insulin complex was then incubated with horse-radish peroxidase (HRP)-
conjugated anti-insulin antibody (100 pi, 30 min, RT). Wells were washed for five
times again to remove excess HRP-conjugate. The bound HRP conjugate on the
microplate well was detected following incubation (40 min, RT) with
tetramethylbenzidine (TMB) substrate solution (100 pi) in the dark. This enzymatic
reaction was stopped by addition of sulphuric acid (0.5 M, 100 pi). Absorbances at
450 nm and 630 nm (measuring absorbance at 450 nm, subtracting absorbance at 630
nm) were measured with an OPTImax™ Tunable Microplate Reader (Molecular
Devices, USA). Insulin concentrations were evaluated against the standard curve
obtained by plotting the resultant absorbance difference versus corresponding
concentrations of insulin standards. The Rvalues of the acceptable standard curves
were >0.99. The minimum detection limit of this assay is O.lng/ml. The intra-assay
precision was <6%.
2.6.4 Quantification of ACTH by ELISA
Mouse plasma ACTH was quantified by an ACTH ELISA kit (Biomerica, Newport
Beach, USA). This is a two-site ELISA for the specific measurement of the
biologically active 39 amino acid chain ofACTH, in contrast to an alternative ACTH
radioimmunoassay (RIA) which is known to react with proopiomelanocortin
(POMC), pro-ACTH, ACTH and some fragments ofACTH.
Plasma samples, controls and a series ofACTH standards representing a range of
concentrations (0, 7.1, 18.5, 70, 215 and 515 pg/ml, 200 pi each), respectively, were
simultaneously incubated with a biotin coupled goat polyclonal antibody to C-
terminal ACTH 34-39 (25 pi) and a HRP labelled mouse monoclonal antibody to N-
terminal ACTH 1-24 (25 pi) in a streptavidin-coated microplate well without
exposure to light on an orbital shaker (170 ± 10 rpm, 4 h ± 30 min, RT). Following
incubation, the complexes of biotinylated antibody - ACTH - HRP conjugated
antibody were bound to the wells.
At the end of the incubation, the wells were washed five times to remove unbound
components and the immobilized complex was incubated with the substrate TMB
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(150 pi) without exposure to light on an orbital shaker (170 ± 10 rpm, 30 ± 5 min,
RT). An acidic stopping solution (sulphuric acid, 0.5 M, 100 pi) was then added,
generating a yellow coloured product. The absorbance (7,450 nm) of the solution in
the wells was measured by OPTImax™ Tunable Microplate Reader (Molecular
Devices, USA) against a blank of distilled water. A calibration curve of resultant
absorbance versus concentration was constructed using results obtained from the
standards. The Rvalues were >0.99 for the standard curves to be accepted.
Concentrations ofACTH present in the samples were determined from the curves.
Samples were assayed in singlicate due to paucity of sample. The minimum detection
limit of this assay is 0.46 pg/ml.
2.6.5 Quantification of NEFAs
NEFAs in plasma samples were quantified by the 96-well Serum/Plasma Fatty Acid
Kit (Zen-Bio, Research Triangle Park, NC, US) based on the following reactions.
NEFAs and CoA were firstly converted to fatty acyl-CoA thiol esters, in the presence
of acyl-CoA synthetase, which subsequently reacted with oxygen in the presence of
acyl-CoA oxidase, producing hydrogen peroxide. Thereafter 3-methyl-N-ethyl-N-(P-
hydroxyethyl) -aniline and 4-aminoantipyrine were oxidized by hydrogen peroxide in
the presence of peroxidase and produced a purple product with an absorbance of 550
nm. The concentrations ofNEFAs in plasma were determined by spectrophotometry.
The kit standard solution was reconstituted and diluted with the Dilution Buffer to
give a range of concentrations (1.4, 4.1, 12.3, 37, 111, 333 and 1000 pM) with
Dilution Buffer as the zero standard. Standards and samples (5 pi) were pipetted into
a 96-well plate with Dilution Buffer (48 pi) followed by FFA Reagent A (50 pi,
reconstituted with FFA Diluent A). The plate was gently shaken and allowed to
incubate (10 min, 37 °C) prior to addition of FFA Reagent B (100 pi) to each well.
Then the plate was shaken gently and incubated again (10 min, 37 °C), and
equilibrated to RT for 5 min before the absorbance was measured by OPTImax™
Tunable Microplate Reader at 540 nm (Molecular Devices, USA). The value of the
zero standard was subtracted from all values including the standards. The results
were then calculated from the standard curve, plotting the corrected absorbance
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versus concentrations of standards. The R values were >0.99 for the standard curves
to be acceptable. Samples were assayed in singlicate due to paucity of sample. The
limit of detection of this kit was 0.68 pM.
2.6.6 Quantification of cytokines by Cytometric Bead Array
The amount of cytokines in biological fluids was determined by flow cytometry, an
analysis tool that discriminates different particles on the basis of size and colour,
using the BD Cytometric Bead Array (CBA) Mouse Inflammation Kit (BD
Biosciences, Oxford, UK).
The CBA kit applied six different microparticles (7.5 pm polystyrene beads) that
were dyed to give discrete fluorescence signals which could be amplified and
detected by the FL3 detection channel of a flow cytometer (BD FACSArray™
BioAnalyzer, BD Biosciences Immunocytometry Systems, San Jose, CA). The six
beads in the Mouse Inflammation Kit were coated with capture antibodies specific
for IL-6, IL-10, MCP-1, IFN-y, TNFa and IL-12p70 proteins. The fluorescence
intensity characteristics of each type of bead were distributed from brightest to
dimmest in this order. Each antibody-bound bead captured a given cytokine which
could be detected as a discrete population with unique FL3 intensity that could be
distinguished in a mixture of beads with different antibodies. The specifically
captured cytokines were detected via a direct immunoassay using six specific
detection antibodies conjugated with phycoerythrin (PE), providing a fluorescent
signal that could be detected by the FL2 detection channel (Figure 2.1). This signal
was proportional to the concentrations of the cytokines in the test matrix. Therefore
the concentrations of the six analytes in a single sample could be determined.
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Figure 2.1 A schematic of the "cytokine sandwich" in a CBA assay. Beads of
different fluorescence intensity, coated with specific cytokine antibodies and detector
cytokine antibodies coupled to phycoerythrin (PE), were incubated with sample or
standards and analyzed by flow cytometry.
One pre-mixed vial of lyophilized standards containing the six recombinant proteins
was reconstituted in the Assay Diluent provided (0.2 ml) and equilibrated for 15 min
before dilutions to achieve a series of solutions containing 20, 40, 80, 156, 312.5,
625, 1250, 2500 and 5000 pg/ml of protein respectively with the Assay Diluent used
as a blank. The appropriate amount of Capture Beads were pooled together and
mixed by vortexing before adding to all the assay wells (25 pi per well) in a 96-well
plate. The dilutions of standards (25 pi) were added to the control assay wells and the
test samples (25 pi) to the test assay wells. The PE Detection Reagent (25 pi)
provided, containing six specific antibodies, was added to all wells prior to
incubation of the plate (2 hours, RT, without light) in order to form sandwich
complexes. After incubation, Wash Buffer (120 pi per well) was added before
centrifugation (330 g, 5 min, RT). Thereafter the supernatant was discarded by
inversion and the plate dried carefully on paper tissues. The bead pellets were
resuspended in Wash Buffer (120 pi) before analysis on BD FACSArray™
Bioanalyzer.
Data were acquired and analyzed using BD CBA Analysis software. The parameters
FSC (forward light scatter) and SSC (side light scatter) were employed to exclude
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any sample particles other than the 7.5pm polystyrene beads. Using a BD
FACSArray flow cytometer, the Yellow detection channel (FL2, 564-606 nm,
measuring fluorescence following excitation by 532nm laser) was used to measure
the PE-labeled reporter reagent, and bead populations were identified from the
emissions in the Red (FL3, 653-669 nm, measuring fluorescence excited by 635 nm
laser) and Far Red (>685 nm, measuring fluorescence excited by 532 nm laser)
detector channels. The fluorescence intensity data from each bead in each of the two
detector channels were plotted in a two-dimensional dot-plot (FL2 vs FL3) by the
BD CellQuest™ Analysis Software, such that the six discrete FL3 microparticle dye
intensities were distributed along the Y-axis.
The results were calculated by interpolation onto the six standard curves, plotting
cytokine concentrations of standards versus the mean fluorescence intensity (MFI) of
FL2 using a four-parameter logistic curve fitting model. Standard curves were
accepted if the R values were >0.99. The assay sensitivity of IL-6, IL-10, MCP-1,
TNFa, (IFN)-y and IL-12p70 were 5, 17.5, 52.7, 7.3, 2.5 and 10.7pg/ml, respectively.
The samples were assayed in singlicate due to paucity of sample.
2.7 Statistics
Data were analysed statistically by one-way or two-way ANOVA, or repeated
measures ANOVA, followed by Holm-Sidak post-hoc test where appropriate. The




Investigation of the effects of




Glucocorticoids exert many of their numerous actions via GRs. GRs are ligand-
activated transcription factors which regulate gene transcription, either through
transactivation or transrepression. Previous work has suggested that 5a-reduced
glucocorticoids may mimic their parent steroid at GR and hence may play a role in
the magnitude of activation of the receptor (Baxter and Tomkins 1971; Dubrovsky et
al. 1987; Golf et al. 1984; Mclnnes et al. 2004). This may be of importance in
disorders where expression of 5a-reductases are altered e.g. obesity (Andrew et al.
1998; Livingstone et al. 2000; Livingstone et al. 2005). However, the molecular
mechanisms underlying the effects of 5a-reduced metabolites have not been clearly
elucidated, although Mclnnes et al suggested that the time course of effects may
differ from that of corticosterone. Therefore in this chapter the intracellular responses
to 5aTHB will be investigated.
Without ligand binding, GRs stay in cytoplasm, associated with the heat shock
protein based chaperone machinery. Upon ligand binding, the nuclear localization
signals (NLSs) are exposed which enable GRs to translocate into the nucleus (Smoak
and Cidlowski 2004). It has previously been reported that 5aTHB, the 5a-reduced
tetrahydro metabolite of corticosterone, is effective in displacing dexamethasone
from binding sites in hepatocytes and increasing the transcription ofMMTV reporter
gene in transfected Hela cells as well as hepatic PEPCK and TAT in hepatoma cells
in vitro (Mclnnes et al. 2004). However, the ability and efficiency of 5aTHB in
driving GR translocation have not been studied specifically. This chapter will
investigate the effects of 5aTHB on this process by utilising fluorescent microscopy
to monitor the movement of green fluorescent protein (GFP) -tagged GR (GFP-GR)
in living cells, and further detect the mobility of GFP-GR post-translocation by
means of fluorescence recovery after photobleaching (FRAP).
Following GR translocation, activated GRs regulate gene transcription via
transactivation or transrepression mechanisms. Glucocorticoid induced
transactivation can be mediated by GR homodimer binding to palindromic GRE in
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the promoter or enhancer regions of target genes or by non-palindromic dimer
binding to GRE half sites. (Schoneveld et al. 2004). Mclnnes et al. demonstrated that
5aTHB activated the induction ofmRNA expression ofTAT and PEPCK
(palindromic GRE) in H4IIE hepatoma cells, which was inhibited by GR antagonist,
RU486 (Mclnnes et al. 2004). Moreover, 5aTHB increased the expression ofMMTV
reporter gene (GRE half sites) in transiently transfected Hela cells (Mclnnes et al.
2004), and the effect was additive to that of corticosterone (Mclnnes et al. 2004).
This chapter will further investigate the time course and dose response to 5aTHB in
transactivation of glucocorticoid target genes in H4IIE cells. Furthermore, the effects
of 5aTHB on gene transactivation via different GR binding mechanisms (binding to
GRE or GRE 1/2s) will also be investigated and compared in transiently transfected
Hela cells.
Glucocorticoids induce transrepressive actions by direct or indirect interaction ofGR
with target genes. It has been demonstrated in rats that plasma ACTH was
suppressed following intraperitoneal administration of 5aTHB (Mclnnes et al. 2004).
This suppression ofACTH was possibly a transrepressive effect of 5aTHB on
mRNA expression of POMC, regulated via GR binding to the negative GRE (Drouin,
et al. 1993a). Therefore, in this chapter the effects of 5aTHB on POMC transcription
will be investigated in AtT20 cells, the mouse pituitary corticotroph tumor cell line.
Lastly glucocorticoids have profound anti-inflammatory and immunosuppressive
effects, one ofwhich is to alter the secretion of a variety of cytokines, increasing
anti-inflammatory cytokines such as IL-10 and suppressing pro-inflammatory
cytokines including TNFa, IL-6 and MCP-1 (Schoneveld et al. 2004). These actions
are mediated via GR-protein binding mechanisms. GR binds to the subunits of pro¬
inflammatory transcription factors NFkB and AP-1, thereby inhibiting the gene
transcription of pro-inflammatory cytokines. GR has also been shown to bind
directly to the transcription factor STAT3 to activate the expression of anti¬
inflammatory cytokines (Unterberger et al. 2008). The ability of 5aTHB to initiate
these responses has not been previously studied and the work presented here will
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investigate the ability and efficiency of 5aTHB to affect cytokine secretion in bone
marrow derived macrophages.
Aims
The aims of this chapter were to investigate the effects of 5aTHB on




3.2 Methods and materials
3.2.1 Maintenance of cell lines
3.2.1.1 H4IIE (rat hepatoma cells)
H4IIE cells were cultured in 75 cm2 flasks in normal-serum medium, which was
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) heat-
inactivated foetal bovine serum (FBS), penicillin (100 IU/ml), streptomycin (100
pg/ml) and L-glutamine (200 mM). Serum-free medium was also prepared with the
same components omitting the FBS. Cells were incubated in a humidified
atmosphere in 95% air and 5% CO2 at 37 °C.
Cells were routinely passaged when confluent, usually twice a week. For
subculturing, cells were washed with serum-free medium (7 ml) and trypsin/EDTA
(trypsin (0.05% w/v) and EDTA (0.01% w/v); 2 ml), and then cells incubated with
trypsin/EDTA (2 ml, 1-2 min, 37 °C). The flasks were shaken until cells were
released from the flask surface. Cells were resuspended in normal-serum medium (10
ml). 1/10 to 1/4 of cells were left for maintenance in the flasks, and the rest were
aspirated or transferred to other containers. The normal-serum medium (12 ml final
volume) was added to the flasks before cells were incubated in the conditions
described above, unless otherwise stated.
3.2.1.2 HEK293 (human embryonic kidney cells)
HEK293 cells were cultured and passaged under the same conditions as those
described for H4IIE cells (see 3.2.1.1) except for the nature of the growth surface.
The culture flasks were coated with poly-d-lysine before use (see 3.2.1.6).
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3.2.1.3 AtT20 (mouse pituitary corticotroph tumor cells) and Hela
(human cervical carcinoma cells)
AtT20 cells were cultured in 162 cm2 flasks under the same conditions as those
described for H4IIE cells (see 3.2.1.1). The volume ofmedia and trypsin/EDTA was
increased by a factor of 2 for washing, passaging and maintenance. Cells were
passaged every five days and diluted 1 in 5 in normal-serum medium.
3.2.1.4 Preparation for stripped-serum medium
Heat-inactivated FBS (500 ml) was mixed with dextran-coated charcoal (5 g) and
stirred for 16-24 hours at 4 °C. The serum was filtered using 5 pm and 0.45 pm
filters (Sartorius, Germany) successively and sterilized by filtration (0.20 pm filter
(Nalgenec, Nalge Nunc International, NY, USA)). The filtered serum was dispensed
into 50 ml aliquots and stored at -20 °C. The stripped-serum medium was prepared
with the same components as the normal culture medium (see 3.2.2.1) with the
normal FBS replaced by the stripped-serum, to avoid interference from background
concentrations of glucocorticoids found in FBS.
3.2.1.5 Quantification of cells by haemocytometry
The haemocytometer was prepared by breathing on the slide and gently pushing the
edges of the coverslip on either side of the chamber until the coverslip was firmly
attached to the chamber where Newton's rings appeared. Cell suspension was added
to both sides of the chamber (10 pi to each). Cells were counted in the four corner
quadrants of each side of the chamber along two of the four edges. For each side, the
total number was divided by four, and the average of both sides equated to the
number of cells per mm2. This value was multiplied by 104 to give the number of
cells per ml of the cell suspension. The appropriate number of cells was added
accordingly to the size of the multiple-well plates.
3.2.1.6 Preparation of poly-d-lysine coated flasks and plates
Poly-d-lysine (BD Biosciences, Bedford, MA, USA; MW (molecular weight)
500,000 - 550,000 daltons) is a synthetic molecule used as a thin coating to enhance
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the attachment of cells to plastic and glass surfaces. Diluted poly-d-lysine in DPBS
was added to flasks or 6-well plates (5.0 pg per cm2 of growth surface) and allowed
to incubate (lh, RT). The remaining solution was aspirated before washing the flasks
or plate wells with DPBS following aspiration. They were either ready to use or air
dried (RT) with sterility maintained.
3.2.1.7 Preparation of steroid treatments
Corticosterone, 5aTHB or dexamethasone was dissolved separately in ethanol to
make a stock (1 M). Solutions were stored in -20 °C. A series of dilutions of each
steroid were prepared with ethanol.
3.2.2 Quantification of GFP-GR translocation in HEK293 cells
3.2.2.1 Transient transfection of GRs in HEK293 cells
HEK293 cells (see 3.2.2.2) were transiently transfected with plasmid DNAs of
pGEM (Promega, Madison, US), pEGFP-Nl or pGFP-rGR (Prima, et al. 2000).
pGEM (inert DNA, Promega) was transfected as a mock transfection which would
not induce fluorescence in cells, and additionally to confirm the absence of
fluorescent contamination formed from any reagent. pEGFP-Nl (N stands for N
terminus, meaning that it is designed to fuse proteins to the N terminus of EGFP)
transfection was used as positive control which would confirm the success of
transfection and induce fluorescence in the whole cell including cytoplasm and
nucleus, regardless of the position ofGRs. All the plasmids were prepared from two
batches to avoid false results caused by mutations during bacterial cloning.
The day before transfection, HEK293 cells were plated at a density of 2-3x103 cells
per well in poly-d-lysine coated (see 3.2.1.6) six-well plates and incubated in the
atmosphere of 95% air and 5% CO2 at 37 °C overnight in normal-serum medium (2
ml per well). On the day of transfection when they were 80-90% confluent, cells
were washed and cultured in antibiotic-free medium (2 ml per well) with stripped-
serum for one hour prior to transfection.
69
For each well to be transfected, FuGENE HD transfection reagent (5 pi, Roche
Applied Science, Indianapolis, IN, USA) was incubated (5 min, RT) in reduced-
serum medium Opti-MEM (100 pL, GIBCO, Parsley, UK) in a microtube. Then the
plasmid DNA, pGEM, pGFP-GR or pEGFP-N 1 (2 pg each) was added respectively
to the FuGENE/Opti-MEM mixture prior to incubation (15 min, RT). The entire
volume ofmixture was added to the corresponding wells, and then the cells were
incubated under the same conditions as described above.
3.2.2.2 Observation and quantification of GFP-GR translocation in
transiently transfected HEK293 cells
Twenty-four hours after transfection, HEK293 cells were first checked using
fluorescent microscopy (Model: Axiovert 25, Carl Zeiss, Germany; objective, Zeiss
LD Achrostigmat 40x/0.50 Ph2 Var2; ocular lens, E-Pl 10x/20) which was
connected to a camera and a computer with the imaging programme MCID Basic 7.0
(Imaging Research Inc., Canada). Photos were taken prior to steroid treatment if
transfection efficiency met requirements, i.e. fluorescence in the cells was bright
enough to be visible and cells were not initially contaminated with steroid (this was
noted as nuclear translocation without addition of steroid). Cells were then incubated
with glucocorticoid or vehicle (ethanol only, 0.1-0.2% volume ofmedium). Three
fields were chosen randomly per well and photos were taken at chosen time points.
Cells were counted afterwards from the archived photographs.
All the fluorescent cells in the photographs were counted and recorded in a semi¬
quantitative manner (Galigniana, et al. 1998). Cells where the fluorescence in the
nucleus was distinctly stronger than in the cytoplasm were recorded as nuclear-
translocated cells. Where the fluorescence was equally strong in nucleus and
cytoplasm, they were not included in the count of nuclear-translocated cells. The
percentage of nuclear-translocated cells was consequently calculated. The
experiments were performed in triplicate.
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3.2.2.3 Time course study of GR translocation
HEK293 cells which had been successfully transfected with GFP-GR were incubated
with 5aTHB, corticosterone, dexamethasone (1 pM each) or vehicle (ethanol, 2 pi).
Photographs of fluorescent cells were taken at 15 min, 30 min, 2 h, 5 h and 24 h.
3.2.2.4 GR nuclear export
HEK293 cells were transfected with GFP-GR and first incubated with medium
containing 5aTElB, corticosterone, dexamethasone (1 pM each) or vehicle (ethanol,
2 pi) for 24 hours. Then the culture medium containing the steroid treatment was
aspirated, and cells were washed twice and replaced with fresh steroid-free medium.
Photographs of fluorescent cells were taken at 30 min, 2 h, 5 h and 24 h after
washing.
3.2.2.5 Dose response to corticosterone
GFP-GR transfected HEK293 cells were incubated with increasing concentrations of
corticosterone (3, 10, 30, 100 nM), and photographs were taken at 15 min, 30 min, 2
h, 5 h and 24 h.
3.2.2.6 Co-incubation with corticosterone and 5aTHB
HEK293 cells transfected with GFP-GR were incubated with varying amounts of
corticosterone (0.3, 1 or 3 nM) plus a higher concentration of 5aTHB (100, 300 nM
or 1 pM). Cells were observed and photographs taken at 45min post transfection.
3.2.3 Fluorescence recovery after photobleaching (FRAP)
FRAP analysis allows measuring the mobility of the fluorescence-labelled proteins
(e.g. GFP-GR) by confocol microscopy. In FRAP, a small area of living cell is
beached, without damage to the protein, by a short laser pulse, and the fluorescence
intensity in the bleached and nonbleached areas before and after bleaching is
measured using time-lapse microscopy. Following the bleach, the fluorescence in the
bleached area recovers immediately as a result of fast exchange of GFP-GR between
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bleached and nonbleached areas. Subsequently, the fluorescence in the two areas
becomes completely balanced. The recovery kinetics ofGFP-GR is dependent on
their mobility; immobile proteins show no recovery (Phair and Misteli 2001).
HEK293 cells were seeded and transfected in a 35 mm dish with a glass bottom (10
mm diameter) in the centre of the culture area (MatTek Corporation, MA, USA) in
order to produce high-resolution microscopic images. Cells were incubated with
5aTHB or corticosterone (1 pM each) for 24 hours before FRAP analysis was
performed while the dish was maintained warm on a hot plate (37 °C) stacked on top
of the observation platform. Cells were observed by a Zeiss LSM 510 (Axiovert
100M) confocal laser scanning microscope, using a Plan-Neofluar 40* oil immersion
objective (1.3 numeric aperture).
Cells were excited with an argon laser at 488 nm, and emission was collected using a
505 nm long-pass filter through a pinhole of 66 pm. Images were taken every 500 ms
at a resolution of 512 by 512 pixels (45.0 by 45.0 pm). After the first image, a
selected rectangular region of fixed size (90 by 15 pixels) in the nucleus was
bleached at a set laser power ofmaximal 15.0 mW. Fluorescence intensity in either
bleached or unbleached region in the nucleus was quantified at every 500 ms using
LSM software. In each experiment, two dishes, including 20 cells in total, were
analyzed per treatment.
The FRAP data curve was created from the data of fluorescence intensity. To correct
for differences in expression level between individual cells, fluorescence data for the
bleached region and unbleached region in the nucleus were normalized to the level
before bleaching. In addition, at all time points data were normalized to the
fluorescence in unbleached region in the nucleus in order to correct for the loss in
fluorescence due to the bleach pulse and the imaging. Thus, in mathematical terms
FRAP curves were created using the following equation:
Ft = (N0 • Bt) / (Nt • B0)
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Where Ft is the normalized fluorescence at time point t; No and Nt are the
fluorescence in the non-bleached region in the nucleus at time points 0 and t,
respectively, and Bo and Bt are the fluorescence in the bleached region at time points
0 and t.
Subsequently, the normalized FRAP curve was plotted as a non-linear regression
model using GraphPad Prism 4, described by the equation:
Ft= Fmax x (1 - e ~kt)
The half life (ti/2) ofmaximal recovery was determined, which is defined as the time
point after bleaching at which the normalized fluorescence has increased to half the
amount of the maximal recovery.
ti/2 = In 0.5 / (- k) = 0.69 / k
3.2.4 Quantification of transcription by reporter assays
3.2.4.1 Transient transfection in Hela cells
Hela cells were transiently transfected with plasmids encoding rat GR and a reporter
gene, MMTV-LTR-luciferase (Lefebvre, et al. 1991) or rPNMT-998/-466-luciferase
(Adams, et al. 2003). The process of transfection was the same as described for
HEK293 cells (see 3.2.2.1) except that: 1) Hela cells were seeded in non-coated six-
well plates; 2) the volume ofFuGENE HD transfection reagent used for Hela cells
was 4pl; 3) the total amounts of plasmid DNAs transfected were 2.2 pg per
transfection.
The components of each transfection were shown in Table 3.1. The transfection of
pGEM (inert DNA) was the negative control; and pGL3-basic (Promega) was an
empty vector control which was a luciferase reporter vector without promoter or
enhancer. Simian virus (SV) 2-luc was a luciferase expression vector not requiring
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induction by glucocorticoids, used as positive control (de Wet, et al. 1987) to
confirm the success of each batch of transfection. When the luciferase activity of
cells transfected with pSV2 was 500 times higher than that of pGL3-basic, the
transfection was deemed successful. The plasmid DNA of pVL342 was designed to
be representative as either rat or mouse GR; KC275 was a reporter gene of P-
galactosidase used as internal control to normalize for transfection efficiency. These
latter two plasmids were kind gifts from Karen Chapman (Centre for Cardiovascular
Science, Queen's Medical Research Institute, the University ofEdinburgh, UK).
Each transfection was performed in triplicate, and the experiment was carried out in
six replicates, on separate days assaying with two batches of plasmids.
Table 3.1 Components of each transfection.
Transfection
DNAfogT^
pGEM pSV2 pGL3 MMTV-LTR PNMT
pGEM 2.2 0.2 0.2 — —
pSV2-luc -- 1 — — --
pGL3-basic -- — 1 — —
MMTV-LTR-luc -- — — 1 —
rPNMT-998/-466-luc — — — — 1
pVL342 — — — 0.2 0.2
KC275 — 1 1 1 1
3.2.4.2 Glucocorticoid treatment
One hour after transfection, cells were incubated for 48 h with corticosterone,
5aTHB (1 pM each) or vehicle (ethanol, 0.1% v/v) before being assayed for
luciferase and p-galactosidase activity.
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3.2.4.3 Luciferase assay
The luciferase activity of the samples from the transient transfection experiment was
assayed by a Luciferase Assay System (Promega, UK).
3.2.4.3.1 Preparation of cell lysates
The 5x lysis buffer provided, containing Bicine buffer and Tween detergents, was
diluted to 1 xbuffer in distilled water and equilibrated to RT before use. The growth
medium from cells was removed, and then cells were rinsed carefully with PBS
which was aspirated as much as possible after washing. The diluted lysis buffer (100
pi per well) was added and the culture plates rocked to ensure complete coverage of
the cells with lysis buffer. The cells were then scraped from wells and transferred to
an Eppendorf tube prior to centrifugation (12,000 g, 2 min, RT) to precipitate any
remaining undissolved cell lysate. The transparent supernatant was used in
subsequent assays of luciferase and P-galactosidase.
3.2.4.3.2 Luciferase assay
The reconstituted Luciferase Assay Reagent was prepared by adding the Luciferase
Assay Buffer provided to the lyophilized Luciferase Assay Substrate (luciferin). The
cell lysate (20 pi per well) was transferred to a 96-well plate (Nunclon Surface,
Denmark). The plate was placed into a Microplate Luminometer (Orion II, Berthold
Detection Systems GmbH, Germany), in which the Luciferase Assay Reagent (100
pi) was injected to each well. The reaction between the substrate luciferin and
2"bcosubstrate ATP Mg was catalyzed by the firefly luciferase produced within the
cells, forming the product of oxyluciferin. During the oxidation of luciferin, light was
produced by converting the chemical energy derived from an electron transition. The
luminescence from each well was read with a 2.05 sec delay after injection, and each
measurement lasted for 10 sec. The values of luminescence were calculated by a
computer programme, Simplicity 4.1 (Berthold Detection Systems, Germany). The
light intensity was proportional to luciferin concentrations in the range of 10"20 to 10"
30




P-Galactosidase was used in conjunction with luciferase reporter genes to normalize
for transfection efficiency. The activity of the P-galactosidase was determined by a
chemiluminescent assay using Galacto-Light Plus (Applied Biosystems, UK) which
provides the chemiluminescent substrate for P-galactosidase.
When the cell lysates were ready and the reagents provided had been equilibrated
(RT), Galacton-Plus substrate diluent (67 pi, 1% v/v in the Reaction Buffer Diluent)
was added to a 96-well plate (Nunclon Surface). The cell lysate (10 pi) was added,
and the plate was allowed to incubate (15-60 min, RT) prior to measurement of the
luminescence using the Orion II Microplate Luminometer, by which the Light
Emission Accelerator (105 pi, light emission triggering solution with luminescence
enhancer) was injected into each well. The luminescence was read immediately after
injection, and each measurement lasted for 5 sec. Luminescence values were
calculated by the programme, Simplicity 4.1 (Berthold Detection Systems). Assays
were performed in singlicate.
3.2.4.5 Data analysis
Data for the transient transfection study were analysed using the raw data of
luminescent intensity of luciferase assay and P-galactosidase assay. The values of the
luciferase activity and P-galactosidase activity were the mean of triplicates of the
experimental values, followed by subtraction of the corresponding mean values of
the background that were produced by transfections with pGEM only. The resultant
luciferase activity was normalized against the associated P-galactosidase activity.
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3.2.5 Investigation of transactivation effects of 5aTHB in
H4IIE cells
3.2.5.1 Time Course of transactivation of GR responsive genes in H4IIE
cells incubated in culture medium with stripped serum
H4IIE cells were incubated in six-well plates with the presence of 5aTHB,
corticosterone (1 pM each) or vehicle (ethanol, 2 pi) for 0, 1, 2, 4, 8, 16 and 24 h.
The incubation was performed in the medium (2ml per well) with stripped serum.
Total RNAs were extracted (see 2.5.1.1) and the transcript abundance of
glucocorticoid responsive genes TAT and PEPCK were quantified by real-time PCR
(see 2.5.5). Their transcript abundances were normalized to that of cyclophilin.
3.2.5.2 Time course of transactivation of GR responsive genes in H4IIE
cells incubated in normal-serum medium
H4IIE cells were incubated in normal culture medium (2 ml per well) with the
addition of the same glucocorticoid or vehicle treatment and processed as above (see
3.2.5.1) for 0, 2, 4, 8, 16 and 24h.
3.2.5.3 Dose response of induction of GR responsive genes in H4IIE
cells incubated in normal-serum medium
H4IIE cells were incubated in normal-serum medium (2 ml per well) with varying
concentrations (3, 10, 30, 100, 300, lOOOnM) of 5aTHB or corticosterone or with
vehicle (ethanol, 2 pi) for 16 h. The transcript abundance of TAT mRNA was
quantified as above (see 3.2.5.1).
3.2.6 Investigation of the transrepression of GR responsive
genes by 5aTHB in AtT20 cells
AtT20 cells are a mouse corticotroph pituitary tumor cell line, which expresses
POMC, the precursor to ACTH and endorphins, before they are secreted. In these
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cells, processing of POMC is suppressed by glucocorticoids (Ooi, et al. 2004), and
the secretion ofACTH may be stimulated by CRH (Aoki, et al. 1997).
The cells were seeded in six-well plates with normal medium (2 ml per well) two
days before the glucocorticoid treatment. Then the medium was removed and
replaced with the stripped-serum medium (2 ml per well). One hour later, cells were
given one of eight treatments, which were 5aTHB, corticosterone, dexamethasone (1
pM each) or vehicle (ethanol, 0.01%) alone and the same treatments with CRH (100
nM). Cells were incubated for 48 h and performed in triplicate. Thereafter the
transcript abundance ofPOMC and CRH receptor 1 was quantified by real-time PCR
(see 2.5.5). The experiment was replicated six times.
3.2.7 Effects of 5aTHB on cytokine release by transactivation
and transrepression mechanisms in bone marrow derived
macrophages (BMDM0s)
3.2.7.1 Bone marrow preparation and macrophage culture
C57BL/6 mice (25 g, 8 weeks old) were acclimatised to housing as described in 2.3.1
for one week before being euthanized by CO2. Femurs with half hipbone and half
tibiae attached were removed and immersed in Hank's balanced salt solution (Lonza).
The following procedures were performed inside a Class II biosafety cabinet. The
femur was separated from the attached bones and surrounding muscle by scraping
with a scalpel and rubbing with bactericidal disinfectant wipes (Premier®, Shermond,
Brighton, England; fluid containing ethanol (70% v/v) and chlorhexidine digluconate
(1% w/v)), and wetting with a few drops of ethanol (70% v/v) for disinfection. Both
ends of the femur were cut offwith a scalpel and the marrow flushed with L929
conditioned medium (LCM, 10 ml) into a 60 ml Teflon pot (Roland Vetter
LaborbedarfOHG, Germany) using a syringe adapted with a 25 Gauge needle (BD
Microlance 3, Spain). LCM consisted of L929 culture medium (20% v/v) (Hosoe, et
al. 1989) and DMEM/F12 medium (80% v/v) supplemented with 10% FBS, L-
glutamine (200 mM), penicillin (100 U/ml) and streptomycin (100 mg/ml). Marrow
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cell clusters within the suspension were dissociated by vigorous pipetting using the
syringe adapted with a 21 Gauge needle. After addition of another 20 ml of the LCM,
the marrow cells were incubated at 37 °C in a humidified atmosphere of 95% air and
5% CO2. During incubation, the culture medium was changed twice (every second
day) by removing half of the old medium (15 ml) and replacing with the fresh LCM
medium (15 ml).
After six days incubation in the Teflon pots, the matured macrophages were
resuspended in the pots by pipetting and then transferred into a 50 ml-tube (CellStar,
Greiner Labortechnik, Germany) prior to centrifugation (220 g, 5 min, RT). Cells
were then resuspended in fresh LCM (1 ml per well) and placed in 12-well plates at a
density of 5x105 cell/ml per well, and incubated at 37°C for 16-24 hours before use.
3.2.7.2 LPS activation of the BMDM0S
When desired, the culture medium in the 12-well plates of the macrophages was
replaced by the fresh LCM containing stripped-serum. Then the macrophages were
primed for lh with dexamethasone, corticosterone, 5aDHB, 5aTHB (1 pM each) or
vehicle (ethanol, 0.01% v/v), and then incubated with LPS (100 ng/ml) for 24h. Each
treatment was performed in triplicate. Thereafter the supernatant was removed and
centrifuged (350 g, 5 min, RT) to remove dead cells that form pellets followed by
another centrifugation (10,000 g, 5 min, RT). Samples were stored at -80°C until
required for the quantification of cytokines using CBA (see 2.6.6).
3.2.7.3 Dose response of glucocorticoid effects on the release of
cytokines stimulated by LPS
BMDM0S were primed for lh by corticosterone or 5aTHB (3, 10, 30, 100, 300 and
1000 nM) or vehicle (ethanol, 0.01% v/v) before they were stimulated by LPS (10 or
100 ng/ml) for another 24 h. Each treatment was performed in triplicate. Then the
supernatant was clarified and samples assayed using the same procedures described
as above (see 3.2.7.2).
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3.2.8 Statistics
Data are presented as mean ± SEM and were analysed by Student's t test, or one-way,
two-way ANOVA, or repeated measures ANOVA, followed by Holm-Sidak post-
hoc test where appropriate.
3.3 Results:
3.3.1 Investigation of the effects of 5aTHB on GFP-GR
translocation in transiently transfected HEK293 cells
3.3.1.1 Controls for transfection
HEK293 cells transfected with plasmid DNA pGEM (inert DNA) did not induce
fluorescence within cells, confirming the absence of fluorescent contamination from
any reagent. The transfection ofpEGFP-Nl as a positive control confirmed the
success of transfection and induced fluorescence to the whole cell including
cytoplasm and nucleus, regardless of the position of GRs. Non-transfected cells in
the pEGFP-Nl transfection remained dark (Figure 3.1).
3.3.1.2 Time course study of GR translocation
GRs shuttle between the cytoplasm and the nucleus, dependent on their association
with glucocorticoids. This dynamic performance can be observed under a fluorescent
microscope in HEK293 cells transfected with GFP-GR.
Without the addition of glucocorticoids, the fluorescent GRs were distinctly excluded
from nuclei of cells (see Figure 3.2, vehicle). Incubation for up to 24 h with 0.1%
ethanol (vehicle) did not affect the localization ofGRs or stability of transfection.
However particular care had to be taken to maintain cleanliness of incubators to
ensure a "glucocorticoid-free environment".
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When glucocorticoids were added to the medium, GRs were activated and started to
translocate into the nucleus. With the addition of dexamethasone (1 pM), GR
translocation was complete within 15 min (Figure 3.3). Similarly, corticosterone (1
pM) induced translocation of GRs into the nucleus within 30 min (Figure 3.4). In
both cases, GRs remained exclusively in the nucleus for periods up to 24 h, and the
cytoplasm was ultimately clear of fluorescence.
With the addition of 5aTHB (1 pM), the process of GR translocation was much
slower and incomplete (Figure 3.5). Nuclear localization ofGRs was not observed
until 2 hours after the treatment of 5aTHB, with both nucleus localization and
nucleus exclusion of GRs observed in some cells throughout the course of
observation up to 24 hours. Nuclear translocation induced by 5aTHB was incomplete
as faint but visible cytoplasm could be observed.
The difference in efficacy between the glucocorticoid treatments was quantified as
the percentage of cells demonstrating nuclear localisation ofGFP-GR.
Corticosterone and dexamethasone were effective in inducing rapid and complete
translocation ofGRs (Figure 3.6). 5aTHB mimicked the effect but in a much slower
and less efficient manner as described above. After incubation for 24 hours, only
82.7±1.5% of cells showed nuclear localization.
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Figure 3.1 Controls for transfection in HEK293 cells. Cells were transfected with (a)
pGEM or (b) pEGFP-Nl (2 pg each). pGEM was transfected as mock transfection,
which did not induce fluorescence within cells. pEGFP-N 1 transfection was used as





Figure 3.2 GFP-GR stayed in cytoplasm without presence of steroids. HEK293 cells
were transfected with GFP-GR (2 pg) and incubated with vehicle (0.1 % ethanol) for
(a) 30 min; (b) 2 h; (c) 5 h or (d) 24 h. Fluorescent GRs were in cytoplasm (open
arrow) excluded from nucleus (solid arrow). Incubation for up to 24 h with vehicle





Figure 3.3 Time course ofGR translocation induced by dexamethasone (Dex).
HEK293 cells were transfected with GFP-GR (2 pg) and incubated with Dex (1 pM)
for (a) 15 min; (b) 30 min; (c) 2 h or (d) 5 h. Dex induced complete translocation of
GRs within 15 min. Thereafter, GRs remained exclusively in the nucleus (solid
arrow) for up to 24 h.
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Figure 3.4 Time course ofGR translocation induced by corticosterone. HEK293
cells were transfected with GFP-GR (2 pg) and incubated with corticosterone (B, 1
pM) for (a) 15 min; (b) 30 min; (c) 2 h or (d) 5 h. Translocation ofGRs by B was
evident within 15 min, but not complete until 30 min. GRs remained exclusively in






Figure 3.5 Time course ofGR translocation induced by 5aTHB. HEK293 cells were
transfected with GFP-GR (2 pg) and incubated with 5aTHB (1 pM) for (a) 15 min;
(b) 30 min; (c, d) 2 h; (e, f) 5 h or (g, h) 24 h. Most GRs did not move into the
nucleus in the first 30min after treatment (a, b). Partial GR translocation was
observed up until 2 h but to a variable degree. Maximal extent of translocation was
observed within 5 h but this was not complete, even after 24 h, with cytoplasmic
fluorescence still evident. Nuclear (solid arrow) translocation induced by 5aTHB
was incomplete as faint but visible figure of cytoplasm (open arrow) could be
observed.
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Treatment, p<0.0001; Time, p<0.0001; Interaction, p<0.0001.
Figure 3.6 Rate ofGR translocation. HEK293 cells were transfected with GFP-GR
and incubated with 1 pM of either 5aTHB, B or Dex or with vehicle (ethanol). Cells
were observed under a fluorescent microscope and translocation counted in three
fields per well at 15 min, 30 min, 2 h, 5 h and 24 h. Data were plotted as the
percentage of cells observed with nuclear translocation of GRs. 5aTHB only started
to exert its effect of translocation after 2h when nuclear translocation induced by Dex
or B was already complete. After 24 h incubation, nuclear localization was only
observed in 82.7±1.5% of cells in the presence of 5aTHB. Data are mean ± SEM of
three experiments with triplicate measurements at every time point for each
experiment. **p<0.01, ***p<0.001 versus vehicle; ###p<0.001 versus B, analyzed
for the effect of 5aTHB by two-way repeated measures ANOVA (one factor
repetition) with Holm-Sidak post-hoc tests.
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3.3.1.3 GR nuclear export
After the medium was replaced (see Figure 3.7), GRs in the 5aTHB-treated cells
started to move out of nucleus into cytoplasm. Five hours later, the number of the
cells with nuclear localisation induced by 5aTHB decreased from a maximum of
82.0±2.3% to 45.6±2.9% post- medium replacement. After 24 hours, only 32.1±6.1%
cells had more GRs in nucleus than in cytoplasm. Unlike 5aTHB, dexamethasone
and corticosterone (1 pM) maintained GRs exclusively in nucleus over 24 hours,





























Treatment, p<0.0001; Time, p<0.0001; Interaction, p<0.0001.
Figure 3.7 GR nuclear export. HEK293 cells transfected with pGFP-GR were
incubated with 1 pM of 5aTHB, B, Dex or vehicle (ethanol) for 24 h before the
culture medium was washed away and replaced with steroid-free medium; thereafter
the changes ofGR localization were recorded and plotted as percentage ofGR
translocated cells at 30 min, 2 h, 5 h and 24 h post-medium replacement. GR was
maintained in the nucleus in cells treated with Dex and B but not in those treated
with 5aTHB. GRs in the 5aTHB treated cells started to move out of nucleus slowly
into the cytoplasm, leaving only 32.1±6.1% of cells with more GRs in nucleus than
in cytoplasm at 24 h. Data are mean ± SEM of three experiments with triplicate
measurements at every time point for each experiment. ***p<0.001 versus vehicle,
###p<0.001 versus B, analyzed for effect of 5aTHB by two-way repeated measures
ANOVA (one factor repetition) with Holm-Sidak post-hoc test.
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3.3.1.4 Dose response to corticosterone
Rat GR has a higher affinity for dexamethasone and corticosterone than 5aTHB. A
study of the time and concentration-dependent effects of corticosterone on GR
translocation was undertaken to establish the relative potency of 5aTHB (see Figure
3.8).
The efficacy could be compared at 30 min when the velocity of GR translocation
increased with the concentration of corticosterone (Figure 3.9) and was sub-maximal.
GRs were translocated into nucleus to 7.2±1.2%, 66.4±3.6% and 77.9±0.8% by
concentrations of corticosterone of 10, 30 and 100 nM, respectively, at 30 min. GR
demonstrated nuclear-localization at 2 h which remained until 24 h, as shown in
Figure 3.9, except for those incubated with 3 nM.
With the presence of 3 nM of corticosterone, GR translocation could not be observed
within 30 min, similarly to 5aTHB (1 pM). The percentage of cells with GR
translocation increased dramatically from 30 min to 2 h to 85.1±0.5%, and continued
to increase slowly to the maximum of 90.8±0.8% at 5 h (Figure 3.10). Between 5 h
to 24 h, GRs moved out of nucleus, leaving 40.6±0.4% of cells with nuclear
localisation ofGR at 24 h (Figure 3.8), similar to 5aTHB (lpM).
Therefore, for further studies, investigating synergism or additive effects on GR
translocation by 5aTHB in the presence of corticosterone, corticosterone
concentrations were maintained at lower than 3 nM, to avoid maximal stimulation
and incubations performed for 45 min.
90
GR translocation in response to





































Treatment, p<0.0001; Time, p<0.0001; Interaction, p<0.0001.
Figure 3.8 GR translocation in response to increasing concentrations of B. pGFP-GR
transfected HEK293 cells were incubated with 3, 10, 30 or 100 nM of B. Cells were
observed under fluorescent microscope and counted from three fields per well at 15
min, 30 min, 2 h, 5 h and 24 h. Data were plotted as the percentage of cells observed
with nuclear translocation ofGRs. The velocity of GR translocation increased with
the concentration of B. Concentrations of B of 10 nM and higher could induce
translocation of GRs to the nucleus in all the cells by 2 h and maintain them there
over 24 h. However, in the presence of 3 nM ofB, GR translocation was only
observed in 85.1±0.5% of cells at 2 h and 90.8±0.8% at 5 h, and GRs moved out of
the nucleus at 24 h, leaving 40.6±0.4% of cells with nuclear localisation of signal.
Data are mean ± SEM of three experiments with triplicate measurements at every
time point for each experiment. *p<0.05, **p<0.01, ***p<0.001 versus 10 nM,
analyzed by two-way repeated measures ANOVA (one factor repetition) with Holm-
Sidak post-hoc test.
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Figure 3.9 Log dose response curve of B to induce GR translocation in the GFP-GR
transfected HEK293 cells. Cells were observed under fluorescent microscope and
counted from three fields per well at 30 min. The percentage of cells showing GR
translocation increased with the concentrations of B (3, 10, 30, 100 and 1000 nM).
Data are mean ± SEM, n=3, triplicates.
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Figure 3.10 The time course curve ofGR translocation induced by 3 nM of
corticosterone over 5 h in GFP-GR transfected cells. Cells were observed under
fluorescent microscope and counted from 3 fields per well at 15 min, 30 min, 45 min,
2 h, 5 h and 24 h. From 45 min to 1.5 h, approximately a quarter of the cells
transfected with GFP-GR demonstrated nuclear localization. Half an hour later, %
cells showing GRs translocated cells increased dramatically to a higher plateau from
2 h to 5 h. Data are mean ± SEM, n=3, triplicates.
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3.3.1.5 Co-incubation with corticosterone and 5aTHB
Since the progress ofGR translocation induced by 3 nM of corticosterone was
submaximal between 45 min to 1.5 h, and the translocation by 1 pM of 5aTHB was
not evident until 2 h, a co-incubation of a small amount of corticosterone (0.3, 1 or 3
nM) with higher dose of 5aTHB (100, 300 or 1000 nM) was performed to determine
whether synergistic or additive effects exist (Figure 3.11).
Without the addition of corticosterone in any dose, GRs remained nuclearly excluded
at 45 min, as described before. With corticosterone alone, GR translocation started to
be observed only with a concentration of 3 nM at this time point. With the presence
of both corticosterone and 5aTHB, their effects on GR translocation were
synergistically magnified. The co-incubation with 5aTHB and corticosterone
accelerated the process of translocation.
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[B], p<0.001; [5aTHB], p=0.015; Interaction, p<0.001
Figure 3.11 GFP-GR translocation induced by co-incubation of B and 5aTHB. GFP-
GR transfected HEK293 cells were co-incubated with corticosterone (0, 0.3, 1, or 3
nM) and 5aTHB (0, 100, 300 nM or 1 pM) for 45 min. Cells were observed under
fluorescent microscope and counted from 3 fields per well. Data were plotted as the
percentage of GR translocated cells. The co-incubation with 5aTHB and
corticosterone accelerated the process of translocation. Their combined effects on
GR translocation were synergistically magnified. Data are mean ± SEM, n=3,
triplicates. *p<0.05, **p<0.01, ***p<0.001 versus [B]=0; ##p<0.01, ###p<0.001
versus [5aTHB]=0; analyzed by two-way repeated measures ANOVA with Holm-
Sidak post-hoc test.
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3.3.1.6 FRAP analysis of GFP-GR
FRAP was applied to quantitatively assess the mobility of GFP-GR within the
nucleus ofHEK293 cells after the translocation induced by corticosterone and
5aTHB (Figure 3.12-13). The difference of half-life of maximal recovery (ti/2) in the
FRAP analysis between corticosterone and 5aTHB suggested that corticosterone
decreased the mobility ofGFP-GR to a greater extent than 5aTHB. However
maximal recovery did not differ following addition of both steroids (Figure 3.14).
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Figure 3.12 Cells undergoing FRAP analysis of nuclear GFP-GR. HEK293 cells
were transfected with GFP-GR and incubated with corticosterone (1 pM) for 24 h. A
small area of the cell (red rectangular area) was bleached and fluorescence started to
recover immediately as a result of the mobility ofGR protein. The background (blue
area) was also detected as control. Fluorescence intensity in either bleached (red area)




Figure 3.13 Schematic superimposed on experimental data to demonstrate FRAP
analysis ofGFP-GR. HEK293 cells were transfected with GFP-GR and incubated
with corticosterone (solid line and arrows) or 5aTHB (dotted line and arrows; 1 pM
each) for 24 h. Fluorescence in bleached area was corrected for the change in non-
bleached area. ti/2 was determined, which is the time when the fluorescence reached
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Figure 3.14 Maximal recovery in the FRAP analysis. Addition of B decreased the
mobility of nuclear GFP-GR to a greater extent than 5aTHB (a). The maximal
recovery was not different between treatments (b). HEK293 cells were transfected
with GFP-GR and incubated with corticosterone or 5aTHB (1 pM) for 24 h.
Fluorescence in bleached area was corrected for the change in non-bleached area.
Three individual experiments were performed by analyzing 18-20 cells in total in
each experimental group. Data are mean ± SEM, n=18-20, *p<0.05, analyzed by
Student's t test.
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3.3.2 Investigation of transactivation effects of 5aTHB in
H4IIE cells
3.3.2.1 Time course of the transactivation effects in H4IIE cells
incubated in culture medium with stripped serum
Corticosterone induced a time dependent increase in mRNA expression ofTAT and
also PEPCK although with less efficiency. However, 5aTHB did not significantly
influence the transcript abundance of genes tested (Figure 3.15). The abundance of
mRNA for the house-keeping gene, cyclophilin was not significantly changed by
treatment (p>0.05).
3.3.2.3 Time course of the transactivation effects in H4IIE cells
incubated in normal-serum medium
The same experiment was performed in normal medium with non-stripped serum,
but once again 5aTHB did not increase the abundance ofmRNAs of TAT or PEPCK
(Figure 3.16).
3.3.2.4 Dose response of induction of GR responsive genes in H4IIE
cells incubated in normal-serum medium
A dose response in TAT mRNA abundance was observed with corticosterone, with a
significant increase starting from the dose of 30 nM of corticosterone, but no


























TAT: Treatment, p<0.001; Time, p<0.001; Interaction, p<0.001.
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Figure 3.15 The abundance ofmRNAs of (a) TAT and (b) PEPCK in H4IIE cells
incubated in stripped-serum medium with the presence of 5aTHB, B (lpM each) or
vehicle (ethanol) for 0, 1, 2, 4, 8, 16 and 24 h. The transcript abundance was
quantified by real-time PCR and normalized for cyclophilin. B induced a time-
dependent increase (p<0.001 vs. vehicle) in the abundance ofmRNA of both genes
however 5aTHB failed to stimulate the transcription. Data are mean ± SEM, n=6.
*p<0.05, **p<0.01, ***p<0.001 versus vehicle, analyzed by two-way repeated
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TAT: Treatment, p<0.001; Time, p=0.041; Interaction, p=0.027.
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PEPCK: Treatment, p=0.002; Time, p<0.001; Interaction, p<0.001.
Figure 3.16 The abundance ofmRNAs of (a) TAT and (b) PEPCK in H4IIE cells
incubated in normal medium with the presence of 5aTHB, B (1 gM each) or vehicle
(ethanol) for 0, 2, 4, 8, 16 and 24 h. The transcript abundance was quantified by real¬
time PCR and normalized for cyclophilin. B increased the transcript abundance of
both genes whereas 5aTHB did not. Data are mean ± SEM, n=3. *p<0.05, **p<0.01,
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Treatment, p<0.001; Time, p<0.001; Interaction, p<0.001.
Figure 3.17 Induction ofmRNA ofTAT in H4IIE cells incubated in normal culture
medium with different doses of 5aTHB or B (0 (ethanol), 3, 10, 30, 100, 300 and
1000 nM) over 16 h. A log dose response in TAT abundance was observed with B
but not 5aTHB, with significant increase starting from the dose of 30 nM of B. Data
are mean ± SEM, n=3, shown with logarithm X axis; **p<0.01, ***p<0.001 versus
[steroid]=0; #p<0.05, ###p<0.001, 5aTHB versus B; analyzed by two-way repeated
measures ANOVA (one factor repetition) with Holm-Sidak post-hoc tests.
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3.3.3 Investigation of transactivation induced by 5aTHB in
transiently transfected Hela cells
The expression of the reporter genes with promoters ofMMTV and PNMT were
stimulated by corticosterone (1 pM) and increased substantially by 30 to 40 fold.
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Figure 3.18 Induction of transiently transfected reporters driven by promoters of
MMTV or PNMT. (a) MMTV-LTR-luc and (b) PNMT-luc were transfected into
Hela cells and incubated with 5aTHB, B (1 pM each) or vehicle (ethanol) for 24 h.
Both reporters were substantially induced by B but not 5aTHB. Data are mean ±
SEM, shown as the fold increase normalized to the luciferase activities of vehicle;
n=6; ***p<0.001 versus vehicle, analyzed by one-way ANOVA with Holm-Sidak
post-hoc tests.
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3.3.4 Investigation of the transrepressive effects of 5aTHB in
AtT20 cells
As shown in Figure 3.19, the basal level of the transcription of POMC was
significantly increased by CRH; whereas the increase was not detected in that of
CRH receptor 1. During the 48 h long incubation, the transcript abundance of POMC
was potently inhibited by corticosterone and dexamethasone but not influenced by
5aTHB, with and without the presence of CRH. CRH receptor 1 expression was
significantly decreased by dexamethasone and corticosterone when cells were treated
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Figure 3.19 Effects of 5aTHB to suppress abundance ofmRNAs for (a) POMC and
(b) CRH receptor 1 (CRH Rl) in AtT20 cells. AtT20 cells were incubated with
5aTHB, B, Dex (lpM each) or vehicle (Veh; ethanol), or each of the four treatments
together with CRH (lOOnM), abbreviated as T+C, B+C, D+C and V+C, respectively,
for 48 hours. The transcript abundance of POMC was quantified by real-time PCR.
The basal level of POMC transcription was increased by CRH; POMC expression
was down regulated by B and Dex, not 5aTHB, with or without the addition of CRH.
Data are mean ± SEM, n=6; ***p<0.001 versus Veh; ###p<0.001 versus V+C;
V vyy
p<0.05, p<0.001 versus other steroid treatment indicated by the bar; analyzed by
two-way ANOVA with Holm-Sidak post-hoc tests.
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3.3.5 Cytokine release from bone marrow derived
macrophages (BMDM0s):
3.3.5.1 Expression of A-ring reductases in BMDM0S
The presence ofmRNAs of A-ring reductases, e.g. 3a-HSD, 5a-reductase type 1,
type 2, and 5P-reductase, was investigated in un-stimulated BMDM0S (Figure 3.20),
using mouse liver as the positive control for 3a-HSD, 5a-reductase type 1, and 5(3-
reductase, and prostate as the positive control of 5a-reductase type 2. None of these
genes were transcribed in BMDM0S. F4/80, which is expressed in macrophages, was
detected as the positive control to ensure the integrity of the mRNA harvested from
BMDM0S.
3.3.5.2 Transactivation of the anti-inflammatory cytokine IL-10
In un-stimulated BMDM0S, both 5aTHB and 5aDHB, along with dexamethasone
and corticosterone (1 pM each), induced the release of IL-10 compared to vehicle.
When the BMDM0S were stimulated by LPS (100 ng/ml), the secretion of IL-10 was
substantially increased, and this response was significantly suppressed following the
addition of dexamethasone or corticosterone but not 5aTHB or 5aDHB (Figure 3.21).
3.3.5.3 Suppression of IL-6, TNFa and MCP-1 from LPS stimulated
BMDM0S
Glucocorticoids suppress the secretion of selected cytokines through a
transrepression mechanism. As shown in Figure 3.22, the release of proinflammatory
cytokines IL-6 and TNFa and chemokine MCP-1 were substantially increased by
LPS but not by glucocorticoids alone. Dexamethasone and corticosterone
significantly reduced the cytokine production following stimulation by LPS, and also
suppressed MCP-1 in un-stimulated macrophages. 5aTHB and 5aDHB suppressed
the releases of IL-6 and TNFa to a much lesser extent, and 5aDHB was more potent
than the tetrahydro reduced form, 5aTHB. The same pattern of data was observed for
MCP-1 but 5aTHB was too weak to reduce the chemokine release following such a
high dose of LPS (100 ng/ml). Therefore, to further elucidate the potency of 5aTHB,
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the dose response of 5aTHB to induce suppression of cytokine release by LPS was
investigated.
The inhibition of LPS-stimulated IL-6 secretion by dexamethasone and
corticosterone was attenuated by RU486, the specific GR antagonist. However,
addition ofRU486 did not affect the suppressive effects of 5aDHB, and potentiated
the inhibition induced by 5aTHB (Figure 3.23).
3.3.5.4 Dose response to the release of cytokines and chemokine
stimulated by different doses of LPS
As shown in Figure 3.24, after incubation with a higher dose of LPS (100 ng/ml) for
24 hours, the production of proinflammatory cytokine IL-6 was reduced by
corticosterone from concentrations above lOnM and by 5aTHB above 300 nM.
When stimulated by a lower dose of LPS (10 ng/ml), 30nM of 5aTHB was able to
reduce the release of IL-6, in contrast to 3nM of corticosterone, indicating a 10 - 30
fold difference in potency.
The suppressive effect of B and 5aTHB on IL-10 secretion post-stimulation by LPS
was much weaker. 1 pM of 5aTHB only demonstrated an effect compared to a lower
dose of 3-30 nM of corticosterone.
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Figure 3.20 Expression ofmRNA of A-ring reductases in BMDM0S. Total RNA (1
|ig) isolated from mouse BMDM0S was amplified by reverse transcription with
specific primers to detect expression ofA-ring reductases. 5a-Reductase type 1
(5aRl), type 2 (5aR2), 3a-HSD, and 5P-reductase were not detected in un-stimulated
BMDM0S. Mouse liver and prostate were used as positive controls where
appropriate. F4/80 was the positive controls for BMDM0S, and was normally
expressed in cells. A reaction without the presence of reverse transcriptase was used
as a negative control.
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Figure 3.21 Secretion of IL-10 from BMDM0S. Matured BMDM0S were primed by
glucocorticoids (dexamethasone (Dex), corticosterone (B), 5aDHB (DHB) or
5aTHB (THB)) for lh prior to the stimulation by LPS for 24h or incubation with
vehicle. Vehicle samples were BMDM0S incubated with ethanol only. The IL-10
released into the culture medium was quantified by CBA. All these four steroid
solutions increased the secretion of IL-10 versus vehicle; LPS stimulated the release
of IL-10 substantially, and this increase was suppressed by Dex and B but not DHB
or THB. Data are mean ± SEM, n=3; *p<0.05, **p<0.01, ***p<0.001 versus vehicle;
y yy
##p<0.01 versus LPS; p<0.05, p<0.01 versus another steroid treatment indicated
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Figure 3.22 Secretion of (a) IL-6, (b) TNFa and (c) MCP-1 from BMDM0S.
Matured BMDM0S were primed by glucocorticoids (dexamethasone (Dex),
corticosterone (B), 5aDHB (DHB) or 5aTHB (THB)) for lh prior to the stimulation
by LPS for 24h. Vehicle samples were BMDM0S incubated with ethanol only. The
cytokines and chemokine released into the culture medium were quantified by CBA.
Dex and B reduced their release following the stimulation by LPS, while 5aTHB and
5aDHB suppressed the release to a lesser extent. Data are mean ± SEM, n=3;
***p<o ooi, versus vehicle; #p<0.05, ###p<0.001 versus LPS; xp<0.05, xxp<0.01
versus another steroid treatment indicated by the bar; analysed by one-way ANOVA
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Figure 3.23 Secretion of IL-6 from LPS-stimulated BMDM0S, with or without the
presence of RU486. BMDM0S were primed by Dex, B, 5aDHB or 5aTHB (1 pM)
or vehicle (ethanol) before they were stimulated by LPS (100 ng/ml) for 24 h. IL-6 in
the culture medium were quantified by CBA. LPS induced IL-6 secretion was
suppressed by all the steroid treatments. RU486 antagonized the suppression induced
by Dex and B but not by 5aDHB and potentiated that of 5aTHB. Data are mean ±
SEM, n=3; Impact of RU486 was analyzed by two-way ANOVA; ***p<0.001
versus LPS; x p<0.01, xxxp<0.001, analyzed by one-way ANOVA with Holm-Sidak
post-hoc tests.
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Figure 3.24 Suppression of LPS-induced production of IL-6 and IL-10 from
BMDM0S, that were primed by B, 5aTHB (3, 10, 30, 100, 300 and 1000 nM) or
vehicle (ethanol) before they were stimulated by LPS (10 or 100 ng/ml) for 24 h. The
cytokines and chemokine released into the culture medium were quantified by CBA.
When incubated with a higher dose of LPS (100 ng/ml), the production of IL-6 was
reduced by B at concentrations of 10 nM and above and by 5aTHB upward of
300nM. When stimulated by a lower dose of LPS (10 ng/ml), 30 nM of 5aTHB was
able to reduce the release of IL-6 (a, b). The suppressive effect of 5aTHB on IL-10
secretion post-stimulation by LPS was much weaker, whereby 1 pM of 5aTHB could
only exert an effect on secretion induced by low-dose LPS (10 ng/ml) (c, d). Data are
mean ± SEM, n=3; *p<0.05, **p<0.01, ***p<0.001 versus vehicle; analysed by one¬
way ANOVA with Holm-Sidak post-hoc tests.
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3.4 Discussion:
In this chapter, the cellular properties of 5aTHB, i.e. GR translocation,
transactivation and transrepression of glucocorticoid responsive genes, have been
investigated. In HEK293 cells that were transiently transfected with GFP-GR,
5aTHB-bound GR showed prolonged process of nuclear translocation, and
accelerated nuclear export following steroid withdrawl. 5aTHB also increased the
nuclear mobility of GFP-GR in the FRAP analysis. However 5aTHB was synergistic
with corticosterone in GR translocation. To investigate the activity of 5aTHB to
transactivate glucocorticoid responsive genes, a number of model systems have been
used. In the H4IIE cells that were cultured in normal medium or the medium with
stripped-serum, 5aTHB did not alter the expression ofPEPCK or TAT. In the
transiently transfected Hela cells, 5aTHB did not increase the expression of the
MMTV and PNMT reporter genes which represent two distinct ways of GR
dimerization. In the aspects of gene transrepression, 5aTHB did not suppress the
expression ofPOMC or CRH receptor 1 in AtT20 cells. However, 5aTHB had
significant anti-inflammatory properties. It induced the release of IL-10 from non-
stimulated BMDM0S, and suppressed the LPS-induced production of TNFa and IL-
6 from BMDM0S.
3.4.1 Effects of 5aTHB on GFP-GR translocation
Natural glucocorticoids, such as Cortisol and corticosterone, circulate either as the
free steroid or approximately 70-90% of total in the circulation bound to serum
corticosterone-binding globulin (CBG) or albumin. However, synthetic
dexamethasone mostly remains as free in circulation and hardly binds to these
proteins (Stewart, et al. 2002). Thus cells were treated with 1 pM of steroids which is
a high concentration to investigate the actions of both dexamethasone and
corticosterone. They both were used as positive controls; however, it was not
possible to compare directly the activities between them since the active free
concentrations were unknown. Mclnnes et al. (2004) has shown that 5aTHB was
able to compete with dexamethasone for its binding sites in hepatocytes with affinity
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similar to that of corticosterone. Therefore, in this section, the binding activities of
5aTHB to GRs or chromatin binding sites were mainly compared to those of
corticosterone.
Glucocorticoids exert their activities via GRs that are ligand-activated nuclear
receptors. GR protein is composed of domain structures, the major ones being the C-
terminal ligand binding domain (LBD) that serves as hormone binding sites and also
contains the nuclear localization signals (NLSs) and ligand-dependent activation
function domain (AF-2); the central DNA binding domain (DBD) that is essential for
target gene binding and GR dimerization; the N-terminal AF-1 activation domain
required for transcriptional activation and association ofGR with other transcription
factors (Smoak and Cidlowski 2004). Without ligand binding, GRs are associated
with the heat shock protein based chaperon machinery in the cytoplasm. Upon ligand
binding, GRs are activated and translocate into nucleus. Intracellular GR distribution
and trafficking can be monitored and analyzed in living cells, into which the chimera
ofGFP-GR is transfected so that the ligand-dependent GR trafficking between
cytoplasm and nuclei is visible under fluorescent microscope (Htun, et al. 1996). The
effects of 5aTFlB versus corticosterone and dexamethasone on GR translocation
from cytoplasm into nucleus have been investigated in the HEK293 cells transiently
transfected with GFP-GR. Compared to dexamethasone and corticosterone, 5aTHB
translocated GRs in a much slower and weaker manner, according to our 24-hour
observation. Additionally, when ligands were washed away after 24 hours incubation
(1 pM), GRs were 'locked' in the nucleus by dexamethasone and corticosterone,
whereas they 'escaped' into cytoplasm following incubation with 5aTHB. As the
GFP-GR translocation was performed using decreasing concentrations of
corticosterone, it was found that 3nM of corticosterone was equivalent to 1 pM of
5aTHB achieving a similar efficacy of translocation within 5 hours. Furthermore, the
interaction between corticosterone and 5aTHB has been revealed by means of co-
incubation of the two ligands, that they have synergetic effects on GR translocation.
To explain the differences between 5aTHB and its parent hormone on the above
observations, the mechanisms of ligand binding and GR translocation need to be
further clarified.
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In the absence of ligand, GR is tethered in the cytoplasm by association with
chaperone proteins that bind to the ligand binding domain (LBD). The LBD has
multiple functions including ligand binding, chaperone association, nuclear location
and transcription regulation. Crystallographic analysis shows the GR LBD contains a
ligand binding pocket which is a feature unique to the GR LBD among other nuclear
hormone receptors. This pocket allows for the selective binding of glucocorticoids
and some mineralocorticoids that have larger substituents at the CI7a position than
other steroids (Necela and Cidlowski 2003). In rodents, 5a-reductase catalyzes the
trans reduction of corticosterone at the double bond of position A4'5, yielding 5aDHB,
which is further reduced promptly by 3a-HSD to 5aTHB (Russell and Wilson 1994)
(the structures of 5aDHB and 5aTHB are in Figure 1.6). The 5a-reduction of
corticosterone does not change the structure at the CI7a position, which allows
5aTHB to bind with GR. However, the polar substituents, at positions C3 or C17 of
the glucocorticoid structure, also affect the specific GR-ligand interaction.
Interestingly, GR, as well as AR, PR and MR preferentially bind the steroid
hormones with a ketone at the C3 position. Analysis of the dexamethasone bound
ligand binding pocket reveals that the hydrophobic residues within GR protein
contact nearly every atom of the steroid core of dexamethasone, and all hydrophilic
groups of dexamethasone form hydrogen bonds with the GR protein (Bledsoe, et al.
2002). The hydrogen bond network between GR and the ligand is likely to contribute
to the high affinity binding of dexamethasone, and an important interaction is with
the C3 ketone group. Indeed, in the structures ofGR, PR and AR, there is a
conserved structure from which the C3 ketone is ready to accept hydrogen bonds;
however, ER prefers to be presented a hydrogen bond donated from its ligand.
Therefore, ER prefers a hydroxyl group at the C3 position whereas GR, AR and PR
select the steroid hormones with a ketone group at C3 (Bledsoe, et al. 2002). This
finding suggested that 5aDHB would be a better ligand for GR than 5aTHB, since
5aDHB has a ketone group at C3 position whereas 5aTHB has a hydroxyl group
produced in the 3aHSD reductive process. However this is in contrast with Mclnnes'
findings that 5aDHB had higher Kd value than 5aTHB, and is less efficient in
displacing dexamethasone from binding sites in hepatocytes (Mclnnes et al. 2004).
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Following from those findings, in this thesis the efficiency of 5aDHB in GR
translocation was not tested, and the course ofGR translocation induced by 5aTHB
showed significant lag in initiation, suggesting that 5aTHB had difficulty in
interacting with GR, and that 5aTHB was not a preferred ligand for GR. Nonetheless
5aTHB was able to translocate conventional GR to the nucleus of the cell where it
may be transcriptionally active.
Upon ligand binding, the GR protein favours closure of the steroid binding pocket,
promoting enough conformational change in the receptor to expose the nuclear
localization signals (NLSs) (Pratt et al. 2006) that are essential for nuclear
translocation. Given a much slower rate of translocation induced by 5aTHB
compared to dexamethasone and corticosterone, it is possible that 5aTFIB may not be
as efficient in inducing conformational changes in GR to reveal NLSs. However, co-
incubation with corticosterone and 5aTHB showed intriguingly synergetic effects on
GR translocation in a concentration-dependent manner, suggesting the interaction
between the two ligands induced functional changes in NLSs. Possibly, the NLS on
GR that were activated by corticosterone opened the nuclear pore more efficiently,
which then leaves a way for the 5aTHB-bound GR to pass through. Alternatively,
perhaps the presence of 5aTHB allosterically enabled binding of corticosterone.
However, the detailed mechanism underpinning the synergetic effects between
5aTHB and corticosterone on GR translocation needs further investigation.
Within the nucleus, GR binds to chromatin binding sites and induces transcriptional
actions. The interaction between the GR and chromatin is an extremely dynamic
rather than a static process (McNally et al. 2000). Then the ligand dissociates from
GR which is released from chromatin by the hsp90/hsp70-based chaperone
machinery. Unligated GRs are collected in a subnuclear compartment which serves
as a nuclear export staging area with binding to the chaperone machinery, and
recycle to chromatin upon rebinding the ligand without exiting the nucleus to regain
functionality (Yang et al. 1997). It is known that after steroid withdrawal, the active
nuclear retention ofGR plays an integral role in its ability to transactivate the
transcription ofMMTV reporter gene (Carrigan et al. 2007); and the ability to bind
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DNA is an important determinant for both nuclear localization and accelerated
nuclear retention (Sackey et al. 1996). In the present study in this chapter, 5aTHB
not only slowed the nuclear import ofGR, but also prolonged the process of nuclear
retention after steroid withdraw). These findings indicated that 5aTHB induced a
conformational change ofGR that may have lower affinity for the chaperone
machinery, weaker ability to bind DNA and to activate gene transcription than the
GRs ligated by dexamethasone or corticosterone.
Nuclear mobility ofGFP-GRs liga ted with 5aTHB or corticosterone was detected
by FRAP analysis. The mobility ofGR is affected by the nature of the ligand bound
to GR which may induce a specific conformational change ofGR to facilitate the
binding to GRE (Meijsing et al. 2007). Dexamethasone, the high-affinity GR ligand,
dramatically decreases the mobility ofGRs in a concentration-dependent manner,
whereas corticosterone with lower affinity decreases GR mobility to a much lesser
extent (Schaaf and Cidlowski 2003). Additionally, previously reported studies on the
effects of geldanamycin (disrupting the assembly of GR-chaperone complex) on
GFP-GR mobility, faster GFP-GR mobility indicated that the chaperone machinery
stabilizes GR binding to chromatin rather than promoting its removal (Pratt et al.
2006). In the present study, increased mobility of GFP-GR by 5aTHB suggested
lower affinity of 5aTHB for GR and incompetent ability of 5aTHB to induce the
conformational change ofGR, which lead to much weaker binding ofGR to GRE
and to the chaperone proteins. It is possible that 5aTHB induced GR may hardly bind
to GRE at all. Furthermore, a number ofGRs with a mutant in the LBD have the
transcriptional activities to induce MMTV expression that correlate positively with
the half life (ti/2) ofmaximal recovery; thus increased nuclear mobility ofGR is an
integrated indicator of decreased signalling ability (Kino et al. 2004). Therefore it is
suggested that 5aTHB has weaker transcriptional ability than corticosterone.
Taken together, all these findings discussed above suggest that 5aTHB ligated GR
may have transformed to the receptor that has less exposed NLSs, weaker abilities of
nuclear retention and DNA binding, and thus weaker transactivation ability than
dexamethasone and corticosterone.
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3.4.2 Effects of 5aTHB on GR transactivation
The effects of 5aTHB on GR transactivation were investigated in a number of in
vitro culture systems, anticipating initial confirmation of the findings ofMclnnes et
al.
Transcriptional induction of two glucocorticoid responsive genes encoding for the
gluconeogenic enzymes PEPCK and TAT in the hepatoma cell line, H4IIE cells, was
quantified following incubation with corticosterone or 5aTHB. Corticosterone
induced a time and dose dependent increase in mRNA abundance; however 5aTHB
had little influence on the gene transcription. This result opposed the previous
findings, in which 5aTElB induced transcription of these genes (Mclnnes et al. 2004).
Further experiments ofMclnnes were revisited to confirm the results ofGR
transactivation induced by 5aTHB. Effects of 5aTHB or corticosterone on
expression of another two glucocorticoid response elements, MMTV-LTR and
PNMT, were quantified by reporter assay in transiently transfected HEK293 cells.
MMTV and PNMT represent two distinct dimerization mechanisms ofGR binding
with the regulatory regions of the gene. To transactivate PNMT, which is similar to
TAT and PEPCK, GRs dimerize through the DNA binding domain and bind to the
consensus GRE and increase transcription; whereas for the MMTV promoter, GRs
bind as monomer to the GRE 1/2s where GRs form dimer through the ligand binding
domain at the directly repeated GREl/2s (Schoneveld et al. 2004; Truss and Beato
1993). As a result, corticosterone substantially activated transcription of both
promoters; however again, 5aTHB did not transactivate these genes.
There are three major differences in methodology between Mclnnes' study and the
ones in this thesis which may explain these contrasting findings and were considered:
1) Mclnnes investigated the mRNA induction after 16 hours (only one time point)
incubation using Northern blotting as opposed Real time-PCR which was used here
to allow processing of a larger number of samples at multiple time points; 2) here the
two housekeeping genes, cyclophilin and 18S, were used for internal controls, which
are commonly used in real-time PCR, whereas U1 was used as a correction in
Northern blotting; 3) here the cells were incubated and treated with stripped-serum
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medium at least initially, as opposed to Mclnnes who used medium contained normal
serum.
To address these experimental confounders, the mRNAs used to detect the
transactivation ofTAT and PEPCK in the archived samples from Mclnnes' study
were re-quantified by real-time PCR using cyclophilin as an internal control, and
results were consistent between methods (data not shown), indicating it was not the
quantification approach that brought about the distinction. Furthermore, the internal
control genes in both experiments were not significantly changed by treatment.
Finally the experiment was re-performed in culture medium containing normal serum
instead of stripped serum. However, again, 5aTHB did not induce transcription of
the two genes.
Although a concrete answer has not been found to explain the discrepancy, at a later
stage in the execution of the work presented in this thesis, the synergetic effects of
5aTHB and corticosterone (at very low concentrations) on GR translocation were
revealed. Thus there is the possibility that the synergism may also exist in responses
to gene transcription. 5aTHB might induce higher levels of transactivation of these
genes in the presence of corticosterone or Cortisol (fetal bovine serum contains
Cortisol of about 30 nM, diluted 1 in 10 to prepare culture medium). This assumption
may explain the increased transcription in Mclnnes' study if batch to batch variation
in concentrations of glucocorticoids in culture medium occurs. However, against this
argument, Mclnnes et al only found additive effects of 5aTHB and corticosterone on
induction ofMMTV reporter gene but not synergetic effects (Mclnnes et al. 2004).
Nonetheless further studies are underway to revisit these effects on gene
transactivation in H4IIE cells. Taken together, in this thesis 5aTHB can poorly
induce GR binding to the GREs in chromatin to regulate transactivation but may
synergise with corticosterone.
In H4IIE cells (rat hepatoma cells) and Hela cells (human cervical carcinoma cells),
3a-HSD is expressed (Penning et al. 1986; Zheng, et al. 2005) and will convert the
5a-dihydro derivatives of glucocorticoids rapidly to 5a-tetrahydro forms. Therefore,
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in these cells the effects of 5aDHB were not investigated. Whereas in bone marrow
derived macrophages, A-ring reductases, e.g. 3a-HSD, 5aRl, 5aR2, and 5p-
reductase were not expressed. In the study performed in the macrophages, 5aTHB as
well as 5aDHB increased IL-10 secretion from unstimulated bone marrow derived
macrophages incubated in stripped-serum medium, and 5aDHB was more efficient
than 5aTHB, which supported the theoretical concept that 5aDHB is a better ligand
for GR than 5aTHB but was contrary to Mclnnes' findings. Binding constants were
assessed in the previous study in hepatic cytosol which contains 3aHSD; if there was
any endogenous NADPH within this preparation then 5aDHB may have been
converted to 5aTHB rapidly. 5P-Reductase is also present in cytosol and may also
have accepted corticosterone as a substrate under the incubation conditions, however
this enzyme is rate-limiting, unlike 3aHSD whose reaction proceeds nearly 100-1000
times more rapidly.
Glucocorticoids mediated increase in IL-10 production is regulated by GR binding to
the transcription factor STAT3 via GR-protein binding mechanism instead ofGR
binding to GRE (Unterberger et al. 2008). Given the findings that 5aTHB increased
IL-10 secretion but did not increase the other glucocorticoid transactivated genes
discussed above, e.g. TAT, PEPCK, PNMT, and MMTV, it seems 5aTHB activated
GRs favour interaction with proteins rather than chromatin. In our study,
corticosterone and dexamethasone significantly suppressed LPS-induced IL-10
secretion whereas only high dose of 5aTHB (1 pM) suppressed low dose LPS (10
ng/ml) -induced IL-10 release. Although it is known that glucocorticoids increase IL-
10 production, the mechanism underpinning the suppressive effects of
glucocorticoids on LPS-induced IL-10 is unclear. The production of LPS-induced IL-
10 in Kupffer cells is autoregulated at the transcriptional level by a negative feedback
mechanism involving the IL-10 receptor (Knolle, et al. 1998), and it has been
demonstrated that TNFa increases the production of lipoprotein-induced IL-10 in
THP-1 cells (macrophage-like cell line) (Giambartolomei, et al. 2002). Thus the
results in our study may be due to the decreased production of TNFa in the steroid-
treated LPS-activated macrophages (which appears more sensitive to dexamethasone
and corticosterone as discussed below) that contribute to the decrease in IL-10.
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3.4.3 Effects of 5aTHB on GR transrepression
The effects of 5aTHB on GR transrepressive actions on POMC and pro¬
inflammatory cytokines have been investigated. GR transrepression is mediated
through either direct or indirect interaction between GRs and target genes.
Mclnnes et al previously showed suppression ofACTH release in rats in response to
intraperitoneal administration of 5aTHB, and this may be explained by a decrease in
transcription of POMC. Thus the effects of 5aTHB on POMC mRNA expression
were investigated in AtT20 cells, the mouse pituitary corticotroph tumor cell line.
AtT20 cells are able to secret ACTH permanently; POMC, the ACTH precursor, is
expressed, synthesized and processed into ACTH before its secretion.
Glucocorticoids inhibit ACTH secretion, while CRH and cytokines, such as IL-6 and
IL-1, upregulate its secretion (Ooi et al. 2004). Studies on the inhibition ofACTH
secretion by glucocorticoids in AtT20 cells often involve the treatment of cells with
CRH to amplify the magnitude ofACTH levels as well as POMC synthesis. The
actions of glucocorticoids in the pituitary gland occurs in two main phases, the early
(0.5-2 h) and slow (>6-8 h) feedback inhibition; both are GR mediated processes, and
both have been studied using the AtT20 cells as a model system. The early inhibitory
action of glucocorticoids is caused by suppression of CRH-evoked intracellular free
calcium transients (Antoni, et al. 1992; Loechner, et al. 1999) and thereby inhibiting
CRH-induced synthesis ofPOMC mRNA and protein; and the slow inhibition
involves the repression of the synthesis ofPOMC (Antoni et al. 1992; Woods, et al.
1992), in which activated GRs bind as a trimer to the negative GRE in the regulatory
region ofPOMC and inhibit gene transcription (Drouin, et al. 1993b). As shown in
our study, dexamethasone and corticosterone dramatically decreased POMC
transcription with or without stimulation ofCRH, and also decreased that ofCRH
receptor 1 only in the presence of CRH, in AtT20 cells with continuous incubation
for 48 h. However, 5aTHB did not decrease the transcription of both genes,
suggesting that 5aTHB did not induce transrepressive effects through GR binding to
the negative GRE. The effects of these steroids on calcium transients were not
studied and may still explain the effects observed previously in rats, although the
time course was slower rather than rapid.
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Dexamethasone inhibits ACTH secretion in 2 h from the AtT20 cells following a
short-term incubation with CRH (30 min). However, corticosterone does not induce
any effect under these conditions unless used at the high concentration of 10 pM and
in the presence of glycyrrhetinic acid (inhibitor of 11 (3-HSDs) (Woods et al. 1992).
The equilibrium of metabolism of dexamethasone by 11 (3-HSD2 in contrast favours
reduction, thus maintaining high levels of active steroid (Best, et al. 1997). Therefore,
the 11 (3-HSD present in the AtT20 cells should be the type 2 isozyme rather than
type 1, so that corticosterone was inactivated rapidly by 11(3-HSD2. However A-ring
reduced steroids may be maintained in these cells since they too are not substrates for
11 (3-HSD2 and this metabolic route does therefore not explain the lack of effect.
A further consideration was whether the cells had been studied over the correct time
interval to observe an effect. CRH can constantly induce POMC mRNA expression
as well as ACTH secretion over 24 h, and the increase in POMC mRNA abundance
continues for another 24 h after CRH withdrawal (Affolter and Reisine 1985).
Additionally, the inhibitory effects of corticosterone last for more than 4 h to
suppress the abundance ofmRNA of CRH receptor 1 in AtT20 cells without the
presence of 1 lp-HSD inhibitor (Iredale and Duman 1997). Therefore, it is likely that
corticosterone can exert repressive effects at the transcriptional level with a long-
term co-incubation of CRH, and the activity of 11P-HSD2 may possibly only have a
brief impact. In our study the experiment has also used dexamethasone as a
guaranteed positive control, although the effects of corticosterone together with
5aTHB on the slow inhibitory manner were also investigated.
Apart from direct binding to DNA, GR can bind to the subunit of a second
transcription factors such as the pro-inflammatory transcription factors NFkB and
AP-1 in a GR-protein manner and transrepress the gene transcription regulated by
these transcription factors (Schoneveld et al. 2004). LPS-stimulated macrophages are
activated through the Toll-like receptor (TLR) 4 which plays a critical role in the
innate immune reactions to recognize the microbial products such as LPS. TLR4 is
predominantly expressed on the cell surface ofmacrophages, dendritic cells and B
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cells (Zhang and Daynes 2007). Once stimulated by LPS, TLR4 signalling triggers
the activation ofNFkB, AP-1 and mitogen-activated protein kinase (MAPK)
cascades, all of which are essential for the LPS-induced production of various
cytokines (Fang, et al. 2004; Fukao and Koyasu 2003). Glucocorticoids suppress the
genomic activity ofNFkB and AP-1 via direct GR binding and thereby inhibit the
synthesis and secretion of cytokines. Glucocorticoids also suppress LPS-induced
activation of p38 MAPK by transactivating the induction ofMAPK phosphatase
(MKP) -1 that is known to inhibit MAPK activation (Bhattacharyya, et al. 2007), and
this induction does not require GR dimerization (Abraham, et al. 2006). Therefore,
glucocorticoid suppression of the LPS-stimulated cytokine production in
macrophages involves transrepression mediated by GR-protein binding mechanism
as well as transactivation that is GR-dimerization-independent.
In our study, dexamethasone, as the most potent anti-inflammatory agent to date,
decreased substantially the production of TNFa, IL-6 and MCP-1 from LPS-
stimulated bone marrow derived macrophages, and corticosterone decreased the
release to a lesser extent. 5aTHB also suppressed the release of cytokines TNFa and
IL-6 from macrophages although to a much lesser extent; and 5aDHB again exerted
a stronger effect than 5aTHB. However, the detailed mechanism through which
5aTHB exerted its effects (i.e. the transrepression or transactivation mechanism
described above) is not known. Moreover, RU486 impaired the suppressive effects of
dexamethasone and corticosterone on IL-6 secretion but did not affect the effects of
5aDHB, and in the contrast potentiated the effects of 5aTHB. This finding suggested
an interesting novel mechanism for 5aTHB-mediated inhibition of TLR4 activated
inflammation however it needs further investigation.
Besides, it is known that 11[3-HSD1 is expressed in mouse macrophages, amplifying
the intracellular activities of glucocorticoids and promoting their anti-inflammatory
effects (Gilmour et al. 2006). Since A-ring reduced steroids are not substrates for




In summary, 5aTHB, with a hydroxyl group at the C3 position, may be an
unfavourable ligand for GR. Thus 5aTHB ligated GR may undergo an insufficient
conformational change that have exhibited prolonged process of nuclear
translocation and accelerated nuclear export following steroid withdrawl, indicating
its weak ability to activate gene transcription. 5aTHB also increased the nuclear
mobility ofGR suggesting its lower affinity for the receptor than corticosterone.
5aTHB was synergistic with corticosterone in GR translocation however this
property has not been investigated at the transcriptional level.
5aTHB did not induce the expression of the glucocorticoid responsive genes tested,
such as PEPCK, TAT, MMTV and PNMT, which are transactivated dependent on
GR-GRE binding. 5aTElB also did not transrepress the expression ofPOMC or CRH
receptor 1, which also requires GR binding to the negative GRE. However, 5aTHB
had anti-inflammatory properties. It induced the release of IL-10 from BMDM0S
which involves GR-protein binding, and suppressed the LPS-induced production of
TNFa and IL-6 from BMDM0S which may involve transrepression mechanism
mediated by GR-protein binding and transactivation mechanism independent ofGR-
dimerization. These findings suggest that GR by 5aTHB can induce responses that
are relatively selective for GR-protein rather than GR-GRE interactions.
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Chapter 4
Investigation of the effects of
5aTHB on transactivation and
transrepression in vivo
4.1 Introduction
Glucocorticoids exert a wide range of effects in target systems throughout the body,
among which they modulate energy homeostasis, increase blood pressure, execute
negative feedback on the HPA axis, and also suppress immune responses. If elevated
glucocorticoids secretion is sustained, such as in the naturally occurring Cushing's
Syndrome or chronic intake of glucocorticoids in the therapy of inflammatory
diseases, these effects can be aggravated and result in impaired glucose tolerance,
insulin resistance, central obesity, hypertension, dyslipidemia, and HPA axis
dysfunction (Walker 2006). Therefore, there is an enormous interest in developing
"dissociated steroids" which control specific pathophysiological functions with
limited metabolic side effects during therapy (Catley 2007; Schacke et al. 2004). If
5a-reduced metabolites of glucocorticoids can be shown to selectively target key
areas ofmetabolism but not others, they may have therapeutic potential. This thesis
is concerned with testing the in vivo effects of 5a-THB.
As shown from the in vitro findings in Chapter 3, 5aTHB did not induce the
expression of glucocorticoid responsive genes, including the ones encoding for the
gluconeogenic enzymes, PEPCK and TAT. However, 5aTHB induced IL-10
secretion and suppressed the production of TNFa and IL-6. Taken together, 5aTHB
might be an anti-inflammatory steroid lacking metabolic effects. Additionally,
Mclnnes et al. have shown that administration of 5aTHB in vivo suppressed the
levels of plasma ACTH, suggesting its negative feedback effect of glucocorticoids on
the HPA axis, although repression ofPOMC was not observed in AtT20 cells. Thus
this steroid has some of the desirable characteristics of a dissociated steroid in vitro.
This chapter will investigate whether this pattern of effects of 5aTHB are
recapitulated in vivo.
The hypothesis of this chapter is that 5aTHB will not activate transcription of genes




The aims of this chapter are to investigate:
1) The effects of 5aTHB on fuel metabolism following acute administration;
2) The effects of 5aTHB on the HPA axis and fuel metabolism following chronic
infusion;
3) The anti-inflammatory effects of 5aTHB following chronic treatment.
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4.2 Methods and materials
4.2.1 Maintenance of animals
Male C57BL/6 mice (Charles River, Kent, UK) were obtained at 8 weeks of age and
used when their body weights were > 25 g. Mice were maintained as described in
Section 2.3.1. Upon arrival, they were allowed to acclimatise to the new environment
for at least one week before any experiments were performed.
4.2.2 Study of acute administration of glucocorticoids
4.2.2.1 Preparations of injection solutions
4.2.2.1.1 Glucocorticoid solutions dissolved in DMSO: ethanol: saline
(13:1:6 v/v)
Corticosterone or 5aTHB (0.003 g) were dissolved in dimethyl sulfoxide (DMSO,
1.56 ml) and mixed thoroughly in a glass vial. Ethanol (120 pi) was added slowly.
The solution was stored in -20 °C until required when it was thawed at RT and saline
(720 pi, 0.9 % w/v) was added slowly to mix. The final solution was examined for
clarity before administration.
4.2.2.1.2 Glucocorticoid solutions dissolved in DMSO
Appropriate amounts of corticosterone or 5aTHB were weighed and dissolved in
DMSO in glass vials and mixed thoroughly by sonicating for approximately 15 min.
4.2.2.2 Terminal procedures
Animals were decapitated under controls ofminimum achievable stress. Trunk blood
was collected into EDTA microvettes (Sarstedt, Germany), and plasma was prepared
immediately by centrifugation (1000 g, 5 min, 4 °C). Livers were removed. Two
pieces of liver (<100 mg) were snap frozen, and the remainder was immersed in
glucose/Hepes buffer for preparation of cytosol.
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4.2.2.3 Time course of induction of hepatic TAT expression in C57BL/6
mice
C57BL/6 mice (n=5) were injected subcutaneously (s.c.) with 5aTHB, corticosterone
(25 pg/mouse, 100 pi each) or vehicle (DMSO: ethanol: saline (0.9 % w/v) = 13:1:6
v/v) at 08:30 h on each day of experiment. Once treated, mice were either culled
immediately (0 h) following the terminal procedures above (see 4.2.2.2) or put back
to clean cages and removed for culling after 1 h, 3 h or 6 h. TAT activity in hepatic
cytosol was measured by the TAT assay (see 4.2.5.3).
4.2.2.4 TAT activity in response to different vehicle injections
Four mice were injected (s.c.) with Treatment A (vehicle solution (100 pi) used in
4.2.2.3) by syringes (BD Micro-Fine, 29G, BD Medical-Diabetes Care, France) or
Treatment B (DMSO only, 20 pi) by Insulin Pens (NovoPen®3, 30G, Novo Nordisk
A/S, Bagsvaerd, Denmark), while Group 'V' were left quietly without disturbance.
They were all culled at 3 h after injections. Flepatic TAT activity was assayed
afterwards (see 4.2.5.3).
4.2.2.5 Optimisation of injection volumes
Corticosterone (25 mg/ml in DMSO, 20 or 50 pi, n=3) and vehicle (20, 50, 100 pi of
DMSO, n=2) were injected s.c. into C57BL/6 mice by Insulin Pen. Mice were culled
3h post-injection. Hepatic TAT activity was measured by TAT assay afterwards (see
4.2.5.3).
4.2.2.6 Dose response of glucocorticoids delivered in low volume
C57BL/6 mice (n=3-7) were injected s.c. by Insulin Pens with 20 pi of either
corticosterone (25, 75, 250, 750 mg/ml), 5aTHB (75, 250 mg/ml) or vehicle
(DMSO). The maximum dose was limited by the solubility of the steroids. Three
hours after injections, mice were culled and hepatic TAT activity was measured (see
4.2.5.3).
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4.2.3 Investigation of transactivation and transrepression
effects of 5aTHB following chronic infusion in C57BL/6 mice
4.2.3.1 Experimental design
Two pre-treatment blood pressure measurements were carried out in order to
acclimatise animals to the measurements. After surgery to implant minipumps (Day
0), animals (12 mice per group) were infused with corticosterone, 5aTHB (50 pg/day)
or vehicle (DMSO: propylene glycol = 1:1, v/v) using osmotic pumps. Animals were
weighed on Day 0, 1, 4, 6 and 11, and blood pressure measured on Day 1,4,6 and 11.
Glucose tolerance tests were carried out on Day 7. Animals were culled; blood and
tissue collected on Day 14. A second series ofmice were infused with the same
treatments but did not undergo the above procedures to provide sufficient blood for
analysis of plasma ACTH.
4.2.3.2 Mini-osmotic pump implantation
Mini-osmotic pumps were loaded with solutions of corticosterone, 5aTHB or vehicle
(see 2.2.1.2, 50 pg/day). C57BL/6 mice were operated on Day 0 using the surgical
procedures described in Section 2.3.2.
4.2.3.3 Measurement of systolic blood pressure
On mornings of Day 1,4,6 and 11, systolic blood pressure of each animal was
measured as described in Section 2.4.1.
4.2.3.4 Glucose tolerance/insulin sensitivity
A glucose tolerance test was performed on Day 7 as described in Section 2.4.2.
4.2.3.5 Terminal procedures
Animals were culled, and trunk blood and tissues were collected as described in
Section 2.4.3.
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4.2.4 Activation of whole blood by LPS
Heparinized trunk blood was activated by increasing doses of LPS to study the
impact of 5aTHB on cytokine release from white blood cells. The experiment was
performed as described in Section 2.4.4.
4.2.5 Enzymology
4.2.5.1 Preparation of cytosol
Fresh liver samples were immersed in glucose/Hepes buffer before being cut into
small pieces and homogenized using a mechanical homogeniser (Model PRO 200,
PRO Scientic Inc, Monroe, CT, USA). Homogenates were centrifuged (1,000 g, 10
min, 4 °C) to precipitate unhomogenized tissue and heavy membranes (Livingstone,
et al. 2000b). The supernatant was removed and subject to further centrifugation
(124,000 g, 45 min, 4 °C; Optime TLX Ultracentrifuge, Beckman, Palo Alto, CA,
USA). The subsequent clear supernatant was the cytosol which was transferred
carefully into fresh tubes without the upper fatty layer and stored at -80 °C until
required.
4.2.5.2 Determination of protein concentrations
The protein concentrations of cytosolic samples were determined using the Bio-
Rad® protein assay kit (BioRad, Hemel Hempstead, UK) which is a dye-binding
assay, based on the shift of absorbance maximum for an acidic solution of
Coomassie® Brilliant Blue G-250 from 465 nm to 595 nm upon binding to proteins.
The concentration of protein present in the sample is proportional to the increase of
absorbance at 595nm.
A series of solutions of bovine serum albumin (BSA, fraction V) representing a
range of concentrations (0, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 and 1.2 mg/ml) were prepared
in duplicate with distilled water. Protein assay dye reagent (1 in 5) and cytosolic
samples (1 in 50) were diluted in distilled water. Protein standards or cytosol
dilutions (20 pi) were added respectively to diluted dye (2 ml), vortexed and
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incubated (RT, 10 min). The mixtures were dispensed in duplicate into a flat-bottom
96-well plate (CellStar, Greiner Labortechnik, Germany). Thereafter, the
absorbances of solutions resulting from the standards and samples were measured at
A.595 nm using OPTImaxTM Tunable Microplate Reader (SOFTmax PRO,
Molecular Device, Ismaning, Germany). The concentrations of protein in each
sample were calculated from the standard curve, obtained from the linear relationship
between absorbance against concentration. The intra-assay coefficients of variation
were <10 %, and the values ofR of acceptable standard curves were >0.99.
4.2.5.3 Tyrosine aminotransferase (TAT) activity assay
TAT is a cytosolic enzyme which contributes to the pathway involved with hepatic
gluconeogenesis. It is significantly upregulated by the glucocorticoids (Grange, et al.
2001). TAT activity was determined by the spectrophotometric method of
Diamondstone (1966), which was based on the reactions consisting of following two
steps, and had been optimised for TAT in rat liver. The structures relating to the key
reagents are shown below in Figure 4.1. However, here the assay described as
follows was optimised to measure the hepatic TAT activity in mice.
Reaction 1: L-Tyrosine + q-ketoglutarate TAT^ pHPP+ L-glutamate
Reaction 2: pHPP + OH" ► pHBA+oxalate








All the following solutions except NaOH were prepared with potassium phosphate
buffer (0.2 M, pH 7.3). Tyrosine solution (10 M, 2.8 ml), pyridoxal phosphate (1.33
M, 0.1 ml), and diluted sample (0.5 mM, 0.2 ml) were successively added into a 10-
ml glass tube (Fisher Scientific, Pittsburgh, PA, US) and incubated in a water-bath
(30 min, 37 °C) before addition of a-ketoglutarate (0.3 M, 0.1 ml). Then the cytosol
samples were added and well mixed, and incubated in the water-bath for another
lOmin (Reaction 1) before NaOH (10 M, 0.2 ml) was added and mixed immediately
on a vortex. The reaction system was then allowed to stand at RT (Reaction 2),
yielding pHBA with maximal absorbance at 331 nm. After 70 min, the absorbance
(7331 nm) was recorded using a spectrophotometer (UV-160A, Shimadzu Europa
GmbH). The reference solution for the absorbance reading was prepared by adding
the NaOH just before a-ketoglutarate to inactivate the enzyme.
The following equation was used to calculate TAT activity from absorbance values
(the absorption coefficient for pHBA under the conditions of this assay is 1.99
Lxmmof'xmm"1):
TAT activity (mmol/mg/min) = 1030 x absorbance / 19.9
4.2.5.4 Optimisation of TAT assay
The TAT assay was optimised to measure the activity ofTAT in livers ofmice.
Before the final method (see 4.2.5.3) was determined, a series of validation
experiments were performed to establish suitable reaction conditions.
4.2.5.4.1 Optimisation ofReaction Time 2 in mock system
The time of Reaction 2 was determined by investigating the kinetics of pHBA
formation in alkali. NaOH (10 M, 0.1 ml) was added to pHPP (4.85xl0"5 M, 2.8 ml)
and tube shaken immediately. The mixture was transferred into silica cells (1cm3)
without delay. Absorbance (7,331 nm) was recorded every minute for 100 min using
the UV-visible spectrophotometer (UV-160A, Shimadzu Europa GmbH).
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4.2.5.4.2 Linearity of absorbance with changes in pHPP concentration in
mock system
Conditions as described in section 4.2.5.4.1 were used except for variation of pHPP
concentrations: 0 (vehicle, water), 5, 10, 20, 40, 60, 80, 100 pM and absorbance
recorded after 70 min.
4.2.5.4.3 Optimisation of Reaction Time 2 in enzyme system
The length of Reaction Time 2 was checked again when pHPP was generated using
diluted mouse cytosol. This experiment was performed by the same procedure as
described in the final protocol (see 4.2.5.3), except for
1) Concentration of cytosol (0.5 mg/ml);
2) Absorbance was recorded every minute for 80 min.
4.2.5.4.4 Optimisation of Reaction Time 1 in enzyme system
The procedure was the same as described in the final protocol (see 4.2.5.3) except for
1) Reaction Time 1 was varied from 0 to 18 min;
2) Concentration of cytosol was 0.5 mg protein/ml.
4.2.5.4.5 Linearity of absorbance with changes in protein
concentrations
Various dilutions of the same cytosol sample (0.5, 1, 2, 4 and 6 mg/ml) were
prepared in potassium phosphate buffer (0.2 M, pH 7.3). Conditions remained the
same as above (see 4.2.5.4.4), with lOmin for Reaction Timel.
4.2.6 Molecular biology: quantification of mRNA abundance
of genes of interest
Total RNAs were isolated from snap frozen livers (see 2.5.1.1), pituitaries (see
2.5.1.3), subcutaneous fat and retroperitoneal fat (see 2.5.1.2) before RNA
quantification (see 2.5.2). First strand cDNA was synthesised by reverse transcription
(see 2.5.3). The mRNA abundances ofTAT, PEPCK and angiotensinogen (Agt) in
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liver, POMC and CRH receptor 1 in pituitary, 11P-HSD1, Agt, IL-6, TNFa and
MCP-1 in subcutaneous and retroperitoneal fat were quantified by real-time PCR
(see 2.5.5) and normalised against levels of the house-keeping gene cyclophilin A.
4.2.7 Biochemical assays
4.2.7.1 Quantification of plasma corticosterone
Corticosterone in plasma prepared from trunk blood was quantified by RIA (see
2.6.1).
4.2.7.2 Quantification of plasma glucose
Glucose in plasma collected during the glucose tolerance test was quantified by
hexokinase assay as described in Section 2.6.2.
4.2.7.3 Quantification of plasma insulin
Insulin in plasma collected during the glucose tolerance test was quantified by
ELISA as described in Section 2.6.3.
4.2.7.4 Quantification of plasma ACTH
ACTH in plasma prepared from trunk blood was quantified by ELISA (see 2.6.4).
4.2.7.5 Quantification of plasma NEFAs
NEFAs in plasma collected during the glucose tolerance test were quantified by
spectrophotometry as described in Section 2.6.5.
4.2.7.6 Quantification of cytokines
Cytokines in samples collected in LPS-activated whole blood were quantified by
CBA assay as described in Section 2.6.6.
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4.2.7.7 Quantification of steroids by gas chromatography / mass
spectrometry (GCMS)
Plasma 5aTHB was quantified from the remaining plasma samples (10-20 pi
remaining) when other assays had been complete. Since it was not possible to test
5aTHB in individual samples, the plasma of animals receiving the same treatment
was pooled (yielding 150 pi), allowing the determination of an average concentration.
Corticosterone and 5aTHB in the remainder of solutions used for the chronic
infusion treatment were quantified by GCMS to confirm that both steroids neither
degraded nor had precipitated out of solution.
4.2.7.7.1 Extraction of steroids from plasma
Glass tubes were prepared containing internal controls epi-corticosterone (epi-B) and
epi-THB (containing 10 pg of both steroids in ethanol; Steraloids, Newport, RI, USA)
prior to reduction to dryness under oxygen-free nitrogen (OFN) at RT. Standards of
corticosterone and 5aTHB (0, 1, 2, 5, 10, 15, 20 ng of both in ethanol) or samples
were added respectively to the tubes, and water (HPLC grade) was added to make the
final volume to 200 pi. Then ethyl acetate (2 ml) was added and mixed so that
steroids were extracted into the upper organic phase from lower water phase.
Supernatant was transferred to glass vials and reduced to dryness under OFN. The
remaining steroids in the water phase were extracted again by adding to another 2 ml
of ethyl acetate, and supernatant was transferred to the same vials and reduced to
dryness.
4.2.7.7.2 Derivatisation ofsteroids
The extracted steroids exhibit poor peak shapes and poor resolution if analysed in
their natural state by GCMS. Thus they were derivatised so that they were more
amenable to this method (more volatile and thermally stable). The steroids
underwent a two-step derivatisation.
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Firstly, methoxyamine (2%, v/v) in dry pyridine (50 pi) was added to each vial, and
incubated (60 °C, 30 min) with the dried residues. Under these conditions, the
carbonyl groups formed oxime derivatives (CH30N=R) that improved
chromatographic performance and separation. Samples were reduced to dryness
under OFN at 60 °C.
Secondly, trimethylsilylimidazole (TMSI, 50 pi), a strong silyl donor, was added and
incubated (100 °C, 2 h) in capped vials; under these conditions, the hydroxyl groups
were silylated where active hydrogen was replaced by trimethylsilyl (TMS).
4.2.7.7.3 Isolation of derivatisedsteroids
Derivatised steroids were isolated from residues by passing through Lipidex 5000
columns. Lipidex 5000 (1 ml; Perkin Elmer, UK) was added to a Pasteur pipette
plugged with silanised glass wool, and prepared with mobile phase (cyclohexane:
hexamethyldisilazane: pyridine, 98:1:1, v/v) by passing the mobile phase three times
(1 ml each) through the columns. Eluate was discarded.
Samples and standards were reconstituted with mobile phase (1 ml) and applied to
columns and allowed to pass through. Vials were also washed twice with mobile
phase (0.5 ml each) and these washings were also passed through columns. Lastly
fresh mobile phase (1 ml) was passed through columns. All eluate was collected into
the fresh vials and reduced to dryness under OFN at 60 °C. Dried samples were
reconstituted in hexane (200 pi), half ofwhich was transferred to auto sampler vials
and ready for GCMS analysis. Otherwise samples were stored at -20 °C until
required.
4.2.7.7.4 Quantification of 5aTHB by GCMS
Gas chromatographic mass spectrometric (GCMS) analysis was performed in
selected ion monitoring (SIM) mode using a Polaris Q GC-ion trap gas
chromatography/mass spectrometer GC/MS (Thermo Finnigan, UK), fitted with a
Db5MS capillary column (crossbond, 5 % diphenyl, 95 % dimethyl polysiloxane;
length, 30 m; internal diameter, 0.25 mm; film thickness, 0.25 pm; Alltech, Camforth,
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UK). Epi-corticosterone and epi-tetrahydrocorticosterone (epi-THB) were used as
internal standards for the corticosterone and 5aTHB being measured. The initial oven
temperature was 150 °C which was maintained for 1 min; then it was increased by 30
°C/min to 200°C and then by 8 °C/min to 300 °C and maintained for 8 minutes.
Injection temperature was 240 °C, with a flow rate of helium of 1.0 ml/min; the ion
source was heated at 200 °C; and MS transfer line was kept at 280 °C. The mass (mlz)
and typical retention times of the ions monitored are shown in Table 4.1.
Corticosterone and 5aTHB were quantified by integrating the area under each
derivatised steroid peak and calculating the ratio of each peak relative to the peak of
the relevant internal standard. The concentrations of steroid were determined by
interpolation onto a linear calibration line of peak area ratio (PAR) versus
concentrations of standards where R>0.99 was deemed acceptable. The minimum
detection level for steroids was less than 1 nM.






Corticosterone 18.83, 18.95 548
Epi-corticosterone 18.32, 18.85 548
5aTHB 16.55, 16.96 564
Epi-5aTHB 16.31, 16.94 564
4.2.8 Statistics
Data are presented as mean ± SEM and were analysed by one-way, two-way, or
three-way ANOVA, or repeated measures ANOVA, followed by Holm-Sidak post-




Hepatic TAT and PEPCK were measured as indicators of the metabolic effects of the
positive effects of glucocorticoids on gene transcription mediated via GR binding to
GREs. The following steps were performed to optimise the assay to quantify TAT in
mouse liver.
4.3.1.1 Optimisation of Reaction Time 2 in mock system
The absorbance had reached a plateau by 70 min, when the coefficient of variation
within 5 min was <5 %. This was selected as the time of incubation in routine assays
(Figure 4.2).
4.3.1.2 Linearity of absorbance with changes in pHPP concentration in
mock system
The absorbance of the production pHBA was proportional to the concentrations of
pHPP, within the range of 0 - 100 pM, under the mock conditions (Figure 4.3).
4.3.1.3 Optimisation of Reaction Time 2 in enzyme system
Following the addition ofNaOH in the presence of enzyme, the absorbance was
maximal after 30 min remained stable for up to 80 min (Figure 4.4). The Reaction
Time 2 was confirmed as 70 min.
4.3.1.4 Optimisation of Reaction Timel in enzyme system
With fixed concentrations of reactants and a Reaction Time 2 of 70 min, the
absorbance of pHBA increased linearly with time of Reaction 1, and was more
reproducible when absorbance values were greater than 0.1 (Figure 4.5). Accordingly,
the value of absorbance was not reliable if the reaction time was less than 6 min.
Therefore, 10 min was used as the Reaction Timel in the subsequent experiments.
139



























Figure 4.2 Kinetics ofpHBA production (Reaction 2) was investigated in a mock
system. With addition ofNaOH (10 M, 0.1 ml) to pHPP (4.85* 10~5 M, 2.8 ml),
pHBA was produced and quantified spectrophotometrically at 33 lnm. The
experiment was performed in duplicate.























Figure 4.3 The amount of pHBA formed (measured by absorbance) was linear with
increasing concentration of pHPP (0, 5, 10, 20, 40, 60, 80, 100 pM), R=0.998. The
absorbance was recorded 70 min after addition ofNaOH.
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Figure 4.4 The kinetics of enzymatic production ofpHBA (Reaction 2). Tyrosine
(10 M, 2.8 ml), pyridoxal phosphate (1.33 M, 0.1 ml), and diluted cytosol (0.5 mg/ml,
0.2 ml) were successively added and incubated (37 °C, 30 min) before incubation
with a-ketoglutarate (0.3 M, 0.1 ml) for lOmin. NaOH (10 M, 0.2 ml) was added and
mixed immediately, and then absorbance at 331 nm recorded every minute for 80
min at RT. The absorbance increased and remained stable after 30 min and up to 80
min.































Figure 4.5 Absorbance was linear with the time length of Reaction 1. Tyrosine (10
M, 2.8 ml), pyridoxal phosphate (1.33 M, 0.1 ml), and diluted cytosol (0.5 mg/ml,
0.2 ml) were successively added and incubated (37 °C, 30 min) before incubation
with a-ketoglutarate (0.3 M, 0.1 ml) for 0 - 18 min. NaOH (10 M, 0.2 ml) was added
and mixed immediately, and then absorbance at 331nm was recorded after 70 min at
RT. R=0.988.
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4.3.1.5 Linearity of absorbance with protein concentrations
Absorbance increased linearly with protein concentrations within the range of 0.5 - 6
mg/ml, and absorbance at 331 nm from 0.1 - 2.0 (Figure 4.6). Absorbance data were
not available with protein concentration higher than 6 mg/ml in this assay because





Figure 4.6 Absorbance increased linearly with protein concentrations of cytosol
samples within the range of 0.5 - 6 mg/ml, and absorbance at 331 nm from 0.1-2.0,
R=0.999. Conditions were the same as described in Figure 4.5 except for the
concentrations of cytosol.
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4.3.2 Investigation of transactivation effects of 5aTHB by
acute administration of glucocorticoids to C57BL/6 mice
4.3.2.1 Time course of TAT induction following acute administration of
glucocorticoids
Plasma corticosterone, glucose and insulin, and hepatic TAT activity, were assessed
following acute administration of glucocorticoids.
Since the process of injection may induce an acute stress, circulating corticosterone
levels were initially measured to ensure to the concentration of corticosterone
achieved exceeded any stress response induced by the injection. As shown in Figure
4.7 (1), following injection of corticosterone, plasma corticosterone was elevated
immediately, reached peak level at 1 h following the injection, and was cleared from
circulation afterwards. In the animals receiving vehicle and 5aTHB, corticosterone
levels also increased significantly at 1 h and returned to basal level afterwards.
However, circulating corticosterone in these two groups was significantly lower than
in those animals receiving corticosterone; and prolonged clearance of corticosterone
was seen in animals receiving 5aTHB. Plasma 5aTHB was below the limits of
detection in the GCMS assay in the small blood volumes from individual mice and
was therefore measured in a sample pooled from several mice.
In the same animals, hepatic TAT activity was increased by injection of
corticosterone reaching a peak at 3h. Although a similar time course was evident
with 5aTHB, the extent of induction was less and indistinguishable from vehicle
(Figure 4.7 (1)) which itself induced TAT expression and could be attributed to the
increase in endogenous corticosterone caused by injection. These changes in TAT
activity were not manifest in changes of circulating glucose but corticosterone alone
caused an increase in plasma insulin at 6 h (Figure 4.7 (2)).
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The effects of vehicle treatment on plasma corticosterone could be due to either the
injection itself or the irritation induced by the injection solution, indirectly inducing
adrenal synthesis of corticosterone. Alternatively, the vehicle itself could have
induced changes in hepatic metabolism, perhaps in a response to eliminate the
xenobiotic solvents. Therefore, before proceeding with further assessment of steroids,
efforts were made to suppress the vehicle response. A time point of 3 h was selected
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TAT: Treatment, p=0.066; Time, p<0.001; Interaction, n.s.
Figure 4.7 (1) (a) plasma B and (b) hepatic TAT activity in C57BL/6 mice 0, 1, 3
and 6 h after animals had been injected s.c. with 5aTHB, B (25 pg/mouse) or vehicle
(100 pi each) in the solution ofDMSO: ethanol: saline (0.9% w/v) = 13:1:6 v/v. The
maximum effect of B to induce TAT activity was observed at 3 h, however vehicle
also showed a significant response, making it difficult to interpret the impact of
5aTHB. Data are mean± SEM, n=5. *p<0.05, **p<0.01, ***p<0.001 versus vehicle,
##p<0.05, 5aTHB versus B; analyzed by two-way repeated measures ANOVA (one


































Insulin: Treatment, n.s.; Time, p=0.037; Interaction, n.s.
Figure 4.7 (2) (a) Plasma glucose and (b) insulin in C57BL/6 mice 0, 1, 3 and 6h
after animals had been injected s.c. with 5aTHB, B (25pg/mouse) or vehicle (lOOpl
each) in the solution of DMSO: ethanol: saline (0.9% w/v) = 13:1:6 v/v. Data are
mean± SEM, n=5. *p<0.05, **p<0.01, ***p<0.001 versus vehicle; analyzed by two-
way repeated measures ANOVA (one factor repetition) with Holm-Sidak post-hoc
tests.
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4.3.2.2 TAT activity in response to different vehicle injections
An experiment was performed to assess the effect of injection of different volumes of
vehicle (Figure 4.8). Compared to the undisturbed mice as control, the hepatic TAT
activity from mice injected with a small volume of DMSO (20pl) remained at the
base line, while the vehicle solution used in 4.3.2.1 (DMSO: ethanol: saline (0.9%
w/v) = 13:1:6 v/v; lOOpl) was able to induce increased TAT activity at 3h (peak
induction in previous experiment). Therefore the injection method was changed to
reduce the volume of solutions.
4.3.2.3 Determination of injection volumes
Since it was planned to investigate the log dose response of corticosterone and
5aTHB, it was anticipated that up to xlOO of the basal dose would be dissolved into
solution. Based on the vehicle test above and in consideration of the limited
solubility of steroids in DMSO, the injection volume was increased marginally,
which would have enabled administration of higher doses. However a stress response
to vehicle was already apparent at 50pl and therefore 20pi was chosen for further
experiments (Figure 4.9).
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Comparison of injection methods
40-i
Figure 4.8 Hepatic TAT activity in response to different vehicle injections. Two
mice in each group were given s.c. injection, either with (A) the vehicle solution (100
pi, DMSO: ethanol: saline (0.9% w/v) = 13:1:6 v/v) or (B) DMSO (20 pi) by Insulin
Pen. (V) Two mice were undisturbed. TAT activity in livers collected at 3h post-
injection was measured by TAT assay. Treatment A increased TAT activity while
Treatment B kept TAT at the basal level.
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Figure 4.9 Hepatic TAT activity in response to different injection volumes of DMSO.
Vehicle (20, 50, lOOpl ofDMSO) were injected s.c. by Insulin Pen. TAT activity in
livers collected at 3h post-injection was measured by TAT assay. Data are
mean±SEM, n=2. Injection volumes > 20pl vehicle increased hepatic TAT activity
more than basal levels.
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4.3.2.4 Dose response of glucocorticoids
Using the approach determined above, false positives caused by stress of injection
could be successfully avoided, allowing detection of smaller changes induced by test
steroids. Indeed, under these conditions, plasma corticosterone increased with the
increasing dose of injected corticosterone, but reassuringly this was only observed in
animals receiving this hormone (Figure 4.10 (1)); animals receiving 5aTHB had
circulating corticosterone not significantly different from vehicle. All doses of
corticosterone increased hepatic TAT activity, although this effect was observed over
a narrow dynamic range. However, 5aTHB failed to increase TAT activity (Figure
4.10 (1)). Plasma glucose or insulin was not significantly affected by either
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Figure 4.10 (1) Dose responses of (a) plasma B and (b) hepatic TAT activity to B
and 5aTHB. C57BL/6 mice (n=3~7) were injected s.c. with 20 pi of either B (25, 75,
125, 250, 750 mg/ml), 5aTHB (75, 250 mg/ml) or vehicle (DMSO). Mice were
culled 3 h following injection. Plasma B was quantified by RIA, and hepatic TAT
activity by TAT assay. A dose response of B was observed in the circulation; hepatic
TAT activity was increased over a narrow dynamic range. 5aTHB did not alter
plasma B, and failed to increase TAT activity. **p<0.01, ***p<0.001 versus vehicle;
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Figure 4.10 (2) Dose responses of (a) plasma glucose and (b) insulin to B and
5aTHB. C57BL/6 mice (n=3~7) were injected s.c. with 20 pi of either corticosterone
(25, 75, 125, 250, 750 mg/ml), 5aTHB (75, 250 mg/ml) or vehicle (DMSO). Mice
were culled 3 h following injection. Plasma glucose was measured by glucose assay,
and plasma insulin by insulin ELISA. No significant changes were observed with
either steroid at 3 h, analysed by one-way ANOVA.
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4.3.3 Investigation the effects of 5aTHB on GR transactivation
and transrepression by chronic infusion in C57BL/6 mice
It was possible that the effect of 5aTHB had been missed following acute injections
of steroids, since 5aTHB might exert a slower action than corticosterone, based on
our in vitro findings in Chapter 3. Therefore, the steroids were administered over a
two week time period, performed by chronic infusion. Effects were sought in aspects
of glucocorticoid action on the HPA axis, fuel metabolism, and inflammation.
4.3.3.1 Infusion of steroids
4.3.3.1.1 Glucocorticoids in circulation
Increased plasma corticosterone concentrations were observed only in the animals
receiving this infusion but not in those receiving vehicle or 5aTHB. Basal
corticosterone levels in the vehicle group confirmed that animals were not stressed
before cull, and in 5aTHB group confirmed that 5a-reduction of corticosterone is an
irreversible metabolic pathway (Figure 4.1 la).
It was not possible to test 5aTHB in individual plasma samples (10-20 pi remaining).
Therefore all remaining plasma samples were pooled when other assays had been
complete to allow the determination of an average concentration by GCMS.
Circulating 5aTHB in animals receiving this steroid was detectable but 10-fold lower
than the circulating corticosterone in animals on corticosterone treatment (Figure
4.1 la). Plasma 5aTHB in animals on other treatments was under the minimum
detection limit.
4.3.3.1.2 Glucocorticoids in infusion solution
The remainder of the infusion solution was measured for concentrations of
corticosterone and 5aTHB after the course of infusion in animals. The concentrations
of steroids in theory (prepared as described in Section 2.2.1.2) and measured in
solution were listed in Table 4.2. These are not substantially different.
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Table 4.2 Concentrations of steroids in the remaining of infusion solution
Measured Concentration Concentration in theory
Corticosterone 3.271 mg/ml (9.4 mM) 4.165 mg/ml (12.0 mM)
5aTHB 4.238 mg/ml (12.1 mM) 4.165 mg/ml (11.9 mM)
4.3.3.1.3 Indices of HPA axis activity
Administration of corticosterone was accompanied by suppression of the HPA axis
reflected in smaller adrenal glands (Figure 4.1 lc), while 5aTHB did not induce this
effect. However, plasma ACTH was suppressed by both steroid treatments (Figure
4.1 lb). In pituitaries, the transcript abundances of POMC and CRH receptor were not
significantly affected by any glucocorticoid infusion (Figure 4.1 Id, e).
4.3.3.2 Body weight and blood pressure
During the experiment, body weight increased with time (p<0.001) and there was a
significant effect of corticosterone but not 5aTHB to reduce body weight on Day 11
(Figure 4.12a), whereas animals on vehicle treatment continued to gain weight.
Treatment with corticosterone or 5aTHB infusion did not induce significant
difference in blood pressure, although a trend for corticosterone induced
hypertension was observed on Day 11 (p=0.08). Some of the systolic blood pressures
were stressed measurements e.g. the increased blood pressures of vehicle cohorts on



























































Figure 4.11 Indices of circulating glucocorticoids and HPA feedback following
infusion (0.5 gl/h, 14d) of 5aTHB or B (50 pg/day) or vehicle (DMSO / propylene
glycol, 1:1), n=12. (a), Plasma B (quantified by RIA) and 5aTHB (quantified by
GCMS) was increased only in the group receiving the relevant steroids (plasma
5aTHB in animals receiving vehicle or B was not detectable), (b), Formalin fixed
right adrenal weights, were reduced only in the group receiving B. (c), Plasma
ACTH (n=10) was suppressed by treatment with both 5aTHB and B. (d, e), Pituitary
mRNA of POMC and CRH receptor 1 (quantified by real-time PCR), was not
affected by any steroid. Data are mean ± SEM, **p<0.01, ***p<0.001 versus vehicle;






































BW increase: Treatment, p=0.473; Time, p<0.001; Interaction, p=0.188.
Blood pressure: Treatment, p=0.626; Time, p<0.001; Interaction, p=0.629.
Figure 4.12 (a) Body weight increase, recorded on Day 0, 1, 4, 6 and 11 after the
surgery ofmini-pump implantation. A significant effect of B to reduce body weight
was shown on Day 11. (b) Systolic blood pressure measured by tail cuffprior to
(Day 0) and after (Day 4, 6 and 11) steroid infusions was not altered by any
treatment. Blood pressure data on Day 0 were the average values from two pre-
treatment measurements. Systolic blood pressure was not affected by steroid
treatment although blood pressure of both steroids and vehicle-treated controls
tended to be higher after minipump implantation. Data are mean ± SEM, n=12,
*p<0.05 versus vehicle, analysed by two-way repeated measures ANOVA (one
factor repetition) with Holm-Sidak post-hoc tests.
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4.3.3.3 Weights of organs
Smaller thymus glands were seen only in animals receiving corticosterone (Figure
4.13a), consistent with higher circulating levels of plasma corticosterone detected in
these animals. Other organ weights were unaffected (expressed as weight in Figure
4.13(1), or in relation to body weight in Figure 4.13(2)). Subtle redistribution of fat
to subcutaneous depots was observed following infusion of corticosterone only
(Figure 4.14a), while other adipose tissues were not affected (expressed as weight in
Figure 4.14(1) or in relation to body weight in Figure 4.14(2)).
4.3.3.4 Glucose tolerance tests
Following fasting for six hours, basal plasma glucose was not altered by either
steroid infusion. Circulating glucose was elevated soon after intraperitoneal
administration of glucose in all animals and was cleared after 15 min (Figure 4.15a)
in response to insulin action. Flowever glucose tolerance was not significantly altered
by either treatment. Animals receiving corticosterone infusion showed increased
plasma insulin at 15 min (Figure 4.15b) and NEFAs at 90min (Figure 4.15c)
following glucose administration; however 5aTHB did not exert any significant
effects.
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Figure 4.13 (1) Organ weights, (a) Thymus weights were reduced only in the group
receiving B. Weights of (b) spleens, (c) livers, (d) kidneys and (e) quadriceps were
not affected by either treatment. These organs were weighed immediately after
dissection on Day 14. Data are mean ± SEM, n=12, **p<0.01, analysed by one-way
ANOVA with Holm-Sidak post-hoc tests.
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Figure 4.13 (2) Organ weights presented as percentage of body weights, (a) Thymus
weights were reduced only in the group receiving B. Weights of (b) Spleens, (c)
livers, (d) kidneys, and (e) quadriceps were not affected by either treatment. These
organs were weighed immediately after dissection on Day 14. Data are mean ± SEM,
n-12, **p<0.01, analysed by one-way ANOVA with Holm-Sidak post-hoc tests.
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Weights of organs (1) - Adipose tissue






























Figure 4.14 (1) Weights of adipose depots, (a) subcutaneous, (b) retroperitoneal, (c)
omental, (d) mesenteric, and (e) epididymal fat. Five pads of adipose tissue were
weighed immediately after dissection on Day 14. Only the weight of subcutaneous
fat increased upon treatment with B (See Figure 4.14(2)). Other fat pads were
unaffected. Data are mean ± SEM, n=12, analysed by one-way ANOVA with Holm-
Sidak post-hoc tests. *p<0.05 versus vehicle.
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Figure 4.14 (2) Weights of adipose depots presented as percentage of body weights,
(a) Subcutaneous, (b) retroperitoneal, (c) omental, (d) mesenteric, and (e) epididymal
fat. Five pads of adipose tissue were weighed immediately after dissection on Day 14.
Only the weight of subcutaneous fat increased upon treatment with B. Other fat pads
were unaffected. Data are mean ± SEM, n=12, analysed by one-way ANOVA with
Holm-Sidak post-hoc tests. *p<0.05 versus vehicle.
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T 1 1 1 1 1 1
0 15 30 45 60 75 90
Time (min)
Glucose: Treatment, p=0.292; Time, p<0.001; Interaction, p=0.281.
Insulin: Treatment, p=0.180; Time, p<0.001; Interaction, p=0.044.
Figure 4.15 (1) (a) Plasma glucose and (b) insulin in glucose tolerance test (GTT).
Mice were fasted for 6 h before they were injected i.p. with 2 g/kg BW of glucose,
and blood samples were collected at 0, 15, 30, 60 and 90 min. (a) Plasma glucose and
(b) insulin are presented in time course curves. Glucose concentrations were not
significantly different between each group during the time course ofGTT. Animals
receiving B infusion showed elevated plasma insulin at 15 min following glucose
administration however 5aTHB did not exert such significant effect. Data are mean ±
SEM, n=12, **p<0.01, ***p<0.001 versus vehicle, #p<0.05, ##p<0.01 5aTHB
versus B, analysed by two-way repeated measures ANOVA (one factor repetition)
with Holm-Sidak post-hoc tests.
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0 15 30 45 60 75 90
Time (min)
NEFAs: Treatment, p=0.071; Time, p<0.001; Interaction, p=0.043.
B vs. vehicle, p=0.025.
Figure 4.15 (2) (c) Plasma NEFAs in glucose tolerance test. Mice were fasted for 6 h
before they were injected i.p. with 2g/kg BW of glucose, and blood samples were
collected at 0, 15, 30, 60 and 90 min. Animals receiving B infusion showed elevated
plasma NEFAs at 90 min following glucose administration however 5aTHB did not
exert such significant effect. Suppression from basal level (0 min) to 15 min
following glucose injection was not significantly different between treatments. Data
are mean ± SEM, n=12, ***p<0.001, versus vehicle, #p<0.05, 5aTElB versus B,
analysed by two-way repeated measures ANOVA (one factor repetition) with Holm-
Sidak post-hoc tests.
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4.3.3.5 Glucocorticoid responsive genes in liver
Changes were not observed in either hepatic TAT activity or in abundance of
transcript for TAT, PEPCK or angiotensinogen following either corticosterone or
5aTHB infusion (Figure 4.16).
4.3.3.6 Glucocorticoid responsive genes in adipose tissues
The glucocorticoid responsive gene transcripts in adipose tissue, 11(3-HSD1, was
significantly increased in both subcutaneous and retroperitoneal fat pads in response
to infused corticosterone, while increased angiotensinogen expression was only
detected in retroperitoneal fat following the same treatment. However, changes in





















































Figure 4.16 Hepatic TAT activity (a) and (b, c, d) mRNA abundance of hepatic
glucocorticoid responsive genes, TAT, PEPCK and angiotensinogen (Agt),
quantified by real-time PCR normalized against cyclophilin. None of these indices of
hepatic genes or enzyme activity was altered significantly by B or 5aTHB. Data are
mean ± SEM, analysed by one-way ANOVA, n=12.
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Figure 4.17 Transcript abundance of (a, b) glucocorticoid responsive gene 11 p-
HSD1 and (c, d) angiotensinogen (Agt) in subcutaneous (SC) and retroperitoneal (RP)
adipose tissue. mRNAs were quantified by real-time PCR normalized against
cyclophilin. 1 lp-HSDl expression was significantly increased in both SC and RP fat
in response to B infusion while increased Agt induction was only observed in RP fat.
5aTHB did not induce transcription of either gene in either fat pad. Data are mean ±
SEM, n=12. *p<0.05, **p<0.01 versus vehicle, analysed by one-way ANOVA with
Holm-Sidak post-hoc tests.
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4.3.3.7 Cytokine expression in adipose tissues
Transcript abundances of pro-inflammatory cytokines TNFa, IL-6 and MCP-1 in
adipose tissues, subcutaneous and retroperitoneal fats, were not significantly altered
by any infusion (Figure 4.18).
4.3.3.8 Cytokine release in LPS stimulated whole blood
In whole blood stimulated by LPS in a range of concentrations, production of pro¬
inflammatory cytokines TNFa and IL-6 were significantly suppressed by
corticosterone. 5aTHB exhibited suppressive effects on TNFa levels, and there was a
trend for it to suppress IL-6 (Figure 4.19(1)). Secretion ofMCP-1 and IL-10 was not
affected by corticosterone or 5aTHB. The data pertaining to MCP-1 demonstrated a



















































MCP-1 in RP fat
-r T
Vehicle 5aTHB
Figure 4.18 Transcript abundance of cytokines (a, b), TNFa; (c, d), IL-6; (e, f),
MCP-1 in subcutaneous (SC) and retroperitoneal (RP) adipose tissue was measured
by real-time PCR normalized against cyclophilin. The abundance ofmRNAs of these
cytokines was not altered significantly by any treatment. Data are mean ± SEM,
n=12, analysed by one-way ANOVA.
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TNFa: Treatment, p=0.012; Dose, p<0.001; Interaction, p=0.108.
TNFa: B vs. vehicle, p=0.005; 5aTHB vs. vehicle, p=0.020.
b. IL-6
300-1
0 0.01 0.1 1 10 100
LPS (ng)
IL-6: Treatment, p=0.224; Dose, p<0.001; Interaction, p=0.227.
IL-6: B vs. vehicle, p=0.030; 5aTHB vs. vehicle, p=0.090.
Figure 4.19 (1) Release of pro-inflammatory cytokines (a) TNFa and (b) IL-6 from
LPS (0, 0.01, 0.1, 1, 10 and lOOng) activated whole blood that was collected from
mice infused with B, 5aTHB or vehicle. TNFa and IL-6 were significantly
suppressed by B. 5aTHB suppressed TNFa significantly, and there was a trend for it
to suppress IL-6. Data are mean± SEM, n=3-6. *p<0.05, **p<0.01, ***p<0.001
versus vehicle, analysed by two-way repeated measure ANOVA (one factor
repetition) with Holm-Sidak post-hoc tests.
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IL-10: Treatment, p=0.380; Dose, p=0.002; Interaction, p=0.116.
Figure 4.19 (2) Release of chemokine (c) MCP-1 and (d) anti-inflammatory cytokine
IL-10 from LPS (0, 0.01, 0.1, 1, 10 and lOOng) activated whole blood that was
collected from mice infused with B, 5aTHB or vehicle. Secretion ofMCP-1 and IL-
10 was not affected by B or 5aTHB. Data are mean ± SEM, n=3-6, #p<0.05 versus B,




In this chapter, the effects of 5aTHB in vivo have been investigated by the
approaches of acute administration or chronic infusion of 5aTHB into C57BL/6 mice,
and compared to those of its parent hormone corticosterone. By means of acute
administration, 5aTHB did not increase the hepatic TAT activities in time course or
dose responses, or affect the circulating levels of glucose or insulin following
administration. Chronic infusion of 5aTHB suppressed ACTH levels, as previously
reported in rats (Mclnnes et al. 2004), but did not affect blood pressure, body or
organ weight, nor did it affect the glucose tolerance or insulin sensitivity. Similar to
the in vitro findings, 5aTHB did not induce the glucocorticoid transactivated genes
in liver and adipose tissue, but had suppressive effects on the production of LPS-
induced pro-inflammatory cytokines from blood immune cells. These findings
support the hypothesis that 5aTHB is a "dissociated steroid", suppressing
inflammation without influencing metabolism, while exerting negative feedback on
the HPA axis.
4.4.1 Effects of 5aTHB by acute administration
To investigate the acute effects of 5aTHB, an injection method was established to
eliminate the stress response to either the physical aspects of the injection or the
vehicle solution of the injection. In the first attempt to establish the time course of
5aTHB action, steroid was dissolved in 100 pi of a mixture ofDMSO, ethanol and
saline (13:1:6, v/v). Following the injection, plasma corticosterone in animals
receiving this steroid was elevated instantly, suggesting rapid transit of the injected
corticosterone from subcutaneous tissue into system circulation, particularly given
the time between injection and decapitation was within 30 seconds. This was
followed by an induction of activity ofTAT at 3h, which was a slower process since
it involves GR activation, translocation, gene transcription and protein expression in
hepatocytes. Circulating corticosterone and hepatic TAT activity returned to basal
levels at 6 h, accompanied by an increase in insulin to maintain metabolic
homeostasis.
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Meaningful comparisons between the effects of corticosterone and 5aTHB were not
possible in initial studies due to experimental confounders. At baseline, the levels of
corticosterone in animals receiving 5aTHB or vehicle were not changed, however
they did rise significantly over the first hour after treatment, albeit the peak levels in
animals receiving corticosterone were significantly higher than those receiving
5aTHB or vehicle. This elevation in plasma corticosterone may have been generated
from adrenals upon the activation of the HPA axis, stimulated by the psychological
response to the stress of injection or the irritant nature of the injection solution. Lack
of cross-reactivity of 5aTHB in the radioimmunoassay of corticosterone was
confirmed. Increases in hepatic TAT activity were also detected at 3 h following
injection of vehicle or 5aTHB, although again the largest increase was observed in
animals receiving corticosterone. This response may have been induced by the
elevated circulating corticosterone and/or the vehicle solution might have led to a
direct stimulation of hepatic metabolism to eliminate the xenobiotic solvents.
Interestingly, increased plasma corticosterone levels were sustained from 1 h to 3 h
in the animals receiving 5aTHB injection, indicating a prolonged clearance of
corticosterone caused by the exogenous 5aTHB, perhaps through competition for a
shared route of elimination.
To address concerns about the effect of vehicle and hence afford a more stable and
lower baseline, steps were taken to alleviate stressors. Thereafter, the injection
method was modified in order to avoid the stress response, and finally 20 pi of
DMSO was used as the solvent for further investigation of the dose response ofTAT
by corticosterone and 5aTHB. Under these conditions, the vehicle injection did not
induce any change in TAT activities nor did it cause an increase in corticosterone
levels. Further, corticosterone was not elevated following 5aTHB administration, by
way of reassurance that 5aTHB cannot be metabolised in the reverse direction to
corticosterone. Hepatic TAT activity was significantly increased in a dose dependent
manner by corticosterone, showing a narrow dynamic range of induction. However,
5aTHB did not alter TAT activity at 3 h. Plasma glucose and insulin were not
significantly changed at 3 h by any treatment.
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In conclusion, 5aTHB did not increase the activity of the hepatic gluconeogenic
enzyme TAT in this model system, mirroring the data generated in vitro in Chapter 3.
However given the in vitro findings that 5aTHB took longer to induce GR
translocation than corticosterone, it may not have been appropriate to investigate the
effects of 5aTHB at the same time point as those of corticosterone. This is supported
by Mclnnes' in vivo findings that an intraperitoneal injection of 5aTHB suppresses
plasma ACTH levels 1 h later than that of corticosterone (Mclnnes et al. 2004).
Therefore, an experiment with chronic administration of 5aTHB in vivo was
necessary.
4.4.2 Effects of 5aTHB by chronic administration
Following chronic infusions of 5aTHB or corticosterone, a series of physiological
and metabolic parameters were measured indicative of glucocorticoid action.
Infusion of corticosterone dramatically increased plasma concentrations of this
hormone, while treatment with 5aTHB and control did not, again confirming that 5a-
dehydrogenation does not regenerate corticosterone from 5a-reduced metabolites.
Furthermore, the mice were not exhibiting signs of global stress throughout the
experiment. Circulating levels of 5aTHB were very low: only a few nM of 5aTHB
were detected in animals receiving this compound, and it was un-detectable in
animals of the other groups, suggesting the clearance of 5aTHB was more rapid than
corticosterone. The concentrations of steroids in residual infusion solutions were
checked and confirmed that both steroids remained stable in the infusate throughout
the experiment.
Considering the low levels of plasma 5aTHB, it was striking to find that plasma
ACTH was significantly suppressed by chronic infusion of 5aTHB. This confirms
the previous finding that an acute intraperitoneal injection of 5aTHB (5 mg/kg BW)
in adrenalectomized rats suppressed plasma ACTH albeit 1 h later than the
emergence of the suppressive effect of corticosterone (Mclnnes et al. 2004). These
results generated by the two approaches confirmed the ability of 5aTHB to induce
negative feedback of the HPA axis, in which both the hypothalamus and pituitary can
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be the target of negative regulation mediated by glucocorticoids. Surprisingly, the
transcript abundance ofPOMC and CRH receptor type 1 in the pituitary were not
directly affected by any infusion treatment. This was consistent with the in vitro
findings with 5aTHB performed in the AtT20 cells, although in that model
corticosterone did cause this change. Since POMC and CRH receptor 1 were down-,
and up-, regulated by glucocorticoids and CRH respectively, it is likely that the
inhibition ofACTH was a result of suppression of CRH in the hypothalamus induced
by the glucocorticoids.
Adrenal size was reduced in animals receiving corticosterone but not 5aTHB. This
discordance with plasma ACTH results may reflect the time of blood sampling. The
animals of this experiment were culled in the morning when circulating ACTH were
at their lowest (rodents are nocturnal with a circadian rhythm ofHPA activity
opposite to that of humans (Windle et al. 1998)). Since the adrenal size was clearly
reduced in animals receiving the more potent glucocorticoid, corticosterone, it seems
likely that 5aTHB levels were sufficient to suppress ACTH at the nadir, but perhaps
not at the zenith thus allowing unsuppressed endogenous corticosterone levels to
maintain the adrenals at their normal sizes. Thus further experiments to investigate
the levels of corticosterone and ACTH in late afternoon could be performed.
Alternatively, rather than exert central suppressive effects, treatment of 5aTHB may
affect the peripheral clearance of corticosterone by competition with liver enzymes,
e.g. 20a- and 20P-HSDs that catalyze the reduction of both the hormone and its
tetrahydro metabolites (Kawamura et al. 1981), thus may result in lower ACTH
required to maintain the levels of corticosterone. As this may not be as profound to
suppress ACTH-adrenal function as administration of corticosterone, adrenal
shrinkage was not detectable.
At the molecular level, the mechanism of glucocorticoids inhibition ofCRH
transcription has been well documented. CRH induced increase in POMC
transcription involves increased expression of c-fos and c-jun (Autelitano and Cohen
1996; Autelitano and Sheppard 1993), AP-1 nucleoproteins. Glucocorticoids inhibit
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CRH gene transcription through a mechanism whereby GR monomer directly binds
to the negative GRE in the CRH gene as well as to AP-1 (Malkoski and Dorin 1999;
Malkoski, et al. 1997). Therefore, the suppressive effects of 5aTHB observed here
during the circadian nadir may indicate the weak potency of 5aTHB to induce GR
interactions between AP-1 and the negative GRE of CRH. Since the brains were
collected from the animals receiving steroid infusions at cull, the expression ofCRH
in the hypothalamus could be measured by in situ hybridisation to address this
hypothesis.
During the 14 days infusion of corticosterone, the anticipated metabolic responses
were observed. Corticosterone suppressed body weight gain, indicating an increasing
rate of proteolysis in skeletal muscles of animals receiving the hormone, although
individual organ weights were not significantly changed. Decreased thymus size
induced by corticosterone infusion was anticipated. It is well-recognised that
circulating glucocorticoids invoke thymus involution (van den Brandt, et al. 2007).
Fat was subtly redistributed to subcutaneous depots. Within the subcutaneous and
retroperitoneal adipose depots, 1 lp-HSDl mRNA (a glucocorticoid responsive gene
in adipose) was upregulated. As a result, the activity of corticosterone was boosted in
these adipose depots increasing lipolysis and release of free fatty acids and glycerol
into circulation, contributing to hyperinsulinaemia and rebound hyperlipidemia in the
glucose tolerance test. Since 5aTHB is not a substrate for 1 lp-HSDl (Tomlinson and
Stewart 2001), the activities of 5aTHB were not amplified. However, in liver,
gluconeogenic genes PEPCK and TAT were not significantly upregulated and
neither was TAT activity, perhaps because the liver samples were collected when
animals were not fasted.
None of these effects of corticosterone were observed following infusion of 5aTHB
(or vehicle) in agreement with the previous acute study and in vitro data, suggesting
that this steroid does not alter metabolism when administered in vivo. It is important
to recognise however that the circulating concentration achieved of 5aTHB was 10
fold lower than that of corticosterone and perhaps different results would be
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encountered if their circulating concentrations were matched, as opposed to their
infusion rates.
Additionally, angiotensinogen gene transcription was increased by infusion of
corticosterone, not 5aTHB, in retroperitoneal adipose tissue. Angiotensinogen is a
glucocorticoid responsive gene and present in liver and adipose tissue; it is the
unique substrate of renin and the precursor of angiotensin II in the renin-angiotensin
system (RAS), which plays an important role in the regulation of blood pressure as
well as sodium and fluid balance (Aubert, et al. 1997). With chronic exposure to
corticosterone in adipose tissue, increased 11[3-HSD1 amplified the corticosterone
action on angiotensinogen expression, thereby potentially contributing to the
marginal hypertension induced by infusion of corticosterone (Masuzaki et al. 2003).
However in this study, treatment of corticosterone did not significantly affect the
systolic blood pressure, which is possibly due to the short term infusion period or the
limited sensitivity of the blood pressure measurement. 5aTHB did not induce the
activation of angiotensinogen expression, and also did not increase the blood
pressure.
Besides angiotensinogen, adipose tissue also produces pro-inflammatory molecules,
so-called "adipokines", such as TNFa, IL-6, TGF-pi, C-reactive protein, soluble
ICAM, and MCP-1. The secretion of these proteins is significantly increased in
adipose tissue of obese cohorts compared with lean individuals (Weisberg, et al.
2003), which plays a crucial role in the development of obesity-induced insulin
resistance (Xu, et al. 2003). Thus, although glucocorticoids have adverse metabolic
effects, they may, paradoxically, act to suppress inflammation and protect against
metabolic syndrome. For example, it was reported that dexamethasone suppressed
IL-6 production in cultured obese human adipocytes ex vivo (Fried, et al. 1998). Here
in this thesis, in view of the in vitro evidence that 5aTHB could suppress secretion of
pro-inflammatory cytokines and also stimulate IL-10 secretion, gene transcriptions of
these adipokines were measured following infusion of corticosterone and 5aTHB.
However, the adipokines were not affected by any treatment. The cytokine secretion
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remained at basal levels in the tested fat depots. This may have been because the
C57BL/6 mice in this study were not obese.
However, in marked contrast with the lack of effect of 5aTHB on cardiometabolic
variables, the in vitro evidence of the effects of 5aTHB to modulate cytokine
secretion was recapitulated in LPS-stimulated whole blood collected at cull from the
animals receiving chronic infusion treatment of this compound. The concentrations
of test glucocorticoids in the whole blood can be extrapolated from the plasma levels,
such that elevated corticosterone was present only in samples collected from animals
receiving corticosterone, whereas basal corticosterone and increased 5aTHB levels
were present following treatment with 5aTHB. In the vehicle group, only basal
corticosterone level was present. The leucocytes in whole blood included monocytes,
lymphocytes, neutrophils, basophils, and eosinophils (Smits, et al. 1998). LPS is a
powerful stimulant to induce secretion of cytokines mainly, but not exclusively, from
monocytes; this can be inhibited by glucocorticoids and, for example,
dexamethasone inhibits secretion of monokines more than it does to lymphokines in
natural human whole blood (Franchimont, et al. 1998). Secretion of TNFa was
significantly suppressed by corticosterone and 5aTHB in response to a wide range of
LPS concentrations from 0.1 to 100 ng. Similarly, IL-6 secretion was suppressed by
corticosterone with secretion also tending to be lower with 5aTHB treatment. These
findings support and extend the in vitro study in which 5aTHB suppressed the
secretion of LPS-induced TNFa and IL-6 from bone marrow derived macrophages
(Chapter 3). The suppression of cytokine release from cells in whole blood by
5aTHB was similar to that of corticosterone indicating considerable potency given
that circulating concentrations of 5aTHB are 10 fold lower than those of
corticosterone. Therefore, this dose of 5aTHB achieved equivalent effects as 10 fold
higher dose of corticosterone on cytokine suppression but not on fuel metabolism
related glucocorticoid responsive genes.
4.4.3 Summary
To summarize, acute or chronic administration of 5aTHB did not induce any
alterations ofmetabolic parameters normally associated with glucocorticoid excess,
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but it did exhibit suppressive effects on the HPA axis as well as immune responses.
The suppression ofACTH induced by 5aTHB was not through inhibition ofPOMC
expression, and may be via reduced secretion of CRH or the influence of 5aTHB on
corticosterone clearance by competition with liver enzymes. Moreover, 5aTHB
suppressed the production of pro-inflammatory cytokines, TNFa and IL-6, from
blood immune cells. Suppressive effects on CRH, TNFa and IL-6 involve a common
mechanism whereby monomeric GR binds to NFkB or AP-1, suggesting that the
physiological functions of 5aTHB may be exerted in this manner.
In the following chapter, the impact of hepatic 5a-reduction that produces the 5a-
tetrahydro metabolites of glucocorticoids has been investigated using the 5aRl-null
mice. The anti-inflammatory effects of 5aTHB following the peritoneal
administration of LPS in vivo will be further investigated in Chapter 6.
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Chapter 5
Investigation of the function of
5a-reductase type 1 (SRD5A1)
using SRD5A1 knock-out mice
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5.1 Introduction
Metabolism of glucocorticoids mainly takes place in liver through the A ring-
reductases, including 5a-, and 5p-reductases, and 3a-HSDs. Reactions catalyzed by
5a- and 5(3- reductases involve the irreversible trans and cis, respectively, reduction
of the double bond at position A4'5 of A-ring, yielding trans 5a- and cis 5P- dihydro
glucocorticoids, which are further reduced by 3a-HSD into 5a- and 5P- tetrahydro
derivatives.
Two isozymes of 5a-reductases, 5aRl and 5aR2, have been cloned from different
genes, SRD5A1 and SRD5A2. The isozymes are expressed in a tissue-specific pattern.
In rats, 5aRl is the only isozyme expressed in liver and adipose tissue (Normington
and Russell 1992), and 5aR2 are mostly present in tissues ofmale reproductive
system (Normington and Russell 1992; Russell and Wilson 1994). In general, the
5aR2 has 10-20 fold higher affinity for androgens, progesterone, and corticosterone
than 5aRl. 5p-reductase is expressed predominantly in liver (Kondo et al. 1994).
In idiopathic obesity, abnormal glucocorticoid metabolism through A-ring reduction
is associated with the adverse consequences of obesity. In obese humans, 5a-
reductase activity is enhanced (Andrew et al. 1998); and decreased 5a-reductase
activity is observed in weight loss (Tomlinson et al. 2008b). In obese Zucker rats,
hepatic mRNA transcription of 5aRl is increased, and insulin sensitization can
ameliorate the increase in A-ring reductases (Livingstone et al. 2000; Livingstone et
al. 2005). Thus in the context of the data presented earlier, the upregulation may
modify adverse effects of glucocorticoids.
At the outset of this thesis, it was uncertain whether we would predict that 5aRl
deficiency results in exaggerated GR activation, due to accumulation of
corticosterone in the liver, or attenuated GR activation, due to loss of the contribution
made to GR activation by 5a-reduced corticosterone metabolites. Conversely, it was
unclear if increased 5aRl would amplify or attenuate GR activation. From the results
of the previous chapters, it now appears that the consequences of variations in 5aRl
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activity may be selective, with 5a-reduced corticosterone metabolites making a
positive contribution to GR signalling with respect to inflammatory signalling but
having a neutral effect on metabolic signalling. Consequences for HPA axis function
are hard to predict since we have discordant in vitro and in vivo results and 5a-
reduced corticosterone metabolites may act not only on central regulation ofACTH
secretion but also may influence peripheral clearance of corticosterone, with
secondary changes in the HPA axis.
Transgenic mice with 5aRl knock-out have been generated and used as an animal
model to specifically study the roles of this isozyme (Mahendroo et al. 1996). The
male 5aRl knock-out mice appear normal and can breed. Female mice can become
pregnant, but exhibit parturition and fecundity defects due to elevated progesterone
(Mahendroo et al. 1999) and estrogen (Mahendroo et al. 1997) levels, respectively,
suggesting a critical role of 5aRl in steroid metabolism. However, the metabolic
consequences from loss of 5aRl have not been explored and an overt phenotype is
not observed when mice are maintained on a normal diet. Recently Livingstone et al.
in our lab have investigated the effects of high-fat diet on 5aRl-null mice and found
that inhibition of 5aRl resulted in detrimental metabolic effects characterized by
glucose intolerance and fatty liver (Livingstone et al. 2008), consistent with
accumulation of the parent steroid in the liver. This raises the hypothesis that 5aRl
acts to protect against adverse changes in metabolism induced by glucocorticoids.
Immune regulation in these animals has not been studied.
Aims
The aims of this chapter were to investigate the panel ofmetabolic, inflammatory
and HPA axis variables used in Chapter 4 to assess the phenotype of 5aRl knock-out
mice, and to challenge these mice with chronic infusion of corticosterone to test
whether their responses in each of these domains are modified in the absence of the
capacity to generate 5a-reduced corticosterone metabolites.
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5.2 Methods and materials
5.2.1 Background and maintenance of animals
5.2.1.1 Background
Steroid 5aRl (SRD5A1) knock-out (SRD5A1mice were of a mixed strain of
C57BL/6J/129/SvEv, generated previously in the Russell laboratory (South Western
University, Dallas, USA) by injection of blastocysts with modified ES cells
(Mahendroo et ah, 1996). Embryos were imported from the Jackson laboratory
(Westgrove, PA, US), and a colony was generated by Dr Dawn Livingstone in our
laboratory. To generate SRD5A1'1' mice, SRD5A1 heterozygous females were
routinely mated to heterozygous males to avoid problems of parturition in the
homozygote mothers. Offspring of both sexes were produced with normal Mendelian
ratios of wild type, heterozygous, and homozygous genotype with no abnormalities
affecting sexual development or survival. The offspring of these matings were
genotyped using a multiplex PCR assay (adapted from Mahendroo et al., 1996).
5.2.1.2 Maintenance
Male SRD5A1 knock-outs mice (ISRD5A1''') and their wild-type (SRD5Al+,+)
littermates were 20 weeks old and weighed 30±3 g at the start of the study. Animals
were maintained under controlled conditions as described in Section 2.3.1.
5.2.2 Experimental design
Twenty-four male SRD5A1 knock-out mice and 24 wild-types were divided into two
groups (n=12/group). Before mini-osmotic pump implantation, two pre-treatment
blood pressure measurements were carried out. On Day 0, mice of each genotype
were implanted with mini-pumps that infused either corticosterone (50 pg/day) or
vehicle (DMSO: propylene glycol —1:1, v/v). Mice were weighed on Days 0, 1, 4, 6
and 11, and blood pressure measured on Days 1, 4, 6, and 11. Glucose tolerance tests




5.2.3.1 Mini-osmotic pump implantation
All mice received their operations according to the surgical procedures described in
Section 2.3.2.
5.2.3.2 Measurement of systolic blood pressure
Systolic blood pressure of each animal was measured as described in Section 2.4.1.
5.2.3.3 Insulin sensitivity
Glucose tolerance test was assessed as described in Section 2.4.2.
5.2.3.4 Terminal procedures
Animals were killed, and trunk blood and tissues collected as described in Section
2.4.3.
5.2.4 Activation of whole blood by LPS
Heparinized trunk blood was activated by incubation with increasing doses of LPS to
study the impact of corticosterone on cytokine release from white blood cells. The
experiment was performed as described in Section 2.4.4.
5.2.5 Molecular biology: quantification of mRNA abundance
of genes of interest
Total RNAs were isolated from snap frozen livers (see 2.5.1.1), pituitaries (see
2.5.1.3), subcutaneous fat and retroperitoneal fat (see 2.5.1.2) before RNA
quantification (see 2.5.2). Then the first strand cDNA was synthesised by reverse
transcription (see 2.5.3). The mRNA abundances ofTAT, PEPCK and
angiotensinogen in liver, POMC and CRF receptor 1 in pituitary, 1 lp-HSDl,
angiotensinogen, IL-6, TNFa and MCP-1 in subcutaneous and retroperitoneal fat
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were quantified by real-time PCR (see 2.5.5) and normalised for the abundances of
the housekeeping gene cyclophilin A.
5.2.6 Biochemical assays
5.2.6.1 Quantification of plasma corticosterone
Corticosterone in plasma prepared from trunk blood was quantified by RIA (see
2.6.1).
5.2.6.2 Quantification of plasma glucose
Glucose in plasma collected during the glucose tolerance test was quantified by
hexokinase assay as described in Section 2.6.2.
5.2.6.3 Quantification of plasma insulin
Insulin in plasma collected during the glucose tolerance test was quantified by
ELISA as described in Section 2.6.3.
5.2.6.4 Quantification of plasma NEFAs
NEFAs in plasma collected during the glucose tolerance test were quantified by
spectrophotometry as described in Section 2.6.5.
5.2.6.5 Quantification of cytokines
Cytokines in samples collected in LPS-activated whole blood were quantified by
CBA assay as described in Section 2.6.6.
5.2.7 Statistics
Data are presented as mean ± SEM and were analysed by one-way, two-way, or
three-way ANOVA, or repeated measures ANOVA, followed by Holm-Sidak post-
hoc test where appropriate.
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5.3 Results
5.3.1 Infusion of steroid
Concentrations of corticosterone in knock-out mice infused with vehicle were two
fold greater than wild-type mice although the difference was not statistically
significant. When infused with corticosterone, plasma corticosterone levels were
similar in wild-type and knock-out mice. Size of adrenal glands was not affected by
genotype and was reduced to a similar degree following infusion of corticosterone,
reflecting the suppression of the HPA axis (Figure 5.1).
The mRNA abundance of POMC and CRH receptor 1 in pituitary was quantified and
corrected for abundance of cyclophilin which did not differ between groups (p>0.05).
As shown in Figure 5.2, POMC mRNA was decreased in abundance by
corticosterone in wild-type mice only. Suppression of CRH receptor 1 was not
affected by any treatment in animals of either genotype. Analysis of plasma ACTH
was not possible due to insufficient plasma.
5.3.2 Body weight and blood pressure
There were no significant differences observed in body weight gain or systolic blood
pressures (Figure 5.3), either between genotypes or treatments. Animal body weights
in this experiment may have been temporarily affected by the glucose tolerance test
on Day 7 which required at least six hours fasting. Measurement of systolic blood
pressure in mice on this genetic background was more variable than in C57BL/6
animals, and some values reflect stressed measurements and are difficult to interpret.
Anecdotally the knock-out animals appeared to be more easily disturbed.
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a. Plasma B b. Adrenal
E=3WT c=i KO
Plasma B: Treatment: p=0.049; Genotype, n.s.
Adrenal: Treatment: p<0.001; Genotype, n.s.
Figure 5.1 Following infusion of B (50 pg/day, 14 days) or vehicle, (a) plasma B,
quantified by RIA, n=6-l 1, tended to be increased by infusion of B. (b) Formalin
fixed right adrenal weights, n=12, was reduced by infusion of B. No significant
difference was seen between genotypes following infusions. Data are mean ± SEM,
analysed by two-way ANOVA with Flolm-Sidak post-hoc tests. ***p<0.001 versus
vehicle within KO; ###p<0.001 versus vehicle within WT.
a. POMC b. CRH-R1
POMC: Treatment, p=0.073; Genotype x treatment: p=0.031.
CRH Rl: n.s.
Figure 5.2 Following infusion of B (50 pg/day, 14 days) or vehicle, transcript
abundances of (a) POMC and (b) CRH receptor 1 in pituitaries were quantified by
real-time PCR. The mRNA abundance ofPOMC in pituitary was decreased only in
WT animals receiving B infusion. The mRNA abundance ofCRH receptor 1 was not
affected by treatment or genotype. Data are mean ± SEM, n=5-6; ##p<0.05 versus
vehicle within WT; analysed by two-way ANOVA with Holm-Sidak post-hoc tests.
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a. Body Weight Increase
b. Systolic Blood Pressure
01 23456789 10 11 Day
Body weight increase or Blood pressure: Treatment, Genotype or Time: n.s.
Figure 5.3 (a) Body weight change and (b) blood pressure during chronic infusion of
vehicle or B (50 pg/day, 14 days). Neither parameter was affected. Data points on
Day 0 were the average values from two pre-treatment measurements. Data are mean
± SEM, n=12, analysed by two-way repeated measure ANOVA.
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5.3.3 Weights of organs
Organ and adipose tissue weights are shown in Figures 5.4 and 5.5 (presented as the
actual weights or the percentage of body weight). No differences between genotypes
were observed for any organ or adipose tissue. Weights of thymus and spleen were
reduced in animals infused with corticosterone, and thymus was more sensitive to
this change than spleen, typical of the pro-apoptotic effects of corticosterone.
Decreased liver size was also seen in animals infused with corticosterone. Kidneys
and quadriceps were not affected. Corticosterone caused a redistribution of fat to
mesenteric and subcutaneous adipose tissue while other fat pads were not affected.
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Thymus: Treatment, p=0.002; Spleen: Treatment, p=0.024;
Liver: Treatment, p=0.004; Others: n.s.
Figure 5.4 (1) Weights of organs, (a) Thymus, (b) spleen and (c) liver were
significantly reduced by B infusion, and (d) kidneys and (e) quadriceps were not
affected. No effect of genotype was detected. Data are mean ± SEM, n=12, *p<0.05,
**p<0.01 versus vehicle within KO; #p<0.05 versus vehicle within WT; analysed by
two-way ANOVA with Holm-Sidak post-hoc tests.
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Thymus: Treatment, p=0.005; Liver: Treatment, p=0.026;
Others: n.s. (Spleen: Treatment, p=0.076)
Figure 5.4 (2) Weights of organs presented as percentage of body weight (Onate, et
ah), (a) Thymus, (b) spleen and (c) liver were significantly reduced by B infusion,
and (d) kidneys and (e) quadriceps were not affected. No effect of genotype was
detected. Data are mean ± SEM, n=12, *p<0.05, **p<0.01 versus vehicle within KO;
analysed by two-way ANOVA with Holm-Sidak post-hoc tests.
189









































1=3 WT C3 KO
Mesenteric fat: Treatment: p=0.053. Others: n.s.
Figure 5.5 (1) Weights of adipose tissue. Five pads of adipose tissue (a) mesenteric;
(b) subcutaneous; (c) retroperitoneal; (d) omental and (e) epididymal fat were
weighed immediately after dissection on Day 14. No effect of genotype was detected.
A trend to increased mesenteric adipose tissue was observed following B infusion.
Other fat pads were not affected. Data are mean ± SEM, n=12, analysed by two-way
ANOVA with Holm-Sidak post-hoc tests.
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Weights of organs (2) - Adipose tissue {% BW)
a. Mesenteric fat b. Subcutaneous fat
Vehicle B Vehicle B
Vehicle B Vehicle B
e. Epididymal fat
Vehicle B
Mesenteric fat: Treatment, p=0.012;
Subcutaneous fat: Treatment, p=0.031. Others: n.s.
Figure 5.5 (2) Weights of adipose tissue presented as percentage of body weight
(Onate et ah). Five pads of adipose tissue (a) mesenteric; (b) subcutaneous; (c)
retroperitoneal; (d) omental and (e) epididymal fat were weighed immediately after
dissection on Day 14. No effect of genotype was detected. Mesenteric and
subcutaneous fat were increased following B infusion. Other fat pads were not
affected. Data are mean ± SEM, n=12, analysed by two-way ANOVA with Holm-
Sidak post-hoc tests.
191
5.3.4 Glucose tolerance test
After fasting for six hours, plasma glucose was not different between experimental
groups; hyperinsulinaemia was observed in mice receiving corticosterone.
Following an i.p. dose of glucose, circulating glucose concentrations were elevated
reaching peak values at 15 min and then declined. No differences were observed in
plasma glucose level between genotypes or treatments. Plasma insulin reached peak
levels at 15min in mice of both genotypes. Animals receiving corticosterone had
higher circulating insulin than animals receiving vehicle (Figure 5.6(1)). The data are
presented also as area under curve (AUC) for both glucose and insulin responses.
Animals which received corticosterone infusion showed hyperinsulinemia, but there
was no statistical significance between genotypes and no effect of genotype or
steroid treatment on glucose responses (Figure 5.6(2)).
Suppression of lipolysis, indicated by plasma NEFAs 0 min and 15 min, was also
quantified (Figure 5.6(2)). Overall fasting circulating NEFAs were higher in animals
receiving corticosterone treatment but were not affected by genotype. Following
glucose administration, NEFA levels dropped rapidly during the first 15 min, at
which time there were no differences between groups.
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0 15 30 45 60 75 90
Time(min)
Insulin: Treatment, p<0.001; Time, p<0.001; TreatmentxTime; p<0.001;
Genotype, n.s.; Glucose, n.s.
Figure 5.6 (1) Plasma concentrations of (a) glucose and (b) insulin during a glucose
tolerance test. Mice (WT and KO) received vehicle or B (50 pg/day) and were fasted
for 6 h prior to being injected i.p. with glucose (2 g/kg BW). Samples were collected
at 0, 15, 30, 60 and 90 min.Glucose was quantified by hexokinase assay, and insulin
by ELISA. Plasma glucose was not different between genotypes or treatments.
Animals receiving B showed hyperinsulinaemia compared to control mice. Data are
mean± SEM, n=12; **p<0.01 versus vehicle within KO; #P<0.05, ##p<0.01 versus
vehicle within WT; analysed by two-way repeated measure ANOVA with Elolm-
Sidak post-hoc tests.
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NEFAs: Treatment, p=0.029; Time, p<0.001; Genotype, n.s.
Changes in NEFAs: Treatment, p=0.046; Genotype, n.s.; Interaction, n.s.
Figure 5.6 (2) Plasma concentrations of (c) glucose, (d) insulin, (e) NEFAs, and (f)
changes in NEFA concentrations from 0-15 min, during a glucose tolerance test.
Glucose and insulin are presented as AUC generated from the graphs of Figure
5.6(1). Mice (WT and KO) receiving either vehicle or B (50 pg/day) were fasted for
6 h prior to being injected i.p. with glucose (2 g/kg BW). Samples were collected at 0,
15, 30, 60 and 90 min. Plasma glucose concentrations were not different between
genotypes or treatments. Animals receiving B showed hyperinsulinaemia and
hyperlipidemia compared to control mice. Significant differences of basal fasting
NEFAs and NEFA suppression in 15 min were only observed not between genotypes.
Data are mean ± SEM, n=12; **p<0.01 versus vehicle within KO; #P<0.05,
##p<0.01 versus vehicle within WT; analysed by two-way ANOVA or two-way
repeated measure ANOVA with Holm-Sidak post-hoc tests.
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5.3.5 Glucocorticoid responsive genes in liver
The abundances ofmRNAs of hepatic glucocorticoid responsive genes, TAT,
PEPCK and angiotensinogen, were not significantly altered following the infusion of
corticosterone, and no difference was observed between genotypes (Figure 5.7).
5.3.6 Glucocorticoid responsive genes in adipose tissue
The abundances ofmRNAs of glucocorticoid responsive genes, 1 lp-HSDl and
angiotensinogen, were measured in mesenteric fat tissue (Figure 5.8). Basal
expression of both genes was not affected by genotype. Corticosterone treatment did
increase the expression of 1 lp-HSDl, an effect that was more marked in wild-type





Genotype: n.s.; Treatment: n.s.; Interaction: n.s.
Figure 5.7 Transcript abundance of hepatic GC responsive genes, (a) TAT, (b)
PEPCK, and (c) angiotensinogen (Agt), were quantified by real-time PCR
normalized against cyclophilin. None of these hepatic genes were affected by









































lip-HSDl: Treatment, p=0.041; others, n.s.;
Agt: Genotype, p=0.012; Treatment, p<0.001; Interaction, p=0.040.
Figure 5.8 Transcript abundances of (a) 1 lp-HSDl and (b) Agt in mesenteric
adipose tissue were quantified by real-time PCR normalized against cyclophilin.
Both transcripts were significantly induced following B infusion. Changes of 11 (3-
HSD1 were not different between genotypes, whereas Agt was highly induced by B
in knock-out mice compared to wild-types. Data are mean ± SEM, n=12. ***p<0.001
• vv
versus vehicle within KO; #p<0.05 versus vehicle within WT, p<0.01 versus the
other genotype within the same treatment; analysed by two-way ANOVA with
Holm-Sidak post-hoc tests.
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5.3.7 Cytokine release in LPS activated whole blood
Cytokines were measured in whole blood samples when they were activated by
increasing doses of LPS. As shown in Figure 5.9(1), proinflammatory cytokines
TNFa and IL-6 were increasingly secreted as white blood cells were activated by
LPS of 10 and lOOng, and they were significantly suppressed in samples collected
from animals infused with corticosterone. However, there was no difference between
by genotypes on either treatment.
Figure 5.9(2) shows results of chemokine MCP-1 and anti-inflammatory cytokine IL-
10 measurements. The MCP-1 data were highly variable and no significant effect of
genotype or steroid treatment was seen. Difference was not observed in the infusion
treatments or genotypes. IL-10 in most samples was below the minimum detection
limit of the CBA assay, although the higher concentrations of LPS did stimulate
release.
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Cytokine release in LPS activated whole blood (1)
a.TNFa
i 1 1 1 1 r-




TNFa: Treatment, p=0.004; Dose of LPS, p<0.001; TreatmentxLPS, p=0.015.
IL-6: Treatment, p=0.006; Dose of LPS, p<0.001; TreatmentxLPS, p<0.001.
Genotype: n.s.
Figure 5.9(1) Release of proinflammatory cytokines (a) TNFa and (b) IL-6 from
whole blood, activated by increasing doses of LPS (0, 0.01, 0.1, 1, 10 and lOOng),
collected from mice (WT and KO) that were infused with B or vehicle for 14 days.
They were quantified by CBA assay. TNFa and IL-16 were secreted in increased
amounts as the dose of LPS increased. Their secretion was significantly suppressed
in blood samples collected from animals infused with B. However, no difference was
detected between genotypes. Data are mean ± SEM, n=5-12. *p<0.05, **p<0.01,
***p<0 ooi versus vehicle within KO; #p<0.05, ##p<0.01 versus vehicle within WT;
analysed by two-way repeated measure ANOVA with Holm-Sidak post-hoc tests.
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Cytokine release in LPS activated whole blood (2)
c. MCP-1




MCP-1 and IL-10: Dose of LPS: p<0.001; Treatment or genotype: n.s.
Figure 5.9(2) Release of chemokine (c) MCP-1 (n=3-12) and (d) anti-inflammatory
cytokine IL-10 (n=3-10) from whole blood, activated by increasing doses of LPS (0,
0.01, 0.1, 1, 10 and 100 ng), from mice (WT and KO) that were infused with B or
vehicle for 14 days. They were quantified by CBA assay. Secretion ofMCP-1 and
IL-10 was not significantly different in treatments of genotypes. Data are mean ±
SEM, n=6-12, analysed by two-way repeated measure ANOVA (one factor repetition)
with Holm-Sidak post-hoc tests.
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5.4 Discussion
The role of 5aRl in modulating tissue responses to glucocorticoid were investigated
in SRD5A1'1'mice. Indices of the HPA axis, glucocorticoid target tissues, and glucose
and lipid metabolism were measured, and cytokine production from leucocytes in the
transgenic mice compared to wild-type mice was quantified. To summarise, there
were no differences between wild type and 5aRl-knock-out mice in almost all
variables measured during vehicle treatment. Animals infused with corticosterone
showed changes typical of those reported in Chapter 4 but there were very few
differences between wild-type and knock-out mice. In terms of the HPA axis,
elevated circulating levels of corticosterone were accompanied by reduced adrenal
size, independent of the presence of 5aRl. However, inhibited mRNA expression of
POMC in pituitary was only detected in wild-type mice receiving corticosterone. In
terms ofmetabolism, infusion of corticosterone resulted in smaller liver size and
increased weights of mesenteric and subcutaneous fat depots in both genotypes.
Moreover, animals receiving corticosterone exhibited elevated levels of insulin and
free fatty acids during the glucose tolerance test, irrespective of genotype. In the
mesenteric adipose tissue, expression of 1 lp-HSDl was augmented following
infusion of corticosterone in both genotypes, whereas angiotensinogen expression
was only increased in 5aRl knock-out mice receiving corticosterone.
Immunosuppressive and anti-inflammatory effects of corticosterone were evident but
not affected by transgenic disruption of 5aRl; weights of thymus and spleen were
reduced by corticosterone treatment, regardless of genotype. Similarly, lack of 5aRl
did not alter the anti-inflammatory effects of corticosterone on suppression of LPS-
induced cytokine production from blood leucocytes. It appears, therefore, that
variations in the capacity to produce endogenous 5a-reduced corticosterone
metabolites do not have a marked effect on glucocorticoid-sensitive variables or their
response to exogenous corticosterone.
Corticosterone infusion increased circulating levels of the hormone to the same
extent in both wild-type and knock-out mice, indicating that glucocorticoid clearance
is not affected by genotypes. Since liver is the major organ for glucocorticoid
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clearance and 5aR2 is not expressed in mouse livers (Mahendroo et al. 1996), 5(3-
reductase is the main metabolic enzyme, and 6(3-hydroxylase and 20a- and 20(3-
HSDs are minor enzymes (Kawamura et al. 1981; Quattrochi and Guzelian 2001) in
the liver of 5aRl deficient mice. It appears that 5a-reductases and the other enzymes
may be modulated concordantly to maintain a steady rate of hormone metabolism,
and that they may be able to compensate for lack of 5aRl. It is known that hepatic
6(3-hydroxylase (Quattrochi and Guzelian 2001) as well as renal 11P-HSD2 (Li et al.
1996; Suzuki et al. 2003) are substantially upregulated by glucocorticoids. Moreover,
the Km of 5aRl is in the low micromolar range and hence it will not be functioning
at maximal velocity in the presence of normal baseline levels of corticosterone or
even following corticosterone infusion. As circulating corticosterone was not
different between genotypes, adrenal size in both genotypes was reduced similarly.
5aR2, not 5aRl, is the dominant 5a-reductase expressed in adrenals of male mice
(Mahendroo et al. 1996) where it is thought to regulate steroidogenesis (Luu-The et
al. 2005); therefore adrenal size is unlikely to be affected by local 5aRl deficiency.
However, in the pituitary, POMC expression was only significantly suppressed in
wild-type mice receiving corticosterone infusion; whereas in knock-out mice,
exogenous corticosterone did not affect POMC expression. As the circulating levels
of corticosterone were not different between genotypes, the differential response in
POMC expression was possibly controlled by altered CRH however the reason was
unclear and indeed there was no difference in the expression of CRH receptor 1 in
the pituitary, although CRH itselfwas not quantified. It has been reported in rats that
the 5aRl is the dominant isozyme in the brain, including the regions of
hypothalamus, cerebral cortex, subcortical white matter and purified myelin
membranes (Poletti, et al. 1998). If the main role of 5aRl in these areas was to
inactivate corticosterone, then it might be anticipated that 5aRl knock-out mice
would be less able to inactivate corticosterone and induce greater suppression in
these regions, in contrast to the findings here. However, as it has been shown in
Chapter 4 as well as reported by Mclnnes et al. (2004), 5aTHB has the ability to
suppress the release ofACTH and thus may play a key role in the set point of the
HPA axis. As discussed previously in Chapter 4, 5aTHB may have the ability to
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suppress CRH production via a mechanism whereby involves GR binding to the
subunit ofAP-1. Thus lack of this metabolite locally in the hypothalamus may reveal
its contribution. Another explanation may be that 5aR2 is able to compensate for the
lack of 5aRl in the brain as it does in the male murine reproductive tract
(Mahendroo et al. 1996). In support, 5aR2 is selectively expressed in the
hypothalamus, and it is also expressed in hippocampus after acute stress (Poletti et al.
1998). Therefore, it could be possible that in 5aRl-deficient mice, the expression of
5aR2 was increased to compensate for the missing 5aRl activity in the
hypothalamus. 5aR2 has 10-20 fold higher affinity for corticosterone than 5aRl,
allowing corticosterone to be cleared more efficiently in hypothalamus of knock-out
mice, thereby ameliorating the decrease in POMC expression. These hypotheses
have not been tested, although brains have been archived and could be studied to
quantify CRH and 5aR2 at sites of negative feedback.
In terms of the peripheral actions of glucocorticoids, blood pressure was not different
between 5aRl knock-out and wild-type mice. Glucocorticoids increase blood
pressure through regulation of vascular tone by increasing vasoconstrictive factors
and decreasing vasodilatory proteins, and activating the renin-angiotensin system
(Sato et al. 1994). In the kidney, glucocorticoids cause vasodilatation and increase
glomerular filtration rate (De Matteo and May 1997), and enhance the activity of ion
transporters in the proximal tubules (Brem 2001). The increase in circulating
corticosterone in animals receiving this treatment did not translate into elevated
blood pressure perhaps because of the limited sensitivity of the method of blood
pressure measurement, and this could be improved using telemetry. It would also be
of interest to see whether vascular reactivity and/or renal functions are affected in
knockout mice (with and without corticosterone treatment).
Body weight gain was not changed significantly by genotype or treatment. However,
corticosterone did affect the weight of several organ weights albeit without genotypic
differences being revealed. Infusion of corticosterone caused atrophy of the thymus
and spleen, supporting the fact that glucocorticoids have immunosuppressive effects
on T-cell apoptosis (Ashwell et al. 2000). Lack of 5aRl did not alter the extent of
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changes which again are likely to be a function of circulating steroid concentrations,
although the thymus does expresses 5aRl to a small extent in adult animals (Borlak,
et al. 2004). In the present study, liver weights were reduced by infusion of
corticosterone regardless of genotype. This reduction contrasted with previous
finding of glucocorticoid-induced increases in liver weight which were associated
with hepatic triglyceride and glycogen storage (Santidrian and Young 1980; Mantha
et al. 1999; Bollen et al. 1998; van Schaftingen and Gerin 2002). These increases are
perhaps independent of hepatic 5aRl and may require higher doses of glucocorticoid
hormone. It is significant that infusions of low doses of corticosterone in the present
studies did not provoke the changes in hepatic glucocorticoid responsive genes
including PEPCK, TAT, and angiotensinogen which were observed in more acute
studies with higher steroid doses.
In adipose tissue, among the five adipose depots, weights ofmesenteric and
subcutaneous fat pads were increased in animals receiving corticosterone, which was
more evident when the data were presented as the percentage of body weight; this
bears similarities to the animals in Chapter 4. Although lack of 5aRl did not induce
significant difference in adipose weights between genotypes, local levels of
corticosterone in adipose tissue may have been differently regulated in knock-out
mice. 5aRl is expressed at this site (Normington and Russell 1992) and may act to
inactivate corticosterone. As tested in mesenteric fat depots, expression of the
glucocorticoid responsive gene angiotensinogen was dramatically increased in 5aRl
deficient mice receiving corticosterone treatment (without a change in blood
pressure), whereas the expression in wild-types was not changed. In contrast
however, 1 lp-HSDl was upregulated by corticosterone in animals of both knock-out
and wild-type receiving this hormone. It is not clear why the two glucocorticoid
responsive genes were diversely regulated, but the effects on angiotensinogen
suggest that within the intracellular compartments, glucocorticoid concentrations
may be altered as a result of reduced 5aRl activity. Interestingly, these changes were
revealed in adipose which does not express other clearance mechanisms (e.g. 5(3R,
5aR2, 11P-HSD2), in contrast to liver. Inside the adipocytes, corticosterone
treatment increased the activity of 1 lp-HSDl regenerating more active
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corticosterone thus amplifying the action independent of 5aRl. In the adipose tissue
ofwild-type animals, excessive glucocorticoids may subsequently be inactivated by
5aRl only. However in the 5aRl knock-out mice receiving exogenous corticosterone,
amplified corticosterone levels may have been cleared slowly in adipose tissue, and
therefore angiotensinogen may be dramatically induced. This evidence suggested
that the 5a-reduced metabolism inactivated glucocorticoid actions in adipose tissue
and may play an important role in regulating glucocorticoid action in this tissue.
Additionally, 11(3-HSD1 is responsive to glucocorticoid only but angiotensinogen
regulated by both glucocorticoid and estrogen (Kunapuli et al. 1987), the latter being
higher in 5aRl knock-out mice due to an increased accumulation of androgen
precursors (Martin et al. 2003). This may also be responsible for the diverse
regulation of the two genes. The elevated estrogen levels in the knock-out mice may
have primed for the corticosterone treatment and cause additive effects on
angiotensinogen expression.
Besides the overexpression of 1 lp-HSDl and angiotensinogen, rates of lipolysis in
adipose tissue were altered following glucocorticoid infusion. When treated with
corticosterone, basal levels ofNEFAs were significantly higher and suppression of
lipolysis was greater during the glucose tolerance test, indicative ofmild insulin
resistance. Increased insulin and free fatty acids were also observed in animals
receiving infusion of corticosterone. These changes were not significantly different
between genotypes. However, the impact of 5aRl deficiency on these variations
could be revealed more clearly in 5aRl-null mice predisposed to the Metabolic
Syndrome, e.g. following a high-fat diet, which has been demonstrated recently that
5aRl-null mice showed glucose intolerance and fatty liver (Livingstone et al. 2008).
Cytokine secretion was measured from the LPS stimulated whole blood collected
from mice of 5aRl knock-out or wild-type following infusion of corticosterone.
Production of pro-inflammatory cytokines, TNFa and IL-6, were significantly
suppressed by corticosterone treatment regardless of genotypes. These findings are
consistent with the results shown in Chapter 4. Previously we showed that the 5a-
reduced metabolites may also induce immune suppression and hypothesized that lack
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of the enzyme may to predispose to inflammation. A difference in cytokine release
was not detected between genotypes following infusion of corticosterone. Since most
corticosterone is inactivated by first pass metabolism, corticosterone treatment does
not subsequently elevate 5aTHB in blood (as demonstrated in Chapter 4); hence in
the circulation, blood leucocytes (mainly monocytes/macrophages) would not have
sensed the lack of this metabolite. Macrophages do not express 5aRl (data shown in
Chapter 3) and thus cannot locally synthesise the active metabolite.
These results lead to the conclusion that following chronic glucocorticoid excess,
hepatic 5a-reductase deficiency may be compensated to some degrees by increased
corticosterone metabolism by other routes. However, the adverse metabolic effects of
glucocorticoids are similar in wild-type and 5aRl-knock-out mice, suggesting that
variations in endogenous 5a-reduced corticosterone metabolites do not substantially
modify GR metabolic signalling during glucocorticoid excess. Whether these
metabolites are important during glucocorticoid deficiency has not been tested here.
Regarding inflammatory signalling, in macrophages A-ring reductases, but not 11 (3-
HSD1, are absent, so intact anti-inflammatory effects of glucocorticoids may be
maintained and these cells are responsive to circulating steroid concentrations. It may
only be when immune cells infiltrate tissues containing the enzyme e.g. liver and
adipose, that the paracrine effects of 5aTHB to suppress inflammation come into
play. The potential for interactions between 5aRl and inflammation in liver and





effects of 5aTHB in vivo
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6.1 Introduction
As shown in previous chapters, 5aTHB could exert anti-inflammatory effects in
isolated cells and also ex vivo following infusion in healthy mice. It increased the
secretion of anti-inflammatory cytokine IL-10, and suppressed the production of
LPS-induced pro-inflammatory cytokines TNFa and IL-6, from cultured bone
marrow derived macrophages; and also suppressed LPS-induced release of TNFa
and IL-6 from blood leucocytes harvested at cull, mainly monocytes/macrophages.
However, the anti-inflammatory effects of 5aTHB in vivo have not been tested. As
the investigation in previous chapters was carried out using LPS-stimulated
inflammatory cell models, this chapter will further pursue the effects of 5aTHB on
LPS-induced inflammation in animals. The hypothesis of the study in this chapter is
that 5aTHB will be an immune suppressant during an inflammatory response in vivo.
Aims
The aim of this chapter was to investigate the anti-inflammatory effects of 5aTHB in
mice following intraperitoneal administration of LPS.
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6.2 Methods and materials
6.2.1 Maintenance of animals
Male C57BL/6 mice were maintained as described in Section 2.3.1.
6.2.2 Buffers and solutions
6.2.2.1 Steroid injection solutions
Corticosterone and 5aTHB (0.005 g) were dissolved thoroughly in DMSO (1 ml) on
the day of experiment. Vehicle was DMSO only. They were loaded into Insulin pens
(NovoPen®3, 30G) and stored at RT.
6.2.2.2 LPS injection solution
On the day of experiment, LPS (10 mg) was dissolved thoroughly in PBS (4 ml, see
2.2.4.2) and stored at -4 °C until required.
6.2.2.3 BSA buffer (0.1% w/v)
BSA (0.3g, fraction V) was dissolved in PBS (300ml, see 2.2.4.2).
6.2.3 Administration of steroid and LPS
At 14:00, animals were injected s.c. with corticosterone, 5aTHB (0.1 mg in 20 pi
DMSO per mouse) or vehicle (DMSO, 20 pi), n=8. One hour later, all were injected
i.p. with LPS (100 pi, approximately 10 mg/kg BW).
6.2.4 Terminal procedures
At 09:00 on the next day, 18h after the administration of LPS, mice were decapitated,
and trunk blood was collected immediately into tubes containing EDTA (0.5 M).
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Plasma was prepared thereafter by centrifugation (1000 g, 5 min, 4 °C) and stored at
-20°C until required for quantification of corticosterone and ACTH.
6.2.5 Peritoneal lavage
Post mortem, mouse skin was removed from the abdomen so that the trunk was
exposed. The peritoneal cavity was washed by injecting sterile saline (0.9%, 2 ml,
Fisher Scientific) followed by gently massage on the abdomen. The cavity was
washed for three times. The first lavage fluid was transferred into a 2 ml round-
bottom microtube, and the last two lavages were combined in a 15 ml Falcon tube.
All the tubes were placed on ice.
6.2.6 Preparation of lavage samples
Following centrifugation (1,000 g, 5 min, RT) of all the lavages, the supernatant
from the first lavage fluid was aliquoted to three microtubes for quantification of
cytokines. The supernatant from the other two lavages were discarded. Lavage was
deemed unsuccessful if the peritoneal cavity was contaminated with blood, and the
samples were not processed further.
The cell pellet remaining in the Falcon tubes was resuspended in BSA buffer (0.1%
w/v, 0.5 ml) before cells were transferred into the corresponding microtube
containing cells from the first lavage. Then cells from three lavages were combined
and gently resuspended, and 10 pi was diluted in BSA buffer (0.1% w/v, 90 pi).
6.2.7 Quantification of inflammatory cells
The total number of inflammatory cells in the cell suspension (100 pi) was
determined using a NucleoCassette and a NucleoCounter (ChemoMetec, Denmark).
The reagents provided (Reagent A-100 (100 pi) followed by Reagent B (100 pi))
were added into the suspension and gently flicked to mix. Reagent A-100 (pH 1.25)
was used as a lysis buffer that disaggregated cell clusters and disrupted cell
membranes. Reagent B was a stabilizing buffer that raised the pH value and allowed
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more efficient staining ofDNA in the NucleoCassette. The disposable cassette was
loaded with approximately 50 pi of the sample mixture. The fluorescent dye
propidium iodide immobilized inside the flow channels of the cassette was dissolved
and mixed with the sample, staining the DNA of cell nuclei. The loaded cassette was
then placed in the NucleoCounter which is an integrated fluorescence microscope.
The stained sample mixture (approximately 2 pi) passed into the measurement
chamber of the cassette where the fluorescent image was recorded. The image as
well as the total cell number was generated automatically by NucleoView Software
(ChemoMetec, Denmark).
6.2.8 Cytospin and differential ceil quantification
Approximately 4><104 cells were mixed into the BSA buffer (300 pi) and deposited
by centrifugation (250 g, 3 min, RT) onto a microscope slide by Cytospin-3
(Shandon Scientific Limited, Cheshire, England). One cytospin was prepared per
mouse. Cells on the air-dried slides were fixed in 100 % methanol for lmin and
stained by eosin and methylene blue (Wright's stain) before being washed in distilled
water and allowed to dry. A coverslip was mounted on the slide with the mounting
medium and left over night for stabilization. Differential cell counts were performed
by light microscopy (Model: Axioskop, Carl Zeiss, Germany; objective, Plan-
Neofluar 40x/0.75; ocular lens, E-Pl 10x/20). At least 300 cells were counted per
slide. Standard morphologic criteria were used to identify cell types as follows,
Polymorphonuclear cells:
PMNs, also called neutrophils, are mobile phagocytes that comprise the majority of
blood leukocytes. Their nuclei are multilobed and they stain dark blue.
Eosinophils:
Eosinophils are granular leukocytes which stain with eosin. The cytoplasm contains
numerous coarse, reddish-orange granules.
Basophils andmast cells:
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Basophils and mast cells have similar morphology and functions. They are stained
with basic dyes. There are large, dark-blue granules in the cytoplasm which are
darker than the nuclei.
Lymphocytes:
Lymphocytes are stained with basic dyes and have very little cytoplasm. Their nuclei
are generally round or oval.
Monocytes and macrophages:
Monocytes resemble lymphocytes but are larger. The cytoplasm is grey-blue and
more abundant than in lymphocytes. Their nuclei are lobulated, indented or kidney-
shaped.
Macrophages originate from monocytes. The mononuclear phagocyte system is
composed of both macrophages and monocytes. Macrophages are large and variable-
shaped cells, and have round nuclei and lysosomes in the cytoplasm.
6.2.9 Biochemical assays
6.2.9.1 Quantification of plasma ACTH
ACTH in plasma prepared from trunk blood was quantified by ELISA (see 2.6.4)
6.2.9.2 Quantification of cytokines
Cytokines in plasma and lavage fluid samples were quantified by CBA assay as
described in Section 2.6.6.
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6.3 Results
6.3.1 Activation of the HPA axis
Following the administration of steroids and induction of peritonitis, plasma ACTH
and corticosterone were variable, and not significantly different between
experimental groups (Figure 6.1).
a. Plasma B
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Figure 6.1 Plasma (a) ACTFI and (b) B, quantified by ELISA and RIA respectively,
in mice with 1 h pre-treatment of steroids followed by LPS-induce peritonitis after 18
h. ACTH and B were not significantly different between experimental groups. Data
are mean ± SEM, n=8, analysed by one-way ANOVA.
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6.3.2 Differential cell quantification
Inflammatory cells in the peritoneal lavages including PMNs,
monocytes/macrophages (mono/macro), basophils/mast cells (baso/mast),
lymphocytes and eosinophils were quantified and presented by actual cell numbers
(Figure 6.2(1)) and percentage of total cells (Figure 6.2(2)). Neither steroid had any
effect when compared with vehicle treated controls, although in some case cell
numbers were variable.
6.3.3 Peritoneal cytokines
As shown in Figure 6.3, concentrations of IL-6 produced in the peritoneal cavity
were substantially suppressed by both 5aTHB and B. Peritoneal MCP-1 levels were
not different in animals between the treatment groups.
6.3.4 Plasma cytokines
As shown in Figure 6.4, circulating IL-6 concentrations were elevated in animals
pre-treated by 5aTHB only. Plasma MCP-1 levels were not different in animals






















































Figure 6.2 (1) Differential cells count of peritoneal lavages, (a) PMNs, (b)
mono/macro, (c) lymphocytes, (d) baso/mast, and (e) eosinophils, were not affected
by either steroid treatment when compared with vehicle treated controls. Data are





































Figure 6.2 (2) Differential cells count of peritoneal lavages, presented by percentage
of total cells, (a) PMNs, (b) mono/macro, (c) lymphocytes, (d) baso/mast, and (e)
eosinophils. Neither steroid had any effect when compared with vehicle treated
controls. Baso/mast cells were increased in animals pre-treated with 5aTHB
compared to B. Data are mean ± SEM, n=8, ##p<0.01 versus B, analysed by one¬





















Figure 6.3 IL-6 and MCP-1 concentrations in the peritoneal cavity, (a) IL-6 and (b)
MCP-1 were quantified in the peritoneal lavage fluid by CBA. IL-6 production was
suppressed by 5aTHB and B. Peritoneal MCP-1 was not different between the
treatment groups. Data are mean ± SEM, n=8; *p<0.05, **p<0.01 versus vehicle;





















Figure 6.4 IL-6 and MCP-1 concentrations in the plasma, (a) IL-6 and (b) MCP-1
were quantified in the plasma by CBA. IL-6 production was elevated in animals pre-
treated by 5aTHB only. Plasma MCP-1 was not significantly different between the
treatment groups. Data are mean ± SEM, n=8; *p<0.05 versus vehicle, ##p<0.01
versus B; analysed by one-way ANOVA with Holm-Sidak post-hoc tests.
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6.4 Discussion
Pharmaceutical doses of glucocorticoids have profound anti-inflammatory effects
and exert pleiotropic actions on target cells. Neutrophils are among the first immune
cells to be recruited in response to pathogens and injury. These cells, together with
basophils and eosinophils, secrete proinflammatory cytokines and chemokines that
attract other immune cells to the site of inflammation, and also remove foreign
substances through phagocytosis. Glucocorticoids inhibit the chemotactic activity of
neutrophils, induce apoptosis in basophils and eosinophils, and also suppress
proinflammatory cytokines and chemokines production from these cells (Butts and
Sternberg 2008; Goulding et al. 1998; Sorrells and Sapolsky 2007). Monocytes are
antigen presenting cells with phagocytic properties; macrophages are the mature
form ofmonocytes. They promote inflammatory responses by secreting
proinflammatory cytokines including TNF-a, IL-6 and IL-ip. At the later stage of
inflammation, macrophages remove the phagocytosing granulocytes that have
undergone apoptosis. Glucocorticoids suppress the differentiation ofmonocyte into
macrophages, macrophage phagocytosis, and secretion of proinflammatory cytokines
(Baybutt and Holsboer 1990). Moreover, glucocorticoids induce apoptosis in T
lymphocytes and shift phenotypes from Thl (secreting IL-2 and IFN-y) to Th2
(secreting IL-4 and IL-10) that reduces inflammation (Elenkov and Chrousos 2002).
Lymphocyte trafficking is also inhibited by glucocorticoids (Milad et al. 1994; Tait
et al. 2008).
As shown in previous chapters, 5aTFlB was active to suppress the LPS-induced
production of TNFa and IL-6 from cultured bone marrow derived macrophages and
blood immune cells. In the present study, anti-inflammatory effects of 5aTHB in vivo
were investigated, using the model of LPS induced peritonitis. Intra-peritoneal
administration of LPS causes a dose-dependent endotoxemia and induces a variety of
systemic responses including infiltration of immune cells. In the acute phase after
administration of LPS, neutrophils enter the peritoneal cavity, however at later stages
macrophages are attracted to the site of inflammation.
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It appeared that in the experimental animals, inflammation had resolved at 18 h,
since the numbers of immune cells in the peritoneal cavity were not elevated above
vehicle, and did not differ between steroid treatments. However initial infiltration
was not quantified. Baso/mast cells were increased in mice pre-treated with 5aTHB
compared to those primed with corticosterone but not to the controls. These cells
only represent a small population of the peritoneal immune cell family.
Glucocorticoids can induce apoptosis in basophils, which may have occurred in
response to corticosterone. Nonetheless these findings are weak and the general
picture suggests a lack of change in peritoneal cells.
The activated immune cells release cytokines (e.g. TNFa, IL-ip, and IL-6) in
response to LPS (Romanovsky, et al. 2000). Corticosterone as well as 5aTHB
reduced the production of IL-6 within the peritoneal cavity even up to 18h later,
suggesting the comparable local anti-inflammatory effects of 5aTHB and
corticosterone. These findings support those in previous chapters, although the local
concentrations of LPS and steroid in peritoneal cavity were unknown. MCP-1 was
not suppressed, consistent with equivalent numbers ofmacrophages in the lavage
fluid and also the weaker response of this chemokine in previous Chapters.
A different picture was observed in plasma, where circulating IL-6 was increased
selectively by 5aTHB. There are two routes for LPS to escape from the peritoneal
cavity, the hematogenous and the lymphogenous routes, which are via the portal vain
and the lymph system, respectively (Romanovsky et al. 2000). Cytokines produced
in the peritoneal cavity remain local, whereas those in circulation are primarily
derived from immune cells outside the peritoneal cavity, mainly from monocytes or
endothelial cells (Lenczowski et al. 1997). Appearance of LPS in the general
circulation is a prerequisite for the elevation of circulating IL-6, which plays a
critical signalling role in the LPS-induced activation of the HPA axis (Lenczowski et
al. 1997), with subsequent release ofACTH and corticosterone into the circulation.
In Lenczowski's study in rats, endotoxin appeared in the general circulation within
15 min of the intraperitoneal LPS injection, whereas elevations of plasma ACTH,
corticosterone, and IL-6 concentrations were not detected until 90 min (Lenczowski
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et al. 1997). Moreover, the elevated levels in circulating IL-6, ACTH and
corticosterone correlated with circulating endotoxin, not with local LPS or cytokines
within the peritoneal cavity (Lenczowski et al. 1997).
In the present study, circulating levels ofACTH and corticosterone at 18 hours
following administration of LPS were not significantly different between
experimental groups, perhaps simply because that peak time ofACTH elevation
induced by LPS had passed. Animals were terminated at 9:00 a.m. at the circadian
nadir for HPA hormones. The low levels ofACTH (<80 pg/ml) and corticosterone
(<120nM) suggested that the HPA axis had returned to basal. However, 5aTHB
pretreated mice exhibited higher plasma IL-6 compared to the vehicle and
corticosterone pre-treated animals. The reason of the observed deviation of plasma
ACTH, corticosterone and IL-6 is unknown, and the results were somewhat variable
between individuals (variability was also great in Lenczowski's study), although an
explanation might exist.
It has been reported in rats that the onset ofACTH suppression was observed at 2 h
post-5aTHB injection compared with 1 h post-corticosterone injection. Also the
5aTHB effect lasted longer (up to 6 h, final time point tested) than that of
corticosterone (up to 2 h) (Mclnnes et al. 2004). Plasma ACTH, corticosterone and
IL-6 concentrations peak at about 2 h after intraperitoneal administration of LPS in
rats (Lenczowski et al. 1997). In mice, plasma IL-6 also increased at 2 h post-
challenge and returned to baseline by 6 h (Eskay, et al. 1990). Thus in the present
experiment, the HPA axis would have been suppressed one hour after corticosterone
treatment so that subsequent activation of the HPA axis by LPS may be impaired.
The circulating corticosterone would be mainly exogenous and exert suppressive
effects on IL-6 secretion. Following vehicle treatment, intraperitoneal administration
of LPS would activate the HPA axis in response to cytokine production. Endogenous
corticosterone in circulation would increase to suppress IL-6 production. Eighteen
hours later, plasma IL-6 would already have returned to the basal levels in animals of
the vehicle and corticosterone treated groups. However in animals receiving 5aTHB,
the HPA axis would be suppressed in a slower and weaker manner so that LPS
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activation of the HPA axis might only be partially suppressed. Therefore 5aTHB
treated mice might produce less endogenous corticosterone than the vehicle treated
mice. Circulating 5aTHB was not potent enough to suppress IL-6 secretion from
monocytes/macrophages induced by a large dose of LPS, resulting in higher levels of
plasma IL-6 compared to the IL-6 levels in the other groups. Further time course
studies of responses of the HPA axis and cytokine release to LPS stimulation are
required to validate this explanation.
Moreover, in previously reported studies, plasma levels of IL-6 at 12 h post LPS-
challenge were at least 105 pg/ml (quantified by ELISA) (Bhattacharyya et al. 2007),
far higher than the values observed in the present study (102 pg/ml, quantified by
CBA). This might indicate that, in the present study, IL-6 levels in all animals had
already returned to base line values by 18 h after LPS treatment.
In conclusion, these results performed in vivo demonstrated the potential suppressive
effects of 5aTHB on LPS-induced production of IL-6 in the peritoneal cavity.
Although the impact of 5aTHB pre-treatment on the general circulating levels of
LPS was not tested, 5aTHB may suppress the HPA axis and somehow affect the
resolution of inflammation in vivo, resulting in prolonged elevation of IL-6 in the
circulation. Since intraperitoneal administration of endotoxin resulted in systemic
sepsis rather than restricted inflammation, it was not an ideal animal model in which
to study the anti-inflammatory effects of 5aTHB. Recently in our lab, these
experiments have been taken forward using restricted peritonitis induced by
thioglycollate which has produced reasonable dose-dependent responses of
peritoneal immune cell numbers which could be suppressed by corticosterone. Use of
this model will allow corroboration of these preliminary findings and investigation of
more detailed dose responses.
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Chapter 7
Summary and future work
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The hypothesis of this thesis is that 5aTHB possesses some of the glucocorticoid
agonist properties of its parent steroid corticosterone and hence is not an inert
metabolite. The aims of this thesis were to assess the cellular effects of 5aTHB on
transactivation and transrepression, and the physiological effects of 5aTHB on HPA
axis, fuel metabolism, and immune responses. The work described in this thesis has
demonstrated 5aTHB is a weak GR ligand with suppressive effects on immune
responses but without metabolic effects. Effects on HPA axis were discordant
between cell studies and in vivo studies and are most likely due to indirect effects.
The molecular basis for the selectivity of 5aTHB for anti-inflammatory
glucocorticoid action appears to lie in activation ofGR-mediated protein interactions
but not chromatin binding.
5aTHB induces GR translocation
Data in this thesis have demonstrated that 5aTHB is capable of inducing GR
translocation into nuclei in a slower and weaker manner than corticosterone.
Following translocation, GR ligated with 5aTHB has increased nuclear mobility
assessed by FRAP, and faster nuclear export process after steroid withdrawl,
suggesting 5aTHB has a low affinity for the receptor; and these properties are
associated with decreased ability to bind GRE and thereby decreased transcriptional
abilities (Carrigan et al. 2007; Kino et al. 2004; Sackey et al. 1996). These cellular
properties were determined by the nature of the ligand (Meijsing et al. 2007) since
5aTHB has a less preferable structure for GR binding. 5aTHB has a hydroxyl group
at the C3 position instead of the GR-favored ketone structure (Bledsoe et al. 2002).
5aDHB (with a ketone at position 3) may be a better ligand for GR than 5aTHB and
future studies should investigate the effects of 5aDHB on GR translocation and
transcriptional abilities. However the availability of 5aDHB in cells may be short¬
lived, given the widespread expression of 3aHSD.
5aTHB acted synergistically with corticosterone to induce GR nuclear translocation,
suggesting corticosterone-ligated GR may somehow facilitate the process of 5aTHB
induced translocation or vice-versa. However, the synergistic observation has not
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been tested at the transcriptional levels, and should be further investigated, e.g.
induction ofTAT in H4IIE cells.
5aTHB does not have metabolic effects through gene transactivation
5aTHB did not increase the expression ofmRNAs or activities of proteins of any of
the glucocorticoid responsive metabolic genes that were tested. Since the adverse
metabolic effects of glucocorticoids are mainly mediated via a GR induced
transactivation mechanism (Schacke, et al. 2002), 5aTHB appears inactive in this
respect. The in vitro findings were confirmed in animals receiving acute or chronic
administration of 5aTHB. Indeed, in this thesis 5aTHB did not influence metabolic
profiles, including body and organ weights, blood pressure, glucose tolerance, insulin
sensitivity, or lipid metabolism.
5a-Reductase inactivates glucocorticoids in liver and adipose tissues
5a-Reduction of glucocorticoids in liver or adipose tissue produces the inert 5a-
reduced metabolites, thus inactivating glucocorticoids giving protection from adverse
effects on metabolism. In obesity, although circulating glucocorticoids are normal,
intracellular concentrations of glucocorticoids may be elevated by conversion of 11 -
dehydrocorticosterone (or cortisone in human) to corticosterone (or Cortisol in human)
by local expression of 11P-HSD1, thereby amplifying the glucocorticoid actions.
11P-HSD1 activity has been found to be decreased in liver but enhanced in adipose
tissue (Livingstone et al. 2000; Rask et al. 2001), whereas 5aRl activity is increased
in liver (Andrew et al. 1998; Livingstone et al. 2000; Livingstone et al. 2005), of
obese Zucker rats and humans. Increased hepatic 5aRl can be interpreted as a
compensating mechanism to inactivate locally regenerated glucocorticoids, and to
increase the clearance rates of glucocorticoids together with the impaired hepatic
11P-HSD1 activities. When animals were challenged with chronic corticosterone
excess, deletion of 5aRl may be compensated by increased metabolic rates of
corticosterone through other routes, so that the adverse metabolic effects of
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glucocorticoids are not significantly different between 5aRl-deficient mice and wild-
types.
5aTHB suppresses the HPA axis
It was demonstrated in this thesis that 5aTHB suppresses the circulating ACTH in
vivo, consistent previous findings in rats (Mclnnes et al. 2004). The negative
feedback of glucocorticoids is regulated through the hypothalamus and corticotroph
cells in pituitary. We have found that 5aTHB does not suppress the mRNA
expression ofpituitary POMC in vitro and in vivo. Therefore, it is reasonable to
conclude that 5aTHB may influence the synthesis and secretion of CRH in the
hypothalamus. However, this hypothesis has not been pursued in this thesis and
requires further proof. CRH is synthesized in the PVN of hypothalamus, and its
levels of expression can be detected by in situ hybridization. The brains from animals
receiving chronic steroid infusions were collected at cull. Thus the suppression of
expression ofCRH in response to 5aTHB infusion could be tested in the future
experiment.
Alternatively, chronic treatment of 5aTHB may not have central effects to suppress
the HPA axis but may influence the peripheral clearance of corticosterone by
competition with liver enzymes. This hypothesis needs further investigation in the
future by measuring the hepatic enzymes of steroid metabolism such as A-ring
reductases, 6P-hydroxylase, 20a- and 20|3-HSDs and the metabolites of these
glucocorticoid metabolic pathways.
5aTHB has anti-inflammatory effects
Data in this thesis have demonstrated that 5aTHB has anti-inflammatory effects in
vitro and in vivo. 5aTHB can increase the release of anti-inflammatory cytokine IL-
10 and suppress the LPS-activated production ofpro-inflammatory cytokines TNFa
and IL-6 in the in vitro conditions described in this thesis. 5aTHB also suppressed
the IL-6 levels in the peritoneal fluid in mice following intra-peritoneal
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administration of LPS. Because systemic use of 5aTHB can drive negative feedback
of the HPA axis and LPS activates the HPA axis to a variable degree (Lenczowski et
al. 1997), animal models with non-systemic inflammation may be a better model
system to further investigate the anti-inflammatory effects of 5aTHB. Very recently
in our lab, restricted peritonitis induced by thioglycollate has been proved to be a
better animal model to investigate more detailed effects of 5aTHB. Similarly, croton
oil-induced inflammation in mouse ears also provides a good model to study the
effects of 5aTHB on topical inflammation (Gabor and Razga 1989).
5aTHB was effective through GR-protein binding mechanism?
As described in previous chapters, glucocorticoids exert their genomic effects
through GRs. After translocation, GR binds to the positive or negative GRE of the
target genes, or to a second transcription factors such as NFkB, AP-1 or STATs (i.e.
GR-protein binding) to exert transactivation and transrepression effects. In this thesis,
all the glucocorticoid responsive genes that were modulated by GR-GRE binding
(e.g. PEPCK, TAT, MMTV, PNMT, llp-HSDl, angiotensinogen, POMC, and CRH
receptor 1) did not respond to 5aTHB, whereas all the cytokines tested that were
modulated through a GR-protein binding mechanism (e.g. TNFa, IL-6 and IL-10)
were down- or up- regulated appropriately by 5aTHB. These results suggest that
5aTHB is active through GR-protein binding mechanism as opposed to GR-GRE
binding. Moreover, it is interested to find that RU486 augmented the suppressive
effects of 5aTHB on LPS-induced IL-6 secretion in BMDM0. Although the
mechanism is unknown, further study using RU486 to investigate the GR-protein
interaction may gain further mechanistic insight. The suppressive effects of 5aTHB
can also be investigated in the future by transfection assays with reporter driven by
the collagenase promoter, which is mediated by the GR-protein transrepression
mechanism involving GR binding to AP-1 (Yang-Yen, et al. 1990).
5aTHB-bound GR could notdimerize?
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It has long been recognized that transrepression effects of glucocorticoids on NFkB
and AP-1 are mediated by GR-protein binding mechanism independent ofGR
dimerization, e.g. through GR monomer (Heck, et al. 1997; Heck, et al. 1994). This
has been demonstrated in a number of studies using mutations on the interface of GR
dimer, such as A458T (mutation of alanine 458 to threonine in the second zinc finger
in the DBD of the GR) (Heck et al. 1994; Reichardt, et al. 1998) and 1628A
(mutation of isoleucine 628 to alanine at the core hydrophobic dimer interface in the
LBD of the GR) (Bledsoe et al. 2002). GR with a dimerization-defective mutation in
either the DBD or LBD fails to transactivate gene expression but is capable of
transrepression as efficiently as the wild-type GR. Based on observations using mice
with a GR mutation ofA458T in the DBD, GR induced transactivation ofMKP-1 to
suppress the LPS-induced p38 MAPK signalling has also been shown to be
dimerization independent (Abraham et al. 2006). Similarly in this thesis, 5aTHB
does not transactivate genes requiring GR dimerization but may transactivate or
transrepress genes independent of dimerization. This leads to the possibility that
5aTHB does not induce a sufficient conformational change ofGR structure which
would allow GR to dimerize.
This reasoning may also explain why 5aTHB is able to suppress the expression of
CRH in the hypothalamus. It is known that glucocorticoid repression of CRH
involves direct DNA binding of monomeric GR and AP-1 at discrete adjacent sites in
the promoter region (Malkoski and Dorin 1999). This also leads weight to
proposition that 5aTHB induces transrepression through GR monomer. It will be
interesting to investigate this hypothesis in the future study using the brain samples
described above.
5aTHB is a dissociated steroid
In conclusion, 5aTHB is a GR ligand that is competent to induce transrepressive
effects through monomeric GR-protein mechanism as opposed to GR homodimer
mediated transactivation. Pharmacological dose of 5aTHB selectively induces anti¬
inflammatory effects with limited metabolic adverse effects. Thus 5aTHB could be a
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potential "dissociated steroid" which could be used for long-term treatment for
inflammatory diseases. Nowadays, about 1-3% of adults worldwide are taking long-
term glucocorticoids (McDonough, et al. 2008). Treatment of high-dose
glucocorticoids is associated with 2.5-fold greater risk for cardiovascular events,
including myocardial infarction, angina, angioplasty or coronary revascularization,
stroke, transient ischemic attack, congestive cardiac failure, or cardiovascular death
(Wei, et al. 2004). It has also been revealed that glucocorticoid users in general have
spent more money than non-users on treating glucocorticoid-associated adverse
events (Pisu, et al. 2005). Therefore the development of new "dissociated steroids"
with reduced side effects are highly desirable and would allow safer and more
effective treatments for patients requiring long-term glucocorticoids therapy. The
study in this thesis on the mechanisms and effects of 5aTHB actions not only
discovered the dissociated properties of 5aTHB itself, but also provided a potential





Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J,
Saklatvala J & Clark AR 2006 Antiinflammatory effects of dexamethasone are partly
dependent on induction of dual specificity phosphatase 1. J Exp Med 203 1883-1889.
Adams M, Meijer OC, Wang J, Bhargava A & Pearce D 2003 Homodimerization of
the glucocorticoid receptor is not essential for response element binding: activation
of the phenylethanolamine N-methyltransferase gene by dimerization-defective
mutants. Mol Endocrinol 17 2583-2592.
Affolter HU & Reisine T 1985 Corticotropin releasing factor increases
proopiomelanocortin messenger RNA in mouse anterior pituitary tumor cells. JBiol
Chem 260 15477-15481.
Agarwal AK, Monder C, Eckstein B & White PC 1989 Cloning and expression of rat
cDNA encoding corticosteroid 11 beta-dehydrogenase. JBiol Chem 264 18939-
18943.
Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-
Nii Y, Ohman B & Abrahmsen L 2002 Selective inhibition of 1 lbeta-hydroxysteroid
dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic
mice. Diabetologia 45 1528-1532.
Albiston AL, Obeyesekere VR, Smith RE & Krozowski ZS 1994 Cloning and tissue
distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol
Cell Endocrinol 105 R11-17.
Andersson S, Berman DM, Jenkins EP & Russell DW 1991 Deletion of steroid 5
alpha-reductase 2 gene in male pseudohermaphroditism. Nature 354 159-161.
Andersson S & Russell DW 1990 Structural and biochemical properties of cloned
and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci USA 87
3640-3644.
Andrew R, Phillips DI & Walker BR 1998 Obesity and gender influence Cortisol
secretion and metabolism in man. JClin Endocrinol Metab 83 1806-1809.
Andrews RC & Walker BR 1999 Glucocorticoids and insulin resistance: old
hormones, newt argets. Clinical Science 96 513-523.
231
Antoni FA, Hoyland J, Woods MD & Mason WT 1992 Glucocorticoid inhibition of
stimulus-evoked adrenocorticotrophin release caused by suppression of intracellular
calcium signals. JEndocrinol 133 R13-16.
Aoki Y, Iwasaki Y, Katahira M, Oiso Y & Saito H 1997 Regulation of the rat
proopiomelanocortin gene expression in AtT-20 cells. I: effects of the common
secretagogues. Endocrinology 138 1923-1929.
Ashwell JD, Lu FW & Vacchio MS 2000 Glucocorticoids in T cell development and
function. Annu Rev Immunol 18 309-345.
Aubert J, Darimont C, Safonova I, Ailhaud G & Negrel R 1997 Regulation by
glucocorticoids of angiotensinogen gene expression and secretion in adipose cells.
Biochem J 328 ( Pt 2) 701 -706.
Auphan N, DiDonato JA, Rosette C, Helmberg A & Karin M 1995
Immunosuppression by glucocorticoids: inhibition ofNF-kappa B activity through
induction of I kappa B synthesis. Science 270 286-290.
Autelitano DJ & Cohen DR 1996 CRF stimulates expression ofmultiple fos and jun
related genes in the AtT-20 corticotroph cell. Mol Cell Endocrinol 119 25-35.
Autelitano DJ & Sheppard KE 1993 Corticotrope responsiveness to glucocorticoids
is modulated via rapid CRF-mediated induction of the proto-oncogene c-fos. Mol
Cell Endocrinol 94 111-119.
Banchereau J & Steinman RM 1998 Dendritic cells and the control of immunity.
Nature 392 245-252.
Barnes P 1998 Anti-inflammatory actions of glucocorticoids: molecular mechanisms.
Clinical Science 94 557-572.
Bartholome B, Spies CM, Gaber T, Schuchmann S, Berki T, Kunkel D, Bienert M,
Radbruch A, Burmester GR, Lauster R, Scheffold A, Buttgereit F 2004 Membrane
glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood
mononuclear cells and up-regulated after in vitro stimulation and in patients with
rheumatoid arthritis. FASEB J18 70-80.
232
Baum M, Moe OW, Gentry DL & Alpern RJ 1994 Effect of glucocorticoids on renal
cortical NHE-3 and NHE-1 mRNA. Am JPhysiol 267 F437-442.
Baxter JD & Forsham PH 1972 Tissue effects of glucocorticoids. Am JMed 53 573-
589.
Baxter JD & Tomkins GM 1971 Specific cytoplasmic glucocorticoid hormone
receptors in hepatoma tissue culture cells. Proc Natl Acad Sci USA 68 932-937.
Baybutt HN & Holsboer F 1990 Inhibition ofmacrophage differentiation and
function by Cortisol. Endocrinology 127 476-480.
Beato M & Klug J 2000 Steroid hormone receptors: an update. Hum Reprod Update
6 225-236.
Best R, Nelson SM & Walker BR 1997 Dexamethasone and 11-
dehydrodexamethasone as tools to investigate the isozymes of 11 beta-
hydroxysteroid dehydrogenase in vitro and in vivo. JEndocrinol 153 41-48.
Bhattacharyya S, Brown DE, Brewer JA, Vogt SK & Muglia LJ 2007 Macrophage
glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory
responses by selective inhibition of p38 MAP kinase. Blood 109 4313-4319.
Bland R, Worker CA, Noble BS, Eyre LJ, Bujalska IJ, Sheppard MC, Stewart PM &
Hewison M 1999 Characterization of 1 lbeta-hydroxysteroid dehydrogenase activity
and corticosteroid receptor expression in human osteosarcoma cell lines. J
Endocrinol 161 455-464.
Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler
TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE
2002 Crystal structure of the glucocorticoid receptor ligand binding domain reveals a
novel mode of receptor dimerization and coactivator recognition. Cell 110 93-105.
Bollen M, Keppens S & Stalmans W 1998 Specific features of glycogen metabolism
in the liver. Biochem J 336 ( Pt 1) 19-31.
Borlak J, Schulte I & Thum T 2004 Androgen metabolism in thymus of fetal and
adult rats. Drug Metab Dispos 32 675-679.
233
Boullu-Ciocca S, Paulmyer-Lacroix O, Fina F, Ouafik L, Alessi MC, Oliver C &
Grino M 2003 Expression of the mRNAs coding for the glucocorticoid receptor
isoforms in obesity. Obes Res 11 925-929.
Brem AS 2001 Insights into glucocorticoid-associated hypertension. Am J Kidney
Dis 37 1-10.
Brem AS, Bina RB, Mehta S & Marshall J 1999 Glucocorticoids inhibit the
expression of calcium-dependent potassium channels in vascular smooth muscle.
Mol Genet Metab 67 53-57.
Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C,
Murad P, Lyons V, Mullins JJ, Edwards CR, Seckl JR 1996a Cloning and production
of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2.
Biochem J313 ( Pt 3) 1007-1017.
Brown RW, Chapman KE, Murad P, Edwards CR & Seckl JR 1996b Purification of
11 beta-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel
affinity labelling technique. Biochem J313 ( Pt 3) 997-1005.
Buren J, Liu HX, Jensen J & Eriksson JW 2002 Dexamethasone impairs insulin
signalling and glucose transport by depletion of insulin receptor substrate-1,
phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes.
Eur JEndocrinol 146 419-429.
Buttgereit F & Scheffold A 2002 Rapid glucocorticoid effects on immune cells.
Steroids 67 529-534.
Butts CL & Sternberg EM 2008 Neuroendocrine factors alter host defense by
modulating immune function. Cell Immunol 252 7-15.
Carlstedt-Duke J, Gustafsson JA, Gustafsson SA & Wrange O 1977 Interactions of
corticosterone, 5alpha-dihydrocorticosterone and dexamethasone with proteins in rat-
liver cytosol. Eur JBiochem 73 231-238.
Carrigan A, Walther RF, Salem HA, Wu D, Atlas E, Lefebvre YA & Hache RJ 2007
An active nuclear retention signal in the glucocorticoid receptor functions as a strong
inducer of transcriptional activation. JBiol Chem 282 10963-10971.
Catley M 2007 Dissociated steroids. Scientific World Journal 7 421-430.
234
Chen F, Watson CS & Gametchu B 1999 Association of the glucocorticoid receptor
alternatively-spliced transcript 1A with the presence of the high molecular weight
membrane glucocorticoid receptor in mouse lymphoma cells. JCell Biochem 74 430-
446.
Christenson LK & Strauss JF, 3rd 2001 Steroidogenic acute regulatory protein: an
update on its regulation and mechanism of action. Arch Med Res 32 576-586.
Chung BC, Picado-Leonard J, Haniu M, Bienkowski M, Hall PF, Shively JE &
Miller WL 1987 Cytochrome P450cl7 (steroid 17 alpha-hydroxylase/17,20 lyase):
cloning of human adrenal and testis cDNAs indicates the same gene is expressed in
both tissues. Proc Natl Acad Sci USA 84 407-411.
Cole TJ 1995 Cloning of the mouse 11 beta-hydroxysteroid dehydrogenase type 2
gene: tissue specific expression and localization in distal convoluted tubules and
collecting ducts of the kidney. Endocrinology 136 4693-4696.
Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M & Stewart PM 2000
Expression and functional consequences of 11 beta-hydroxysteroid dehydrogenase
activity in human bone. Bone 27 375-381.
Coppack SW, Jensen MD & Miles JM 1994 In vivo regulation of lipolysis in humans.
JLipid Res 35 177-193.
Cox G 1995 Glucocorticoid treatment inhibits apoptosis in human neutrophils.
Separation of survival and activation outcomes. J Immunol 154 4719-4725.
Croxtall JD, Choudhury Q & Flower RJ 2000 Glucocorticoids act within minutes to
inhibit recruitment of signalling factors to activated EGF receptors through a
receptor-dependent, transcription-independent mechanism. Br JPharmacol 130 289-
298.
Cushing H 1912 The pituitary body and its disorders. Philadelphia, Lippincott.
de Castro M, Elliot S, Kino T, Bamberger C, Karl M, Webster E & Chrousos GP
1996 The non-ligand binding beta-isoform of the human glucocorticoid receptor
(hGR beta): tissue levels, mechanism of action, and potential physiologic role. Mol
Med 2 597-607.
de Kloet ER, de Jong IE & Oitzl MS 2008 Neuropharmacology of glucocorticoids:
focus on emotion, cognition and cocaine. Eur JPharmacol 585 473-482.
235
De Matteo R & May CN 1997 Glucocorticoid-induced renal vasodilatation is
mediated by a direct renal action involving nitric oxide. Am JPhysiol 273 R1972-
1979.
de Wet JR, Wood KV, DeLuca M, Helinski DR & Subramani S 1987 Firefly
luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 7 725-
737.
Degtiar WG & Kushlinsky NE 2001 3alpha-Hydroxysteroid dehydrogenase in
animal and human tissues. Biochemistry (Mosc) 66 256-266.
DeRijk RH, SchaafM & de Kloet ER 2002 Glucocorticoid receptor variants: clinical
implications. JSteroid Biochem Mol Biol 81 103-122.
Diamondstone TI 1966 Assay of tyrosine transaminase activity by conversion of p-
hydroxyphenylpyruvate to p-hydroxybenzaldehyde. Analytical Biochemistry 16 395-
401.
Doering DD, Steckelbroeck S, Doering T & Klingmuller D 2002 Effects of butyltins
on human 5alpha-reductase type 1 and type 2 activity. Steroids 67 859-867.
Domalik LJ, Chaplin DD, Kirkman MS, Wu RC, Liu WW, Howard TA, Seldin MF
& Parker KL 1991 Different isozymes ofmouse 11 beta-hydroxylase produce
mineralocorticoids and glucocorticoids. Mol Endocrinol 5 1853-1861.
Dostert A & Heinzel T 2004 Negative glucocorticoid receptor response elements and
their role in glucocorticoid action. Curr Pharm Des 10 2807-2816.
Drouin J, Sun YL, Chamberland M, Gauthier Y, De Lean A, Nemer M & Schmidt TJ
1993a Novel glucocorticoid receptor complex with DNA element of the hormone-
repressed POMC gene. EMBOJ12 145-156.
Drouin J, Sun YL, Chamberland M, Gauthier Y, Lean AD, Nemer M & Schmidt TJ
1993b Novel glucocorticoid receptor complex with DNA element of the hormone-
repressed POMC gene. EMBO Jounal 12 145-156.
Drouin J, Sun YL, Tremblay S, Lavender P, Schmidt TJ, de Lean A & Nemer M
1992 Homodimer formation is rate-limiting for high affinity DNA binding by
glucocorticoid receptor. Mol Endocrinol 6 1299-1309.
236
Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J,
Goldstein S, Gundberg C, Bradley A, Karsenty G 1996 Increased bone formation in
osteocalcin-deficient mice. Nature 382 448-452.
Dufort I, Soucy P, Labrie F & Luu-The V 1996 Molecular cloning of human type 3 3
alpha-hydroxysteroid dehydrogenase that differs from 20 alpha-hydroxysteroid
dehydrogenase by seven amino acids. Biochem Biophys Res Commun 228 474-479.
Duma D, Jewell CM & Cidlowski JA 2006 Multiple glucocorticoid receptor
isoforms and mechanisms of post-translational modification. JSteroid Biochem Mol
Biol 102 11-21.
Eckel RH, Grundy SM & Zimmet PZ 2005 The metabolic syndrome. Lancet 365
1415-1428.
Edwards CR, Stewart PM, Burt D, Brett L, Mclntyre MA, Sutanto WS, de Kloet ER
& Monder C 1988 Localisation of 11 beta-hydroxysteroid dehydrogenase—tissue
specific protector of the mineralocorticoid receptor. Lancet 2 986-989.
Eijken M, Hewison M, Cooper MS, de Jong FH, Chiba El, Stewart PM, Uitterlinden
AG, Pols HA & van Leeuwen JP 2005 1 lbeta-Hydroxysteroid dehydrogenase
expression and glucocorticoid synthesis are directed by a molecular switch during
osteoblast differentiation. Mol Endocrinol 19 621-631.
Eijken M, Koedam M, van Driel M, Buurman CJ, Pols HA & van Leeuwen JP 2006
The essential role of glucocorticoids for proper human osteoblast differentiation and
matrix mineralization. Mol Cell Endocrinol 248 87-93.
Elenkov IJ & Chrousos GP 2002 Stress hormones, proinflammatory and
antiinflammatory cytokines, and autoimmunity. Ann N YAcad Sci 966 290-303.
Elliott P, Peters RF & White AM 1971 A study of the relationship between
glucocorticoid-induced weight loss in rats and the activity of skeletal-muscle and
cardiac-muscle ribosomes in vitro. Biochem J125 106P-107P.
Encio IJ & Detera-Wadleigh SD 1991 The genomic structure of the human
glucocorticoid receptor. JBiol Chem 266 7182-7188.
Eskay RL, Grino M & Chen HT 1990 Interleukins, signal transduction, and the
immune system-mediated stress response. Adv Exp Med Biol 274 331-343.
237
Evans AL, Brown W, Kenyon CJ, Maxted KJ & Smith DC 1994 Improved system
for measuring systolic blood pressure in the conscious rat. Med Biol Eng Comput 32
101-102.
Exton JH 1979 Regulation of gluconeogenesis by glucocorticoids. Monogr
Endocrinol 12 535-546.
Eyre LJ, Rabbitt EH, Bland R, Hughes SV, Cooper MS, Sheppard MC, Stewart PM
& Hewison M 2001 Expression of 11 beta-hydroxysteroid dehydrogenase in rat
osteoblastic cells: pre-receptor regulation of glucocorticoid responses in bone. JCell
Biochem 81 453-462.
Falardeau P & Martineau A 1989 Prostaglandin 12 and glucocorticoid-induced rise in
arterial pressure in the rat. JHypertens 7 625-632.
Falduto MT, Hickson RC & Young AP 1989 Antagonism by glucocorticoids and
exercise on expression of glutamine synthetase in skeletal muscle. FASEB J 3 2623-
2628.
Fang H, Pengal RA, Cao X, Ganesan LP, Wewers MD, Marsh CB & Tridandapani S
2004 Lipopolysaccharide-induced macrophage inflammatory response is regulated
by SHIP. J Immunol 173 360-366.
Fassler R, Sasaki T, Timpl R, Chu ML & Werner S 1996 Differential regulation of
fibulin, tenascin-C, and nidogen expression during wound healing of normal and
glucocorticoid-treated mice. Exp Cell Res 222 111-116.
Fietta P 2007 Glucocorticoids and brain functions. Riv Biol 100 403-418.
Fleig WE, Noether-Fleig G, Roeben H & Ditschuneit H 1984 Hormonal regulation
of key gluconeogenic enzymes and glucose release in cultured hepatocytes: effects of
dexamethasone and gastrointestinal hormones on glucagon action. Arch Biochem
Biophys 229 368-378.
Franchimont D 2004 Overview of the actions of glucocorticoids on the immune
response: a good model to characterize new pathways of immunosuppression for new
treatment strategies. Ann N YAcad Sci 1024 124-137.
Franchimont D, Louis E, Dewe W, Martens H, Vrindts-Gevaert Y, De Groote D,
Belaiche J & Geenen V 1998 Effects of dexamethasone on the profile of cytokine
secretion in human whole blood cell cultures. Regul Pept 73 59-65.
238
Freeman L, Hewison M, Hughes SV, Evans KN, Hardie D, Means TK &
Chakraverty R 2005 Expression of 1 lbeta-hydroxysteroid dehydrogenase type 1
permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood
106 2042-2049.
Fried SK, Bunkin DA & Greenberg AS 1998 Omental and subcutaneous adipose
tissues of obese subjects release interleukin-6: depot difference and regulation by
glucocorticoid. JClin Endocrinol Metab 83 847-850.
Fried SK, Russell CD, Grauso NL & Brolin RE 1993 Lipoprotein lipase regulation
by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese
women and men. JClin Invest 92 2191-2198.
Fukao T & Koyasu S 2003 PI3K and negative regulation ofTLR signaling. Trends
Immunol 24 358-363.
Fuller PJ & Young MJ 2005 Mechanisms ofmineralocorticoid action. Hypertension
46 1227-1235.
Funder JW, Pearce PT, Smith R & Smith AI 1988 Mineralocorticoid action: target
tissue specificity is enzyme, not receptor, mediated. Science 242 583-585.
Gabor M & Razga Z 1989 Influence of nonsteroidal antiphlogistics on mouse ear
inflammation induced with croton oil. Arch Int Pharmacodyn Ther 299 241-246.
Galigniana MD, Scruggs JL, Herrington J, Welsh MJ, Carter-Su C, Housley PR &
Pratt WB 1998 Heat shock protein 90-dependent (geldanamycin-inhibited)
movement of the glucocorticoid receptor through the cytoplasm to the nucleus
requires intact cytoskeleton. Mol Endocrinol 12 1903-1913.
Gametchu B, Watson CS & Wu S 1993 Use of receptor antibodies to demonstrate
membrane glucocorticoid receptor in cells from human leukemic patients. FASEB J 7
1283-1292.
Gathercole LL, Bujalska IJ, Stewart PM & Tomlinson JW 2007 Glucocorticoid
modulation of insulin signaling in human subcutaneous adipose tissue. JClin
Endocrinol Metab 92 4332-4339.
Giambartolomei GH, Dennis VA, Lasater BL, Murthy PK & Philipp MT 2002
Autocrine and exocrine regulation of interleukin-10 production in THP-1 cells
stimulated with Borrelia burgdorferi lipoproteins. Infect Immun 70 1881-1888.
239
Gilmour JS, Coutinho AE, Cailhier JF, Man TY, Clay M, Thomas G, Harris HJ,
Mullins JJ, Seckl JR, Savill JS, Chapman KE 2006 Local amplification of
glucocorticoids by 11 beta-hydroxysteroid dehydrogenase type 1 promotes
macrophage phagocytosis of apoptotic leukocytes. J Immunol 176 7605-7611.
Gingras MC & Margolin JF 2000 Differential expression ofmultiple unexpected
genes during U937 cell and macrophage differentiation detected by suppressive
subtractive hybridization. Exp Hematol 28 350.
Golf SW, Bepperling F & Graef V 1984 Effect of 5 alpha-dihydrocorticoids on
enzymes of gluconeogenesis in rat liver. Steroids 43 85-91.
Goodwin B, Gauthier KC, Umetani M, Watson MA, Lochansky MI, Collins JL,
Leitersdorf E, Mangelsdorf DJ, Kliewer SA & Repa JJ 2003 Identification of bile
acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X
receptor. Proc Natl Acad Sci USA 100 223-228.
Gorlich D & Kutay U 1999 Transport between the cell nucleus and the cytoplasm.
Annu Rev Cell Dev Biol 15 607-660.
Gorsline J, Harnik M, Tresco PA & Morris DJ 1986 Hypertensinogenic activities of
ring A-reduced metabolites of aldosterone. Hypertension Suppl 18 1-187-191.
Gorsline J, Latif SA & Morris DJ 1988 Changes in 5 alpha- and 5 beta-reductase
pathways of aldosterone metabolism by dietary sodium. Am JHypertens 1 272-275.
Goulding NJ, Euzger HS, Butt SK & Perretti M 1998 Novel pathways for
glucocorticoid effects on neutrophils in chronic inflammation. Inflamm Res 47 Suppl
3 S158-165.
Grange T, Cappabianca L, Flavin M, Sassi H & Thomassin H 2001 In vivo analysis
of the model tyrosine aminotransferase gene reveals multiple sequential steps in
glucocorticoid receptor action. Oncogene 20 3028-3038.
Grange T, Roux J, Rigaud G & Pictet R 1991 Cell-type specific activity of two
glucocorticoid responsive units of rat tyrosine aminotransferase gene is associated
with multiple binding sites for C/EBP and a novel liver-specific nuclear factor.
Nucleic Acids Res 19 131-139.
240
Grundy WN, Bailey TL, Elkan CP & Baker ME 1997 Hidden Markov model
analysis ofmotifs in steroid dehydrogenases and their homologs. Biochem Biophys
Res Commun 231 760-766.
Gwynne JT, Hess B, Hughes T, Rountree R & Mahaffee D 1984 The role of serum
high density lipoproteins in adrenal steroidogenesis. Endocr Res 10 411-430.
Haffner SM 2006 Relationship of metabolic risk factors and development of
cardiovascular disease and diabetes. Obesity (Silver Spring) 14 Suppl 3 121S-127S.
Haller J, Mikics E & Makara GB 2008 The effects of non-genomic glucocorticoid
mechanisms on bodily functions and the central neural system. A critical evaluation
of findings. Front Neuroendocrinal 29 273-291.
Hara A, Matsuura K, Tamada Y, Sato K, Miyabe Y, Deyashiki Y & Ishida N 1996
Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding
protein and an oxidoreductase of human colon cells. Biochem J 313 ( Pt 2) 373-376.
Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P & Cato AC 1997 I kappaB
alpha-independent downregulation ofNF-kappaB activity by glucocorticoid receptor.
EMBO J16 4698-4707.
Heck S, Kullmann M, Gast A, Ponta H, RahmsdorfHJ, Herrlich P & Cato AC 1994
A distinct modulating domain in glucocorticoid receptor monomers in the repression
of activity of the transcription factor AP-1. EMBO J13 4087-4095.
Hench PS 1950 The reversibility of certain rheumatic and non-rheumatic conditions
by the use of cortisone or of the pituitary adrenocorticotrophic hormone. In Nobel
Lectures, Physiology or Medicine, pp 1942-1962. Amsterdam: Elsevier.
Hench PS & Kendall EC 1949 The effect of a hormone of the adrenal cortex (17-
hydroxy-11-dehydrocorticosterone; compound E) and of pituitary
adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin Proc 24 181-197.
Higashijima M, Nawata H, Kato K & Ibayashi H 1987 Studies on lipoprotein and
adrenal steroidogenesis: I. Roles of low density lipoprotein- and high density
lipoprotein-cholesterol in steroid production in cultured human adrenocortical cells.
Endocrinol Jpn 34 635-645.
241
Hillgartner FB, Salati LM & Goodridge AG 1995 Physiological and molecular
mechanisms involved in nutritional regulation of fatty acid synthesis. Physiol Rev 75
47-76.
Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Brad Thompson
E, Rosenfeld MG & Evans RM 1985 Primary structure and expression of a
functional human glucocorticoid receptor cDNA. Nature 318 635-641.
Holmes MC, Sangra M, French KL, Whittle IR, Paterson J, Mullins JJ & Seckl JR
2006 1 lbeta-Hydroxysteroid dehydrogenase type 2 protects the neonatal cerebellum
from deleterious effects of glucocorticoids. Neuroscience 137 865-873.
Holmes MC & Seckl JR 2006 The role of 11 beta-hydroxysteroid dehydrogenases in
the brain. Mol Cell Endocrinol 248 9-14.
Hosoe S, Ogura T, Hayashi S, Komuta K, Ikeda T, Shirasaka T, Kawase I, Masuno T
& Kishimoto S 1989 Induction of tumoricidal macrophages from bone marrow cells
of normal mice or mice bearing a colony-stimulating-factor-producing tumor.
Cancer Immunol Immunother 28 116-122.
Howlett TA, Drury PL, Perry L, Doniach I, Rees LH & Besser GM 1986 Diagnosis
and management of ACTH-dependent Cushing's syndrome: comparison of the
features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf) 24 699-
713.
Htun H, Barsony J, Renyi I, Gould DL & Hager GL 1996 Visualization of
glucocorticoid receptor translocation and intranuclear organization in living cells
with a green fluorescent protein chimera. Proc Natl Acad Sci USA 93 4845-4850.
Iredale PA & Duman RS 1997 Glucocorticoid regulation of corticotropin-releasing
factor 1 receptor expression in pituitary-derived AtT-20 cells. Mol Pharmacol 51
794-799.
Joels M 2007 Role of corticosteroid hormones in the dentate gyrus. Prog Brain Res
163 355-370.
Justesen J, Mosekilde L, Holmes M, Stenderup K, Gasser J, Mullins JJ, Seckl JR &
Kassem M 2004 Mice deficient in 11 beta-hydroxysteroid dehydrogenase type 1 lack
bone marrow adipocytes, but maintain normal bone formation. Endocrinology 145
1916-1925.
242
Kanelakis KC, Shewach DS & Pratt WB 2002 Nucleotide binding states of hsp70
and hsp90 during sequential steps in the process of glucocorticoid receptor.hsp90
heterocomplex assembly. JBiol Chem 277 33698-33703.
Kawamura J, Tanimoto T, Fukuda H & Hayakawa T 1981 Structural requirements in
20-oxo-steroids for interaction with the binding site of 2Obeta-hydroxysteroid
dehydrogenase. Chem Pharm Bull (Tokyo) 29 476-484.
Kennedy B & Ziegler MG 1991 Cardiac epinephrine synthesis. Regulation by a
glucocorticoid. Circulation 84 891-895.
Kenyon C, Saccoccio N, Harnik M & Morris D 1985 The effects of long-term
infusions of the reduced derivatives of aldosterone on water and electrolyte
metabolism. The Adrenal Gland and Hypertension 27 209-214.
Kenyon CJ, Brem AS, McDermott MJ, Deconti GA, Latif SA & Morris DJ 1983
Antinatriuretic and kaliuretic activities of the reduced derivatives of aldosterone.
Endocrinology 112 1852-1856.
Khanna M, Qin KN, Wang RW & Cheng KC 1995 Substrate specificity, gene
structure, and tissue-specific distribution of multiple human 3 alpha-hydroxysteroid
dehydrogenases. JBiol Chem 270 20162-20168.
Kino T, Liou SH, Charmandari E & Chrousos GP 2004 Glucocorticoid receptor
mutants demonstrate increased motility inside the nucleus of living cells: time of
fluorescence recovery after photobleaching (FRAP) is an integrated measure of
receptor function. Mol Med 10 80-88.
Knolle PA, Uhrig A, Protzer U, Trippler M, Duchmann R, Meyer zum Buschenfelde
KH & Gerken G 1998 Interleukin-10 expression is autoregulated at the
transcriptional level in human and murine Kupffer cells. Hepatology 27 93-99.
Kondo KH, Kai MH, Setoguchi Y, Eggertsen G, Sjoblom P, Setoguchi T, Okuda KI
& Bjorkhem I 1994 Cloning and expression of cDNA of human delta 4-3-oxosteroid
5 beta-reductase and substrate specificity of the expressed enzyme. Eur J Biochem
219 357-363.
Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR & Mullins
JJ 1999 Hypertension in mice lacking 1 lbeta-hydroxysteroid dehydrogenase type 2.
J Clin Invest 103 683-689.
243
Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best
R, Brown R, Edwards CR, Seckl JR, Mullins JJ 1997 1 lbeta-hydroxysteroid
dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible
responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94
14924-14929.
Krsek M, Rosicka M, Nedvidkova J, Kvasnickova H, Hana V, Marek J, Haluzik M,
Lai EW & Pacak K 2006 Increased lipolysis of subcutaneous abdominal adipose
tissue and altered noradrenergic activity in patients with Cushing's syndrome: an in-
vivo microdialysis study. Physiol Res 55 421-428.
Kunapuli SP, Benedict CR & Kumar A 1987 Tissue specific hormonal regulation of
the rat angiotensinogen gene expression. Arch Biochem Biophys 254 642-646.
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R,
Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli
C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J,
Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast
differentiation and activation. Cell 93 165-176.
Landfield PW, Baskin RK & Pitler TA 1981 Brain aging correlates: retardation by
hormonal-pharmacological treatments. Science 214 581-584.
Landfield PW, Waymire JC & Lynch G 1978 Hippocampal aging and
adrenocorticoids: quantitative correlations. Science 202 1098-1102.
Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E & Arnaud CD 1998
Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis.
Results of a randomized controlled clinical trial. J Clin Invest 102 1627-1633.
LaPier TK 1997 Glucocorticoid-induced muscle atrophy. The role of exercise in
treatment and prevention. JCardiopulm Rehabil 17 76-84.
Laplace JR, Husted RF & Stokes JB 1992 Cellular responses to steroids in the
enhancement ofNa+ transport by rat collecting duct cells in culture. Differences
between glucocorticoid and mineralocorticoid hormones. JClin Invest 90 1370-1378.
Lazar MA 2002 Mechanism of action of hormones that act on nuclear receptors. In
Williams textbook ofendocrinology, edn 10th, pp 35-44. Eds PR Larsen, HM
Kronenberg, S Melmed & KS Polonsky. Philadelphia: Saunders.
244
Lee YC, Lin HH & Tang MJ 1995 Glucocorticoid upregulates Na-K-ATPase alpha-
and beta-mRNA via an indirect mechanism in proximal tubule cell primary cultures.
Am JPhysiol 268 F862-867.
Lefebvre P, Berard DS, Cordingley MG & Hager GL 1991 Two regions of the
mouse mammary tumor virus long terminal repeat regulate the activity of its
promoter in mammary cell lines. Mol Cell Biol 11 2529-2537.
Lemonde HA, Custard EJ, Bouquet J, Duran M, Overmars H, Scambler PJ &
Clayton PT 2003 Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-
oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. Gut 52 1494-
1499.
Lenczowski MJ, Van Dam AM, Poole S, Larrick JW & Tilders FJ 1997 Role of
circulating endotoxin and interleukin-6 in the ACTH and corticosterone response to
intraperitoneal LPS. Am JPhysiol 273 R1870-1877.
Lewis-Tuffin LJ & Cidlowski JA 2006 The physiology of human glucocorticoid
receptor beta (hGRbeta) and glucocorticoid resistance. Ann N YAcad Sci 1069 1-9.
Lewis-Tuffin LJ, Jewell CM, Bienstock RJ, Collins JB & Cidlowski JA 2007 Human
glucocorticoid receptor beta binds RU-486 and is transcriptionally active. Mol. Cell.
Biol. 27 2266-2282.
Li KX, Smith RE, Ferrari P, Funder JW & Krozowski ZS 1996 Rat 11 beta-
hydroxysteroid dehydrogenase type 2 enzyme is expressed at low levels in the
placenta and is modulated by adrenal steroids in the kidney. Mol Cell Endocrinol 120
67-75.
Liberman AC, Druker J, Perone MJ & Arzt E 2007 Glucocorticoids in the regulation
of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev
18 45-56.
Lin HK, Hung CF, Moore M & Penning TM 1999 Genomic structure of rat 3alpha-
hydroxysteroid/dihydrodiol dehydrogenase (3alpha-HSD/DD, AKR1C9). JSteroid
Biochem Mol Biol 71 29-39.
Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA & Penning TM 1997
Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid
dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3
alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol 11 1971-1984.
245
Lindsay RS, Lindsay RM, Edwards CR & Seckl JR 1996a Inhibition of 11-beta-
hydroxysteroid dehydrogenase in pregnant rats and the programming of blood
pressure in the offspring. Hypertension 27 1200-1204.
Lindsay RS, Lindsay RM, Waddell BJ & Seckl JR 1996b Prenatal glucocorticoid
exposure leads to offspring hyperglycaemia in the rat: studies with the 11 beta-
hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia 39 1299-1305.
Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ &
Walker BR 2000 Understanding the role of glucocorticoids in obesity: tissue-specific
alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141
560-563.
Livingstone DE, Mclnnes KJ, Walker BR & Andrew R 2005 Increased A-ring
reduction of glucocorticoids in obese Zucker rats: effects of insulin sensitization.
ObesRes 13 1523-1526.
Livingstone DE, Walker BR & Andrew R 2008 Increased susceptibility to liver fat
accumulation and insulin resistance, but not obesity, induced by high fat diet in 5
alpha-reductase type 1 knock-out mice. In The Endocrine Society's Annual Meeting.
San Francisco.
Loechner KJ, Knox RJ, McLaughlin JT & Dunlap K 1999 Dexamethasone-mediated
inhibition of calcium transients and ACTH release in a pituitary cell line (AtT-20).
Steroids 64 404.
Lowenberg M, Stahn C, Hommes DW & Buttgereit F 2008 Novel insights into
mechanisms of glucocorticoid action and the development of new glucocorticoid
receptor ligands. Steroids 73 1025-1029.
Lupien SJ, de Leon M, de Santi S, Convit A, Tarshish C, Nair NP, Thakur M,
McEwen BS, Hauger RL & Meaney MJ 1998 Cortisol levels during human aging
predict hippocampal atrophy and memory deficits. Nat Neurosci 1 69-73.
Lupien SJ, Maheu F, Tu M, Fiocco A & Schramek TE 2007 The effects of stress and
stress hormones on human cognition: Implications for the field of brain and
cognition. Brain Cogn 65 209-237.
Luu-The V, Pelletier G & Labrie F 2005 Quantitative appreciation of steroidogenic
gene expression in mouse tissues: new roles for type 2 5alpha-reductase, 20alpha-
hydroxysteroid dehydrogenase and estrogen sulfotransferase. JSteroid Biochem Mol
Biol 93 269-276.
246
Macfarlane DP, Forbes S & Walker BR 2008 Glucocorticoids and fatty acid
metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J
Endocrinol 197 189-204.
Mackenzie SM, Huda SS, Sattar N, Fraser R, Connell JM & Davies E 2008 Depot-
specific steroidogenic gene transcription in human adipose tissue. Clin Endocrinol
(Oxj) 69 848-854.
MacPhee IA, Antoni FA & Mason DW 1989 Spontaneous recovery of rats from
experimental allergic encephalomyelitis is dependent on regulation of the immune
system by endogenous adrenal corticosteroids. J Exp Med 169 431-445.
Mahendroo MS, Cala KM, Hess DL & Russell DW 2001 Unexpected virilization in
male mice lacking steroid 5 alpha-reductase enzymes. Endocrinology 142 4652-4662.
Mahendroo MS, Cala KM, Landrum DP & Russell DW 1997 Fetal death in mice
lacking 5alpha-reductase type 1 caused by estrogen excess. Mol Endocrinol 11 917-
927.
Mahendroo MS, Cala KM & Russell DW 1996 5 alpha-reduced androgens play a
key role in murine parturition. Mol Endocrinol 10 380-392.
Mahendroo MS, Porter A, Russell DW & Word RA 1999 The parturition defect in
steroid 5alpha-reductase type 1 knockout mice is due to impaired cervical ripening.
Mol Endocrinol 13 981-992.
Malkoski SP & Dorin RI 1999 Composite glucocorticoid regulation at a functionally
defined negative glucocorticoid response element of the human corticotropin-
releasing hormone gene. Mol Endocrinol 13 1629-1644.
Malkoski SP, Handanos CM & Dorin RI 1997 Localization of a negative
glucocorticoid response element of the human corticotropin releasing hormone gene.
Mol Cell Endocrinol 127 189-199.
Mancini T, Doga M, Mazziotti G & Giustina A 2004 Cushing's syndrome and bone.
Pituitary 7 249-252.
Mantha L, Palacios E & Deshaies Y 1999 Modulation of triglyceride metabolism by
glucocorticoids in diet-induced obesity. Am JPhysiol 277 R455-464.
247
Martin RM, Lin CJ, Nishi MY, Billerbeck AE, Latronico AC, Russell DW &
Mendonca BB 2003 Familial hyperestrogenism in both sexes: clinical, hormonal, and
molecular studies of two siblings. JClin Endocrinol Metab 88 3027-3034.
Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM,
Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS 2003 Transgenic
amplification of glucocorticoid action in adipose tissue causes high blood pressure in
mice. JClin Invest 112 83-90.
McDonough AK, Curtis JR & Saag KG 2008 The epidemiology of glucocorticoid-
associated adverse events. Curr Opin Rheumatol 20 131-137.
McEwen BS & Magarinos AM 2001 Stress and hippocampal plasticity: implications
for the pathophysiology of affective disorders. Hum Psychopharmacol 16 S7-S19.
Mclnnes KJ, Kenyon CJ, Chapman KE, Livingstone DE, Macdonald LJ, Walker BR
& Andrew R 2004 5alpha-reduced glucocorticoids, novel endogenous activators of
the glucocorticoid receptor. JBiol Chem 279 22908-22912.
McNally JG, Muller WG, Walker D, Wolford R & Hager GL 2000 The
glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science
287 1262.
Meijsing SH, Elbi C, Luecke HF, Hager GL & Yamamoto KR 2007 The ligand
binding domain controls glucocorticoid receptor dynamics independent of ligand
release. Mol Cell Biol 27 2442-2451.
Milad MA, Ludwig EA, Anne S, Middleton E, Jr. & Jusko WJ 1994
Pharmacodynamic model for joint exogenous and endogenous corticosteroid
suppression of lymphocyte trafficking. JPharmacokinet Biopharm 22 469-480.
Mirescu C & Gould E 2006 Stress and adult neurogenesis. Hippocampus 16 233-238.
Mitchell BM & Webb RC 2002 Impaired vasodilation and nitric oxide synthase
activity in glucocorticoid-induced hypertension. Biol Res Nurs 4 16-21.
Molenkamp R, van der Ham A, Schinkel J & Beld M 2007 Simultaneous detection
of five different DNA targets by real-time Taqman PCR using the Roche
LightCycler480: Application in viral molecular diagnostics. J Virol Methods 141
205-211.
248
Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ & Seckl JR
2001 Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose
tolerance in 1 lbeta-hydroxysteroid dehydrogenase type 1 null mice. JBiol Chem 276
41293-41300.
Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR,
Flier JS, Mullins JJ & Seckl JR 2004 Novel adipose tissue-mediated resistance to
diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1 -
deficient mice. Diabetes 53 931-938.
Naray-Fejes-Toth A & Fejes-Toth G 1990 Glucocorticoid receptors mediate
mineralocorticoid-like effects in cultured collecting duct cells. Am JPhysiol 259
F672-678.
Naray-Fejes-Toth A & Fejes-Toth G 1994 11 beta-Hydroxysteroid dehydrogenase in
renal collecting duct cells. Steroids 59 105-110.
Necela BM & Cidlowski JA 2003 Crystallization of the human glucocorticoid
receptor ligand binding domain: a step towards selective glucocorticoids. Trends
Pharmacol Sci 24 58-61.
Nelson MT & Quayle JM 1995 Physiological roles and properties of potassium
channels in arterial smooth muscle. Am JPhysiol 268 C799-822.
Nieman LK & Chanco Turner ML 2006 Addison's disease. Clin Dermatol 24 276-
280.
Nishi M & Kawata M 2007 Dynamics of glucocorticoid receptor and
mineralocorticoid receptor: implications from live cell imaging studies.
Neuroendocrinology 85 186-192.
Normington K & Russell DW 1992 Tissue distribution and kinetic characteristics of
rat steroid 5 alpha- reductase isozymes. Evidence for distinct physiological functions.
JBiol Chem 267 19548-19554.
Nuglozeh E, Mbikay M, Stewart DJ & Legault L 1997 Rat natriuretic peptide
receptor genes are regulated by glucocorticoids in vitro. Life Sci 61 2143-2155.
O'Donnell ME & Owen NE 1994 Regulation of ion pumps and carriers in vascular
smooth muscle. Physiol Rev 74 683-721.
249
Oakley RH, Sar M & Cidlowski JA 1996 The human glucocorticoid receptor beta
isoform. JCell Biol 271 9550-9559.
Ogishima T, Suzuki H, Hata J, Mitani F & Ishimura Y 1992 Zone-specific
expression of aldosterone synthase cytochrome P-450 and cytochrome P-45011 beta
in rat adrenal cortex: histochemical basis for the functional zonation. Endocrinology
130 2971-2977.
Okuda A & Okuda K 1984 Purification and characterization of delta 4-3-ketosteroid
5 beta-reductase. JBiol Chem 259 7519-7524.
Olefsky JM 1975 Effect of dexamethasone on insulin binding, glucose transport, and
glucose oxidation of isolated rat adipocytes. JClin Invest 56 1499-1508.
Onate S, Tsai S, Tsai M & O'Malley B 1995 Sequence and characterization of a
coactivator for the steroid hormone receptor superfamily. Science 270 1354-1357.
Ong JM, Simsolo RB, Saffari B & Kern PA 1992 The regulation of lipoprotein lipase
gene expression by dexamethasone in isolated rat adipocytes. Endocrinology 130
2310-2316.
Ooi GT, Tawadros N & Escalona RM 2004 Pituitary cell lines and their endocrine
applications. Mol Cell Endocrinol 228 1-21.
Palermo M, Marazzi MG, Hughes BA, Stewart PM, Clayton PT & Shackleton CH
2008 Human Delta4-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid
metabolism. Steroids 73 417-423.
Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR &
Mullins JJ 2004 Metabolic syndrome without obesity: Hepatic overexpression of
1 lbeta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci
USA 101 7088-7093.
Penning TM 1999 Molecular determinants of steroid recognition and catalysis in
aldo-keto reductases. Lessons from 3alpha-hydroxysteroid dehydrogenase. JSteroid
Biochem Mol Biol 69 211-225.
Penning TM, Smithgall TE, Askonas LJ & Sharp RB 1986 Rat liver 3 alpha-
hydroxysteroid dehydrogenase. Steroids 47 221-247.
250
Perez P, Page A, Bravo A, Del Rio M, Gimenez-Conti I, Budunova I, Slaga TJ &
Jorcano JL 2001 Altered skin development and impaired proliferative and
inflammatory responses in transgenic mice overexpressing the glucocorticoid
receptor. FASEB J15 2030-2032.
Phair RD & Misteli T 2001 Kinetic modelling approaches to in vivo imaging. Nat
RevMol Cell Biol 2 898.
Picado-Leonard J & Miller WL 1987 Cloning and sequence of the human gene for
P450cl7 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for
P450c21. DNA 6 439-448.
Pierotti S, Gandini L, Lenzi A & Isidori AM 2008 Pre-receptorial regulation of
steroid hormones in bone cells: insights on glucocorticoid-induced osteoporosis. J
Steroid Biochem Mol Biol 108 292-299.
Pisu M, James N, Sampsel S & Saag KG 2005 The cost of glucocorticoid-associated
adverse events in rheumatoid arthritis. Rheumatology (Oxford) 44 781-788.
Poletti A, Coscarella A, Negri-Cesi P, Colciago A, Celotti F & Martini L 1998 5
alpha-reductase isozymes in the central nervous system. Steroids 63 246-251.
Pratt WB, Galigniana MD, Harrell JM & DeFranco DB 2004 Role of hsp90 and the
hsp90-binding immunophilins in signalling protein movement. Cell Signal 16 857-
872.
Pratt WB, Morishima Y, Murphy M & Harrell M 2006 Chaperoning of
glucocorticoid receptors. Handb Exp Pharmacol 111-138.
Prima V, Depoix C, Masselot B, Formstecher P & Lefebvre P 2000 Alteration of the
glucocorticoid receptor subcellular localization by non steroidal compounds. J
Steroid Biochem Mol Biol 72 1-12.
Quattrochi LC & Guzelian PS 2001 Cyp3A regulation: from pharmacology to
nuclear receptors. Drug Metab Dispos 29 615-622.
Rabbitt EH, Lavery GG, Walker EA, Cooper MS, Stewart PM & Hewison M 2002
Prereceptor regulation of glucocorticoid action by 11 beta-hydroxysteroid
dehydrogenase: a novel determinant of cell proliferation. FASEB J16 36-44.
251
Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O & Walker
BR 2001 Tissue-specific dysregulation of Cortisol metabolism in human obesity. J
Clin Endocrinol Metab 86 1418-1421.
Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P,
Schmid W, Herrlich P, Angel P, Schutz G 1998 DNA binding of the glucocorticoid
receptor is not essential for survival. Cell 93 531-541.
Roland BL, Krozowski ZS & Funder JW 1995 Glucocorticoid receptor,
mineralocorticoid receptors, 11 beta-hydroxysteroid dehydrogenase-1 and -2
expression in rat brain and kidney: in situ studies. Mol Cell Endocrinol 111 Rl-7.
Romanovsky AA, Ivanov AI, Lenczowski MJ, Kulchitsky VA, Van Dam AM, Poole
S, Homer LD & Tilders FJ 2000 Lipopolysaccharide transport from the peritoneal
cavity to the blood: is it controlled by the vagus nerve? Auton Neurosci 85 133-140.
Ross ME, Evinger MJ, Hyman SE, Carroll JM, Mucke L, Comb M, Reis DJ, Joh TH
& Goodman HM 1990 Identification of a functional glucocorticoid response element
in the phenylethanolamine N-methyltransferase promoter using fusion genes
introduced into chromaffin cells in primary culture. JNeurosci 10 520-530.
Ruiz OS, Wang LJ, Pahlavan P & Arruda JA 1995 Regulation of renal Na-HC03
cotransporter: III. Presence and modulation by glucocorticoids in primary cultures of
the proximal tubule. Kidney Int 47 1669-1676.
Russell DW & Wilson JD 1994 Steroid 5 alpha-reductase: two genes/two enzymes.
Annu Rev Biochem 63 25-61.
Russell SB, Trupin JS, Kennedy RZ, Russell JD & Davidson JM 1995
Glucocorticoid regulation of elastin synthesis in human fibroblasts: down-regulation
in fibroblasts from normal dermis but not from keloids. J Invest Dermatol 104 241-
245.
Sackey FN, Hache RJ, Reich T, Kwast-Welfeld J & Lefebvre YA 1996 Determinants
of subcellular distribution of the glucocorticoid receptor. Mol Endocrinol 10 1191-
1205.
Samra JS, Clark ML, Humphreys SM, MacDonald IA, Bannister PA & Frayn KN
1998 Effects of physiological hypercortisolemia on the regulation of lipolysis in
subcutaneous adipose tissue. JClin Endocrinol Metab 83 626-631.
252
Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR & Seckl JR
2004 1 IBeta-hydroxysteroid dehydrogenase inhibition improves cognitive function
in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA 101 6734-6739.
Santidrian S & Young VR 1980 Effect of corticosterone and protein malnutrition on
muscle protein breakdown in vivo in rats as measured by the urinary excretion of 3-
methylhistidine. Rev Esp Fisiol 36 205-214.
Sapolsky RM, Romero LM & Munck AU 2000 How do glucocorticoids influence
stress responses? Integrating permissive, suppressive, stimulatory, and preparative
actions. Endocr Rev 21 55-89.
Sarnstrand B, Brattsand R & Malmstrom A 1982 Effect of glucocorticoids on
glycosaminoglycan metabolism in cultured human skin fibroblasts. J Invest
Dermatol 79 412-417.
Sato A, Suzuki H, Murakami M, Nakazato Y, Iwaita Y & Saruta T 1994
Glucocorticoid increases angiotensin II type 1 receptor and its gene expression.
Hypertension 23 25-30.
Sawmynaden P & Perretti M 2006 Glucocorticoid upregulation of the annexin-Al
receptor in leukocytes. Biochem Biophys Res Commun 349 1351-1355.
SchaafMJM, Champagne D, van Laanen IHC, van Wijk DCWA, Meijer AH, Meijer
OC, Spaink HP & RichardsonMK 2008 Discovery of a functional glucocorticoid
receptor beta-isoform in zebrafish. Endocrinology 149 1591-1599.
SchaafMJM & Cidlowski JA 2003 Molecular determinants of glucocorticoid
receptor mobility in living cells: the importance of ligand affinity. Mol Cell Biol 23
1922-1934.
Schacke H, Docke WD & Asadullah K 2002 Mechanisms involved in the side effects
of glucocorticoids. Pharmacol Ther 96 23-43.
Schacke H, Schottelius A, Docke W-D, Strehlke P, Jaroch S, Schmees N, Rehwinkel
H, Hennekes H & Asadullah K 2004 Dissociation of transactivation from
transrepression by a selective glucocorticoid receptor agonist leads to separation of
therapeutic effects from side effects. Proc Natl Acad Sci USA 101 227-232.
Schleimer RP & Bochner BS 1994 The effects of glucocorticoids on human
eosinophils. JAllergy Clin Immunol 94 1202-1213.
253
Schoneveld OJ, Gaemers IC & Lamers WH 2004 Mechanisms of glucocorticoid
signalling. Biochim Biophys Acta 1680 114-128.
Seckl JR & Walker BR 2004 1 lbeta-hydroxysteroid dehydrogenase type 1 as a
modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol
Metab 15 418-424.
Shneider BL, Setchell KD, Whitington PF, Neilson KA & Suchy FJ 1994 Delta 4-3-
oxosteroid 5 beta-reductase deficiency causing neonatal liver failure and
hemochromatosis. JPediatr 124 234-238.
Silvestrini G, Ballanti P, Patacchioli FR, Mocetti P, Di Grezia R, Wedard BM,
Angelucci L & Bonucci E 2000 Evaluation of apoptosis and the glucocorticoid
receptor in the cartilage growth plate and metaphyseal bone cells of rats after high-
dose treatment with corticosterone. Bone 26 33-42.
Smith L & Smith JB 1994 Regulation of sodium-calcium exchanger by
glucocorticoids and growth factors in vascular smooth muscle. JBiol Chem 269
27527-27531.
Smith SS, Gong QH, Hsu FC, Markowitz RS, ffrench-Mullen JM & Li X 1998
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an
endogenous steroid. Nature 392 926-930.
Smits HH, Grunberg K, Derijk RH, Sterk PJ & Hiemstra PS 1998 Cytokine release
and its modulation by dexamethasone in whole blood following exercise. Clin Exp
Immunol 111 463-468.
Smoak KA & Cidlowski JA 2004 Mechanisms of glucocorticoid receptor signaling
during inflammation. Mech Ageing Dev 125 697-706.
Song IH & Buttgereit F 2006 Non-genomic glucocorticoid effects to provide the
basis for new drug developments. Mol Cell Endocrinol 246 142-146.
Sorrells SF & Sapolsky RM 2007 An inflammatory review of glucocorticoid actions
in the CNS. Brain Behav Immun 21 259-272.
Stahn C, Lowenberg M, Hommes DW & Buttgereit F 2007 Molecular mechanisms
of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell
Endocrinol 275 71-78.
254
Stewart PM 2002 The adrenal cortex. In Williams textbook ofendocrinology, edn
10th, pp 491-551. Eds PR Larsen, HM Kronenberg, S Melmed & KS Polonsky.
Philadelphia: Saunders.
Stewart PM, Boulton A, Kumar S, Clark PM & Shackleton CH 1999 Cortisol
metabolism in human obesity: impaired cortisone~>cortisol conversion in subjects
with central adiposity. JClin Endocrinol Metab 84 1022-1027.
Stewart PM, Corrie JE, Shackleton CH & Edwards CR 1988 Syndrome of apparent
mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. JClin Invest 82
340-349.
Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH & Edwards CR 1987
Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase
deficiency comes of age. Lancet 2 821-824.
Stravitz RT & Sanyal AJ 2003 Drug-induced steatohepatitis. Clin Liver Dis 7 435-
451.
Sugiyama T, Scott DK, Wang JC & Granner DK 1998 Structural requirements of the
glucocorticoid and retinoic acid response units in the phosphoenolpyruvate
carboxykinase gene promoter. Mol Endocrinol 12 1487-1498.
Suzuki S, Koyama K, Darnel A, Ishibashi H, Kobayashi S, Kubo H, Suzuki T,
Sasano H & Krozowski ZS 2003 Dexamethasone upregulates 11 beta-hydroxysteroid
dehydrogenase type 2 in BEAS-2B cells. Am JRespir Crit Care Med 167 1244-1249.
Tai TC, Claycomb R, Her S, Bloom AK & Wong DL 2002 Glucocorticoid
responsiveness of the rat phenylethanolamine N-methyltransferase gene. Mol
Pharmacol 61 1385-1392.
Tait AS, Butts CL & Sternberg EM 2008 The role of glucocorticoids and progestins
in inflammatory, autoimmune, and infectious disease. JLeukoc Biol 82 924-931.
Todd-Turla KM, Schnermann J, Fejes-Toth G, Naray-Fejes-Toth A, Smart A, Killen
PD & Briggs JP 1993 Distribution ofmineralocorticoid and glucocorticoid receptor
mRNA along the nephron. Am JPhysiol 264 F781-791.
Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV & Stewart PM 2008a
Impaired glucose tolerance and insulin resistance are associated with increased
255
adipose 1 lbeta-hydroxysteroid dehydrogenase type 1 expression and elevated
hepatic 5alpha-reductase activity. Diabetes 57 2652-2660.
Tomlinson JW, Finney J, Hughes BA, Hughes SV & Stewart PM 2008b Reduced
glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose
tissue insulin sensitization after weight loss. Diabetes 57 1536-1543.
Tomlinson JW & Stewart PM 2001 Cortisol metabolism and the role of 1 lbeta-
hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 15 61-78.
Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS,
Hewison M & Stewart PM 2004 1 lbeta-hydroxysteroid dehydrogenase type 1: a
tissue-specific regulator of glucocorticoid response. Endocr Rev 25 831-866.
Torres JM & Ortega E 2003 Differential regulation of steroid 5alpha-reductase
isozymes expression by androgens in the adult rat brain. FASEB J17 1428-1433.
Truss M & Beato M 1993 Steroid hormone receptors: interaction with
deoxyribonucleic acid and transcription factors. Endocr Rev 14 459-479.
Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, Rosier A,
Bradlow HL & New MI 1979 A syndrome of apparent mineralocorticoid excess
associated with defects in the peripheral metabolism of Cortisol. JClin Endocrinol
Metab 49 757-764.
Unterberger C, Staples KJ, Smallie T, Williams L, Foxwell B, Schaefer A, Kempkes
B, Hofer TP, Koeppel M, Lohrum M, Stunnenberg H, Frankenberger M, Ziegler-
Heitbrock L 2008 Role of STAT3 in glucocorticoid-induced expression of the human
IL-10 gene. Mol Immunol 45 3230-3237.
van den Brandt J, Luhder F, McPherson KG, de GraafKL, Tischner D, Wiehr S,
Herrmann T, Weissert R, Gold R & Reichardt HM 2007 Enhanced glucocorticoid
receptor signaling in T cells impacts thymocyte apoptosis and adaptive immune
responses. Am JPathol 170 1041-1053.
van Schaftingen E & Gerin I 2002 The glucose-6-phosphatase system. Biochem J
362 513-532.
Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C,
Gronemeyer H & Resche-Rigon M 1997 Synthetic glucocorticoids that dissociate
256
transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo.
Mol Endocrinol 11 1245-1255.
Walker BR 2000 Deflazacort: towards selective glucocorticoid receptor modulation?
Clin Endocrinol (Oxf) 52 13-15.
Walker BR 2006 Cortisol—cause and cure for metabolic syndrome? Diabet Med 23
1281-1288.
Walker BR 2007a Extra-adrenal regeneration of glucocorticoids by 1 lbeta-
hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological
target for energy partitioning. Proc Nutr Soc 66 1-8.
Walker BR 2007b Glucocorticoids and cardiovascular disease. Eur JEndocrinol 157
545-559.
Wei L, MacDonald TM & Walker BR 2004 Taking glucocorticoids by prescription is
associated with subsequent cardiovascular disease. Ann Intern Med 141 764-770.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL & Ferrante AW, Jr.
2003 Obesity is associated with macrophage accumulation in adipose tissue. J Clin
Invest 112 1796-1808.
Wilfinger WW, Mackey K & Chomczynski P 1997 Effect of pH and ionic strength
on the spectrophotometric assessment of nucleic acid purity. Biotechniques 22 474-
476,478-481.
Windle RJ, Wood SA, Shanks N, Lightman SL & Ingram CD 1998 Ultradian rhythm
of basal corticosterone release in the female rat: dynamic interaction with the
response to acute stress. Endocrinology 139 443-450.
Wiper-Bergeron N, Salem HA, Tomlinson JJ, Wu D & Hache RJ 2007
Glucocorticoid-stimulated preadipocyte differentiation is mediated through
acetylation of C/EBPbeta by GCN5. Proc Natl Acad Sci USA 104 2703-2708.
Woods MD, Shipston MJ, Mullens EL & Antoni FA 1992 Pituitary corticotrope
tumor (AtT20) cells as a model system for the study of early inhibition by
glucocorticoids. Endocrinology 131 2873-2880.
257
Wurtman RJ & Axelrod J 1966 Control of enzymatic synthesis of adrenaline in the
adrenal medulla by adrenal cortical steroids. JBiol Chem 241 2301-2305.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS,
Tartaglia LA, Chen H 2003 Chronic inflammation in fat plays a crucial role in the
development of obesity-related insulin resistance. JClin Invest 112 1821-1830.
Yang J, Liu J & DeFranco DB 1997 Subnuclear trafficking of glucocorticoid
receptors in vitro: chromatin recycling and nuclear export. J Cell Biol 137 523-538.
Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J & Karin M
1990 Transcriptional interference between c-Jun and the glucocorticoid receptor:
mutual inhibition ofDNA binding due to direct protein-protein interaction. Cell 62
1205-1215.
Yasunari K, Kohno M, Murakawa K, Yokokawa K & Takeda T 1990
Glucocorticoids and atrial natriuretic factor receptors on vascular smooth muscle.
Hypertension 16 581-586.
Yau JL, Noble J, Kenyon CJ, Hibberd C, Kotelevtsev Y, Mullins JJ & Seckl JR 2001
Lack of tissue glucocorticoid reactivation in 1 lbeta -hydroxysteroid dehydrogenase
type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad
Sci USA 98 4716-4721.
Yoshimura C, Miyamasu M, Nagase H, Iikura M, Yamaguchi M, Kawanami O,
Morita Y, Iwata T, Yamamoto K & Hirai K 2001 Glucocorticoids induce basophil
apoptosis. JAllergy Clin Immunol 108 215-220.
Zhang TY & Daynes RA 2007 Glucocorticoid conditioning ofmyeloid progenitors
enhances TLR4 signaling via negative regulation of the phosphatidylinositol 3-
kinase-Akt pathway. J Immunol 178 2517-2526.
Zhang TY, Ding X & Daynes RA 2005 The expression of 11 beta-hydroxysteroid
dehydrogenase type I by lymphocytes provides a novel means for intracrine
regulation of glucocorticoid activities. J Immunol 174 879-889.
Zheng Y, Ye LB, Liu J, Jing W, Timani KA, Yang XJ, Yang F, Wang W, Gao B &
Wu ZH 2005 Gene expression profiles ofHeLa Cells impacted by hepatitis C virus
non-structural protein NS4B. J Biochem Mol Biol 38 151-160.
258
